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Macrophages are present in virtually all tissues and account for approximately 10% of 
all body mass. Although classically credited as the scavenger cells of innate immune 
system, ridding a host of pathogenic material and cellular debris though their 
phagocytic function, macrophages also play a crucial role in embryogenesis, 
homeostasis, and inflammation. De-regulation of macrophage function is therefore 
implicated in the progression of many disease states including cancer, arthritis, and 
atherosclerosis to name just a few. The diverse range of activities of this cell can be 
attributed to its exceptional phenotypic plasticity i.e. it is capable of adapting its 
physiology depending on its environment; for instance in response to different types of 
pathogens, or specific cocktail of cytokines detected. This plasticity is exemplified by 
the macrophages capacity to adjust rapidly its transcriptional profile in response to a 
given stimulus. This includes interferons which are a group of cytokines capable of 
activating the macrophage by interacting with their cognate receptors on the cell. The 
different classes of interferons activate downstream signalling cascades, eventually 
leading to the expression (as well as repression) of hundreds of genes.  
 
To begin to fully understand the properties of a dynamic cell such as the macrophage 
arguably requires a holistic appreciation of its constituents and their interactions. 
Systems biology investigations aim to escape from a gene-centric view of biological 
systems. As such this necessitates the development of better ways to order, display, 
mine and analyse biological information, from our knowledge of protein interactions 
and the systems they form, to the output of high throughput technologies. The 
primary objectives of this research were to further characterise the signalling 
mechanisms driving macrophages activation, especially in response to type-I and type-
II interferons, as well as lipopolysaccharide (LPS), using a ‘systems-level’ approach to 
data analysis and modelling. In order to achieve this end I have explored and 
developed methods for the executing a ‘systems-level’ analysis. Specifically the 
questions addressed included: (a) How does one begin to formalise and model the 
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existing knowledge of signalling pathways in the macrophage? (b) What are the 
similarities and differences between the macrophage response to different types of 
interferon (namely interferon-β (IFN-β) and interferon-γ (IFN-γ))? (c) How is the 
macrophage transcriptome affected by siRNA targeting of key regulators of the 
interferon pathway? (d) To what extent does a model of macrophage signalling aid 
interpretation of the data generated from functional genomics screens?  
 
There is general agreement amongst biologists about the need for high-quality 
pathway diagrams and a method to formalize the way biological pathways are 
depicted. In an effort to better understand the molecular networks that underpin 
macrophage activation an in-silico model or ‘map’ of relevant pathways was 
constructed by extracting information from published literature describing the 
interactions of individual constituents of this cell and the processes they modulate 
(Chapter-2). During its construction process many challenges of converting pathway 
knowledge into computationally-tractable yet ‘understandable’ diagrams, were to be 
addressed. The final model comprised 2,170 components connected by 2,553 edges, 
and is to date the most comprehensive formalised model of macrophage signalling. 
Nevertheless this still represents just a modest body of knowledge on the cell. Related 
to the pathway modelling efforts was the need for standardising the graphical 
depiction of biology in order to achieve these ends. The methods for implementing this 
and agreeing a ‘standard’ has been the subject of some debate. Described herein (in 
Chapter-3) is the development of one graphical notation system for biology the 
modified Edinburgh Pathway Notation (mEPN). By constructing the model of 
macrophage signalling it has been possible to test and extensively refine the original 
notation into an intuitive, yet flexible scheme capable of describing a range of 
biological concepts. The hope is that the mEPN development work will contribute to 
the on-going community effort to develop and agree a standard for depicting 
pathways and the published version will provide a coherent guide to those planning to 
construct pathway diagrams of their biological systems of interest.  
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With a desire to better understand the transcriptional response of primary mouse 
macrophages to interferon stimulation, genome wide expression profiling was 
performed and an explorative-network based method applied for analysing the data 
generated (Chapter-4). Although transcriptomics data pertaining to interferon 
stimulation of macrophages is not entirely novel, the network based analysis of it 
provided an alternative approach to visualise, mine and interpret the output. The 
analysis revealed overlap in the transcriptional targets of the two classes of interferon, 
as well as processes preferentially induced by either cytokine; for example MHC-Class 
II antigen processing and presentation by IFN-γ, and an anti-proliferative signature by 
IFN-β. To further investigate the contribution of individual proteins towards generating 
the type-I (IFN-β) response, short interfering RNA (siRNA) were employed to repress 
the expression of selected target genes. However in macrophages and other cells 
equipped with pathogen detection systems the act of siRNA trasfection can itself 
induce a type-I interferon response. It was therefore necessary to contend with this 
autocrine production of IFN-β and optimise an in vitro assay for studying the 
contribution of siRNA induced gene-knock downs to the interferon response 
(described in Chapter-5). The final assay design incorporated LPS stimulation of the 
macrophages, as a means of inducing IFN-β autonomously of the transfection induced 
type-I response. However genome-wide expression analysis indicated the targeted 
gene knock-downs did not perturb the LPS response in macrophages on this occasion. 
The optimisation process underscored the complexities of performing siRNA gene 
knockdown studies in primary macrophages. Furthermore a more thorough 
understanding of the transcriptional response of macrophages to stimulation by 
interferon or by LPS was required. Therefore the final investigations of this thesis 
(Chapter-6) explore the transcriptional changes over a 24 hour time-course of 
macrophage activation by IFN-β, IFN-γ, or LPS and the contribution of the macrophage 
pathway model in interpreting the response to the three stimuli. 
 
Taken together the work described in this thesis highlight the advances to be made 
from a systems-based approach to visualisation, modelling and analysis of macrophage 
signalling. 
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Chapter 1. Introduction 
 
Mechnikov discovered phagocytosis after experimenting on the larvae of starfish. His 
theory was that certain white blood cells now called phagocytes (from the Greek 
phagos – to eat, cyte – cell) could engulf and destroy harmful bodies such as bacteria. 
In a pioneering experiment he observed these cells surrounding and attempting to 
devour a splinter he had introduced into the transparent body of a starfish larva. He 
proposed the role of these cells was to maintain integrity of the organism by 
protecting the animal from foreign invaders or clearing the body of unwanted cellular 
debris [1-2]. In vertebrates these phagocytes were analogous certain white blood cells. 
In drawing parallels between the phagocytes role in various species or settings, other 
important functions of these cells became apparent. In the tail of the tadpole muscle 
cells were ‘eaten’ at appropriate times of metamorphosis by the adjacent cells. Thus 
under certain developmental conditions, it appeared this cell was ‘responsible’ for 
defining organismal structures [2].  
 
Figure 1.1: Scanning electron micrograph (30 μm × 25 μm) of a phagocytic macrophage; Taken from 
Rosenberger and Finley, 2003 [3]. 
 
 
The pioneering studies of Mechnikov earned him a Nobel prize in 1908. Since then a 
century of research into phagocytes, has shed light on their role in immunology (host 
defence), and other functions beyond simply eating [2], such as growth and 
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development. This progress has seen the characterisation of different phagocyte 
populations and their precursor cells; the key mammalian phogocytes being 
macrophages, dendritic cells, neutrophils and mast cells. This thesis explores the 
signalling events occurring in the macrophage.  
 
The Macrophage 
    
Macrophages are a heterogeneous population of antigen-presenting cells, varying in 
their anatomical location, phenotype, morphology, and specialised physiological 
function. The original definition and term “macro-phage” from the Greek “big-eater”, 
is derived from the prodigious phagocytic properties of the cell. As the elegant studies 
of Mechnikov demonstrated, these phagocytic actions are not only required for the 
propagation of an innate immune response i.e. ridding a host of pathogenic material 
and cellular debris, but are also crucial for non-immunological trophic roles during 
development and homeostasis. Macrophages constitute ~10-15% of cells in most 
tissues and are found in every organ where they have a specialised function and are 
also recruited to sites of infection, injury, and inflammation [4-9].  
 
Origin of Macrophages and the Mononuclear Phagocyte System 
 
In the traditional view, macrophages are derived from pluripotent stem cells in the 
bone marrow which can develop into the macrophage precursors known as 
monocytes. Monocytes then enter the blood stream and under appropriate signals 
differentiate into macrophages. The mononuclear phagocytic system (MPS) is a 
classification scheme for defining macrophages, based on their bone marrow and 
monocytic origins.  The MPS therefore comprises bone marrow progenitors, blood 
monocytes and resident tissue macrophages. In recent years the concept of the MPS 
and specialised cell lineages is being challenged in light of several developments 
including the transdifferentiation of MPS cells into other MPS populations, the 
existence of a separate embryonic phagocyte lineage and the local renewal of tissue 
macrophages as opposed to monocyte recruitment [10]. 
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Macrophages originate from hematopoietic stem cells (HSC) found in both adult bone 
marrow and the developing foetus. However macrophage precursors found in the yolk 
sac may have distinct origins from the macrophage precursors found in adult bone 
marrow and in the foetal liver following the full initiation of hematopoiesis [11-12]. In 
the yolk sac and early hepatic hematopoiesis, primitive macrophages are thought to 
develop from their macrophage precursors without undergoing stages of monocytic 
cell development (as occurs in adult hematopoiesis) [13]. These primitive-foetal 
macrophages have the potential to proliferate and differentiate into resident 
macrophages in tissues in late ontogeny [13]. Later on in foetal hematopoiesis and in 
adult bone marrow, it is the progression through monocytic cell stages that eventually 
gives rise to monocyte-derived macrophages. Monocytes in the bone-marrow 
originate from a common myeloid progenitor. The hematopoetic stages in macrophage 
development are summarised in Figure 1.2 and include the development of the HSC 
into a progenitor of both macrophages and granulocytes i.e. the 
granulocytemacrophage colony-forming-unit (GM-CFU). The GM-CFU population can 
then commit to the macrophage colony-forming unit (M-CFU), or the granulocyte 
colony forming unit (G-CFU) group of cells. The M-CFU differentiate into monoblasts, 
pro-monocytes and monocyte cell stages, prior to becoming macrophages, in a process 
requiring the growth factor CSF-1 (also known as Macrophage Colony Stimulating 
Factor (M-CSF)). Monocytes migrate from the bone marrow into peripheral blood and 
then into tissues. Here they are thought to differentiate into resident macrophages or 
related cells (dendritic cells or osteoclasts) under the influence of appropriate growth 
factors. Other monocytes may migrate into tissues in response to infection/ 
inflammatory stimuli and differentiate into exudate macrophages. However it is now 
also appreciated that resident tissue macrophages possess proliferative capacity and 
can be replenished by self-renewal i.e. autonomously of bone-marrow recruited 
monocytes [10]. Moreover the local proliferation of macrophages, (as opposed to 
recruitment from peripheral blood) has also been demonstrated under certain 
inflammatory pathologies [14].  In general the developmental origins of macrophages, 
process of self-renewal, and function of tissue macrophage subsets are poorly 
understood [15].   
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Figure 1.2: Mononuclear Phagocyte System (MPS); Taken and adapted from Gordon and Taylor, 2005 
[11]. Hematopoietic stem cells (HSC) in the fetal liver or adult bone marrow develop into a progenitor of 
both macrophages and granulocytes; the granulocytemacrophage colony-forming-unit (GM-CFU). The 
GM-CFU population can commit to the macrophage colony-forming unit (M-CFU), or the granulocyte 
colony forming unit (G-CFU) group of cells. The M-CFU differentiate into monoblasts, pro-monocytes 
and monocyte cell stages, prior to becoming macrophages, in a process requiring the growth factor CSF-
1. In mice Ly6C is a marker of the ‘inflammatory’ population of monocytes. The concept of the MPS has 
come under scrutiny following the discovery of a separate embryonic phagocyte lineage in the yolk sac. 
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The G-CFU population develop into neutrophilic granulocytes. Monocytic macrophages 
and neutrophilic granulocytes have therefore been traditionally viewed as distinct 
lineages. However there is a growing body of evidence suggesting a more 
interchangeable relationship, with the proposal that macrophages and granulocytes 
may interconvert [10]. This is based on the observations of highly overlapping 
transcriptional profiles of macrophages and granulocytes as well as the in vitro 
manipulation of granulocytes with various stimuli which induces them to adopt a 
macrophage-like phenotype [10, 16-17]. Macrophages and dendritic cells are also 
highly related cell populations; in fact the concept of distinct macrophage and 
dendritic cell lineages in peripheral tissue is currently being fervently debated [15, 18-
20]. Dendritic cells (DCs) are generally considered the key initiators of the adaptive 
immune response, and are defined by their ability to activate naïve T-cells and the 
expression of particular markers, namely the integrin CD11c. Discrimination between 
macrophage and DC populations is blurred by a range of factors [10] e.g. the 
macrophage differentiation factor CSF-1 has also been shown to influence DC numbers 
(which express the CSF-1R) [21]; purified CD11c- negative macrophages have been 
shown to prime naïve T-cells in vivo [22]; the preferred DC marker CD11c is also 
expressed in some macrophage populations e.g. alveolar macrophages. In fact there 
seems to be no single unambiguous morphological or protein marker of macrophages 
or  DCs, since conventional markers (such as F4/80, CD11c, CD11b and MHC class II) 
have turned out not to be specific [20]. As a result some argue that it is not possible to 
define macrophages and DCs as separate entities [10, 19-20]. Instead they are a 
“continuum of progeny of a common precursor” [20]. Whereas others suggest that 
there is ample evidence correlating the distinct functions of macrophages and DCs 
with different phenotypic markers [20]. More collaborations and open dialogue 
between ‘macrophage’ and ‘DC’ biologists is advocated to being to unravel the 
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Macrophage Growth Factors 
 
Several growth factors are involved in the development of macrophages from 
monocyte populations. Perhaps the most crucial is CSF-1, also called M-CSF. CSF-1 
regulates the survival, proliferation and differentiation of macrophages and their 
precursors. CSF-1 can also synergise with other factors including CSF-2 (GM-CSF) or IL-3 
to mediate the proliferation of early haematopoietic progenitors. In vitro macrophage 
differentiation has also been demonstrated in the presence of CSF-2 and IL-3 in 
combination with CSF-1 [23-24]. The most commonly utilized method of differentiating 
macrophages in vitro is to culture progenitor cells obtained from bone marrow or 
blood in the presence of CSF-1 or in conditioned medium (containing CSF-1 secreted by 
a cell, such as from the L929 murine fibroblast cell line). Monocytes and macrophages 
can also be readily obtained from the peritoneal cavity or lungs.  
 
The CSF-1 receptor, CSF1R, is expressed by all cells of the MPS. The transcription factor 
PU.1 is involved in the regulation of CSF1R expression. PU.1, CSF-1 or CSF1R deficiency 
are all associated with reduced macrophage numbers [25]. Mice with a targeted null 
mutation in Csf1r (Csf1r-/- mice) have a reduced life span (<5 weeks). Mice with a 
naturally occurring mutation in the Csf1 gene (Csf1op/op), known as osteopetrotic mice, 
display a range of developmental abnormalities attributed to reduced macrophage 
populations [25-26]. In particular, a lack of osteoclasts (bone remodelling 
macrophages) in Csf1op/op mice results in osteopetrosis. Csf1op/op rodents are commonly 
referred to as “toothless”, due to lack of teeth. These phenotypic defects can however 
be reversed by systemic CSF1 administration [27]. Although CSF1R is likely to be the 
only receptor for CSF-1, CSF1R also binds IL-34 [28] as well as CSF-1; which may explain 
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Monocyte Populations and Markers of Monocytes and Macrophages 
 
Defining a macrophage has been a constant challenge in developmental biology [25]. 
The complexity of the macrophage is epitomised by the fact no single marker can 
define all populations. Similarly the progenitor cells giving rise to macrophages are 
exceptionally heterogeneous.  Many efforts have been made to define subpopulations 
of monocytes based on the expression of surface markers. It is thought the 
developmental fates and phenotypic properties of monocyte subpopulations are 
defined by the pattern and extent of marker expression. Determining the functional 
roles of monocyte subsets in a physiological context remains a challenge [11].  
 
Human monocyte populations are generally identified and defined by the expression 
of CD14, CD16 and CD64. Incidentally CD14 forms part of the receptor complex for 
lipopolysaccharide (LPS).  CD14hiCD16- monocytes are generally considered to be 
‘classic monocytes’, since they resemble the original description of monocytes. The 
CD14hiCD16- sub-population are highly phagocytic, produce significant amounts of 
cytokines and express CCR2 [11]. CD14+CD16+ monocytes tend to express higher levels 
of MHC class II molecules as well as the chemokine receptor CCR5 and are thought to 
be likely precursors for DCs. Other monocyte subsets are defined using CD64 (FcγRI); 
CD14+CD16+CD64+ population are similar in their characteristics to CD14hiCD16- 
monocytes, but distinct from CD14+CD16+CD64- population [11].  
 
Murine monocytes can be identified by their expression of F4/80 and CD11b, and 
further subdivided based on the expression of CCR2, CD62L and CX3CR1. Ly6C (or GR-
1), a granulocyte surface antigen is also a marker of CCR2+ monocytes and is widely 
used as marker for monocyte subsets in mice [11, 29]. Mouse monocytes that express 
CCR2 (Ly6C+) are considered to be the inflammatory subset, which differentiate into 
macrophages required for pathogen clearance and resolution of inflammation. 
CX3CR1
hi/Ly6C- monocyte subsets are thought to differentiate into tissue resident 
macrophage and DC populations. Certain murine monocyte subsets correspond to 
human monocyte subsets (CCR2+CD62L+CX3CR1lowLy6C+ mouse monocytes are thought 
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to correspond to the classic human monocyte subset; whereas CCR2-CD62L-
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Macrophage Diversity and Biological Functions 
 
The use of antigen markers (F4/80 in mouse and CD68 in mouse and human), has 
permitted the identification of the macrophages in every organ [30]. Development of 
mice expressing an enhanced green fluorescent protein (EGFP) linked to a promoter 
region of CSF1R has further permitted the identification and study of macrophage 
/macrophage-like populations in mouse tissues [4]. These animals are dubbed 
“macgreen mice” and images of fluorescent cell populations across various tissues are 
available on www.macrophages.com. Essentially monocytes adapt to their micro-
environment and develop into the unique categories of macrophages found 
throughout the body. These resident tissue macrophages are distributed during 
development and throughout life. Resident macrophages are often stationed 
strategically, permitting their sentinel function, but also play a role in homeostasis, 
clearance  of senescent cells, initiation of acute inflammation, remodelling and repair  
following inflammation and vascular changes [11]. This specialised function of 
macrophages is largely determined by their anatomical location and macrophages in 
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Tissue Macrophage name Function 




Brain Microglial cell Neuronal survival and connectivity, and repair 
after injury 
Epidermis Langerhans cell Immune surveillance 
Eye Macrophage Vascular remodelling 
Intestine Crypt macrophage Immune surveillance 
Kidney NA Ductal development 
Liver Kupffer cell Clearance of debris from blood and liver tissue 
regeneration after damage; liver development? 
Lung Alveolar Macrophage Immune surveillance 
Mammary 
Gland 
Macrophage Branching morphogenesis and ductal 
Development 
Ovary Macrophage Steroid hormone production and ovulation 
Pancreas Macrophage Islet development 
Testis Macrophage Steroid hormone production; Leydig-cell 
development? 
Uterus Uterine DC Angiogenesis and decidualization 
Uterine macrophage Cervical ripening 
Table 1.1: Macrophage diversity across tissues. Taken and adapted from Pollard, 2009 [25]. 
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Each organ requires a specialised immune response shaped by the organs requirement 
for absolute or relative sterility [31]. For example the spleens response to bacteria is in 
contrast to the gut or colon response to bacteria [31]. Macrophages in the gut are 
highly phagocytic and bactericidal but produce relatively low levels of pro-
inflammatory cytokines [32]. This phenotype is critical in maintaining the balance 
between the response against harmful pathogens and the induction of tolerance to 
commensal bacteria. Thus the tissue micro-environment is significant in defining the 
phenotypic properties of the macrophage. In addition to the organ specific responses, 
macrophages must elicit specialised response to different types of pathogens. Each 
scenario specific response witnesses an adaptation of the gene expression and 
secretory protein profiles of the macrophages. In essence exceptional plasticity and 
heterogeneity are hallmarks of macrophages.  
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Macrophages in Disease Pathologies  
 
Given their heterogeneity and presence in every tissue, it is no surprise that 
macrophages play a role in almost all disease pathologies. The influence of 
macrophage signalling in a given disease can be both beneficial and detrimental to the 
host. Deregulation of macrophage signalling is seen to contribute to a number of 
chronic diseases e.g. cancer where macrophages recruited to the tumour micro-
environment are known as “tumour associated macrophages” (TAMs). The role of 
TAMs in cancer in general is ambiguous and possibly cancer specific. Beneficial roles in 
the context of the host include detection, rejection and killing of cancer cells as well as 
clearance of apoptotic cells. At the same time TAMs are known to promote tumour 
progression and malignancy, for example by promoting angiogenesis [25, 33-35]. In 
fact, TAM density in human tumours correlates with poor prognosis in over 80% of 
cases [36].  
 
Macrophages have also been attributed with the progression of acute and chronic 
symptoms of rheumatoid arthritis. These cells are activated and numerous in the 
inflamed synovial membrane (joint lining) [37-38] and there is a correlation between 
progression of joint destruction and extent of synovial macrophage infiltration [38]. 
Other examples of pathologies where macrophages are implicated include; 
atherosclerosis (where fat-laden macrophages, known as foam cells contribute to 
vascular occlusion); emphysema (which is associated with the uncontrolled activation 
of alveolar macrophages); and septic shock (where an over-zealous cytokine response 
is propagated by macrophages).  
 
Development of targeted therapeutics requires an understanding of the signalling 
pathways underpinning macrophage activity and their deregulation in a given disease 
pathology. Although macrophages have been studied extensively in vitro, the challenge 
remains in translating this research into an in vivo understanding. 




Macrophage Activation Pathways 
 
Macrophage activation has been defined as the “acquisition of competence to execute 
a complex function” [39]. Gene Ontology (GO) describes the term macrophage 
activation as “a change in morphology and behaviour of a macrophage resulting from 
exposure to a cytokine, chemokine, cellular ligand, or soluble factor”. Ultimately 
macrophage activation arises as results of the cells interactions with its surrounding 
environment. These environmental cues are detected by macrophage receptors.  
 
Macrophages express an extensive repertoire of receptors which coupled with 
downstream signalling cascades mediate their activation and capacity to execute any 
number of diverse functions. The receptors may be expressed on the surfaces, in the 
cytosol, as well as vacuolar compartments e.g. endosomes. To avert unnecessary 
activation, inflammation, and/or damage to tissues, macrophages must distinguish 
between self and non-self. The detection of microbes or patterns associated with 
microbes is largely performed by pattern recognition receptors (PRRs). PRR categories 
include scavengers receptors, C-type lectins, Toll-like receptors, NOD-like receptors, 
RIG-like receptors, and others not strictly falling into those categories e.g.  CD14 and 
AIM2 [40].  Between them the range of PRRs detect bacteria, virus, protozoa, fungi and 
their components (examples include; double and single stranded RNA, DNA, CpG DNA, 
flagellin, lipoprotein, envelope proteins, LPS, and lipteichoic acid (LTA)).  
 
Macrophages also respond to endogenous stimuli e.g. cytokines, chemokines and 
growth factors, generated following infection/injury and homeostatic possesses. These 
stimuli are often produced by cells of innate immune system including the 
macrophages themselves and are crucial in defining macrophage activity. One group of 
cytokines central to the investigations in this thesis are known as “interferons”, 
originally coined so due to their ability to interfere with viral replication.  
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Receptors for microbial or endogenous stimuli are coupled to downstream intracellular 
signal transduction pathways. Signalling pathways can broadly be defined as the series 
of interactions between cellular components, usually proteins and proteins complexes, 
which lead to the modulation of a given process.  Some receptor initiated pathways 
are linked to specific downstream response pathways and others converge at common 
factors. The interactions underpinning some of the key signalling pathways activated in 
macrophages are discussed in greater detail in Chapter-2. The functional programmes 
regulated by the vast array of signalling pathways include (but are not limited to) 
growth, survival, apoptosis, migration, phagocytosis, antigen-presentation, 
remodelling, metabolic reprogramming and cytotoxicity [41]. The signalling pathways 
mediating these processes often do so by regulating the expression of specific cohorts 
of genes. In fact macrophage interaction with any given stimulus or combination of 
stimuli elicits a tailored transcriptional response. The customised transcriptional 
responses are necessary to provide functional specificity to a given response. For 
example different pathogens present different challenges for the host; therefore the 
macrophage response must be adaptable to deal with the specific challenges. LPS, an 
outer membrane component of gram negative bacteria, is commonly studied 
transcriptional activator of macrophages. LPS induces a complex transcriptional 
response, comprising multiple gene sets that encode a number of functional 
programmes [42]. The gene sets are often co-ordinately regulated by specific 
transcription factors [42].  
 
Macrophage Activation States  
 
Activated macrophages were originally defined as cells that secreted inflammatory 
mediators and killed intracellular pathogens. It is now appreciated that macrophages 
are a far more heterogeneous group of cells and their ‘activated’ status may in fact 
refer to a number of phenotypes required for performing distinct immunological 
functions.  The terms M1 and M2 polarised macrophages were introduced to reflect 
the two extremes of the activated state which are analogous to T-helper cell 
polarisation (TH1-TH2) [43]. M1 polarised macrophages, otherwise known as “classically 
                                                                                                       Chapter 1: Introduction 
15 
activated” macrophages were originally described as being induced by the TH1 cytokine 
IFN-γ in concert with microbial stimuli (e.g. LPS) or other cytokines (e.g. TNF-α, GM-
CSF) [44]. Cytokine production characteristic of M1 activated macrophages includes 
high expression of the interleukins IL12, IL23, the TH1 cell attracting chemokines CXCL9, 
CXCL10 and nitric oxide [45-46]. In contrast the “alternatively activated” M2 polarised 
phenotype is induced by the TH2 cytokine IL-4 as well as IL-13 [47-49].  IL10, IL-1RA, 
CCL17, CCL22 and CCL24 are examples of cytokines preferentially induced in M2 
polarised cells [46, 50]. M2 macrophages have been further classified into “M2-like” 
categories, which overlap with some but not all significant features of M2 
macrophages (reviewed in [51]). For example in CMV infection of monocytes, the cells 
are biased towards a M1 phenotype but express what are described as typical M2 
cytokines (Il1RA, IL10, CCL18), [52]. Crude categorisation of the physiological roles of 
the polarised macrophages places the M1 subtype as promoters of the TH1 response, 
antigen presentation and as cells with intracellular microbiocidal as well as tumoricidal 
capacity [53]. In contrast alternatively activated macrophages are regarded as 
immunosuppressive cells, which promote the TH2 response, tissue remodelling and 
parasite encapsulation and clearance [49]. Crucially the M1-M2 categories are not the 
only forms of macrophage polarisation but instead represent extremes across a 
spectrum of activation states. Even the advocates of M1-M2 polarisation (theory) of 
macrophage function emphasise this should be viewed as “an operationally useful, 
simplified, conceptual framework” for describing a continuum of diverse functional 
states [46]. Others have proposed grouping of macrophage populations based on their 
different homeostatic activities; host defence, wound healing and immune regulation 
[23].  
 
There is limited understanding of the differential transcriptional cascades and 
secretory responses induced in macrophages following interaction with different 
stimuli (cells, cytokines, microbes). Therefore classifying macrophages based on their 
activation states remains a challenge. Moreover, the mechanism of transcriptional 
control and regulatory events that mediate the expression of functional gene sets is 
not well characterised. Ultimately a better understanding of gene expression patterns 
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in different macrophage populations may aid the development of therapeutics 
targeting this cell (e.g. gene therapy and anti-inflammatory drugs).  
 
Interferon Signalling System  
 
Biological Functions of Interferon Signalling 
 
   
Interferons are a family of multifunctional cytokines that can modulate the 
transcription of subsets of genes in the target cells they stimulate. They are induced 
transiently in vivo and in vitro by viruses, microbial products, or other chemical and/or 
synthetic inducers. The interferon (IFN) family of cytokines are acknowledged as 
fundamental components of the innate immune system. The original definition of 
interferons was based on their ability to “interfere” with viral replication, although 
they are now also known to have anti-microbial, anti-proliferative and 
immunomodulatory effects. Furthermore, interferons are also being investigated for 
their role in the immuno-surveillance for malignant cells. Accordingly IFNs and 
components of the IFN system are exploited clinically for different therapeutic 
indications [54]. Recombinant interferon is used to treat hairy cell and chronic 
myelogenous leukaemias, and has shown to be effective in reducing tumour cell mass 
and/or malignancy of several other cancer types [54]. Interferons are also used to limit 
viral replication and control hepatitis B virus (HBV), hepatitis C virus (HCV), and other 
chronic viral infections (herpes zoster, HSV and cytomegalovirus infections) [54]. One 
type of IFN (known as IFN-β) is effective at reducing episodes of relapsing–remitting 
Multiple sclerosis (MS), an inflammatory disorder of the central nervous system which 
results in demyelination of axons. The therapeutic use of IFN in inflammatory disorders 
is somewhat a paradox given IFNs are immunostimulatory cytokines. However, viral 
infection is postulated to be a likely contributory factor in the pathogenesis of MS and 
early studies did indicate that MS patients secrete less IFN than controls following viral 
infection [55]. Defects in IFN production also contribute to the aetiology of systemic 
lupus erythematosus (SLE), a systemic autoimmune disease. Unabated production of 
IFN is common in SLE patients as is the up-regulation of interferon stimulated genes in 
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the peripheral blood mononuclear cells (PBMCs) of the patients [56-57].  The cellular 
actions of interferons are mediated via their regulation of subsets of genes (known as 
interferon stimulated genes (ISGs)). Different classes of IFNs have largely overlapping 
gene targets, but they also induce distinct sets of ISGs. The transcriptional responses 
induced by two classes of interferons (type-I and type-II) form the basis of the 
investigations in Chapters-4 and -6.  
 
Classification of Interferons 
 
There have been three types of interferons identified, classified according to receptor 
specificity and sequence homology.  Type-I and type-II are by far the best characterised 
and studied interferons to date.  The most recent class of interferon like molecules are 
the IFN-λ molecules, IFN-λ1, λ2, and λ3 also known as interleukins IL29, IL-28A and IL-
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Type I Interferons Type II Interferons Other Interferons 
IFN-α1, -α2, -α4, -α5, -α6, -
α7, -α8, -α10, -α13, -α14, -




IFN-δ *, IFN-ε, IFN-κ, IFN-τ **, 
IFN-ω 
 
IFN- ζ zeta? 
 
* described only for pigs 
** described only for cattle 













Viruses, some intracellular 
bacteria, protozoans, other 
cytokines. 
Induced by: 
Antigen stimulated T-cells, 
Natural Killer (NK) cells, 





increase MHC class I 
expression. 
Functions: 
Antiviral, increase MHC I and 
II expression, growth and 




Table 1.2: Summary of different classes of interferons. An overview of the three different classes of 
interferons including the different types of interferons in each class, their chromosomal location origin, 
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There are two main classes of type-I interferons; IFN-α and IFN-β. In humans there are 
13 known subtypes of IFN-α, and one class of IFN-β [58]. All type-I subtypes share 
considerable structural homology. In contrast to type-I interferons there is only one 
type-II IFN; IFN-γ (originally termed macrophage-activating factor) that is structurally 
unrelated to type-I interferons. Type-I interferons are synthesised in direct response to 
viral infection. Type-II interferons on the other hand are synthesised in response to 
recognition of infected cells by CTLs (CD4+ T helper 1 cells (Th1) and CD8+ T cytotoxic 
lymphocytes) and NK cells. There is now also evidence that other cells types such as B-
cells, NKT cells and professional antigen presenting cells may also secrete IFN-γ [59]. 
All type-I IFNs bind a common cell surface receptor; the type-I IFN receptor and IFN-γ 




Macrophages stimulated with IFN-γ induce direct anti-microbial and anti-tumour 
mechanisms in addition to up-regulating antigen processing and presentation 
pathways [59].  Additionally this cytokine can direct growth, maturation, and 
differentiation of many cell types as well as orchestrating leukocyte attraction. IFN-γ 
increases the expression of Fc receptors for IgG on macrophages and is the only type 
of interferon capable of efficiently up-regulating the MHC Class II expression on a 
variety of cells, and in turn promoting peptide-specific activation of CD4+ T cells [59-
60].  IFN-γ is a key factor required for the ‘classical’ activation of macrophages.  
 
The IFN-γ receptor is comprised of two ligand binding chains (IFNGR1) associated with 
two signal transducing (IFNGR2) chains. Both receptor chains lack intrinsic kinase / 
phosphatase activity and therefore associate with other signalling machinery for signal 
transduction. Arguably the best characterised association is with the JAK-STAT 
signalling cascade. The IFNGR1 intracellular domain contains binding motifs for JAK1 
(Janus tyrosine kinase) and the intracellular region of IFNGR2 contains a binding motif 
for recruitment of JAK2. A phosphorylated IFNG-receptor complex can then transduce 
signal by phosphorylating the signal transducer and activator of transcription (STAT)1 
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on the tyrosine residue at position 701 (Tyr701) [61]. This phosphorylation then results 
in the formation of STAT1-STAT1 homodimers that translocate to the nucleus and bind 
IFN-γ activated sites (GAS) elements in the promotors of certain target genes. The 
transcription of type-II dependent genes is regulated by these GAS elements. Figure 































Figure 1.3: Simplified overview of signalling events following type-I or type-II interferon receptor 
activation. The pathway diagram is depicted using the modified Edinburgh Pathway Notation (a 
graphical notation for biology discussed in Chapter-3), and describes the series of events following type-I 
and type-II receptor engagement with their respective ligands. Type-I receptor activation leads to the 
auto-phosphorylation of the type-I receptor complex, which can then phosphorylate STAT2. 
Phosphorylated STAT2 can combine with STAT1, IRF9 to form the archetypal type-I transcription factor 
ISGF3. The activated type-II receptor complex phosphorylates STAT1, which is then capable of forming a 
STAT1 homodimer, or a complex of STAT1:STAT1:IRF9. The resultant type-I and type-II transcription 
factors bind to specific elements in the ‘interferon stimulated’ genes they target. Overlap between the 
transcriptional targets of type-I and type-II signalling exists.  




Type-I IFNs are secreted at low levels by almost all cell types. Viral infection is generally 
the classical stimuli for IFN-α or IFN-β production.  Hematopoietic cells are the major 
producers of IFN-α, whereas fibroblasts are the major source of IFN-β. IFN-β is also 
produced by macrophages under appropriate stimuli [59].  
 
As with the IFN-γ receptor, the type-I receptor also comprises multi-chain structures 
which are composed of at least two distinct subunits: IFNAR1 and IFNAR2. The IFNAR1 
subunit is constitutively associated the tyrosine kinase 2 (TYK2), whereas IFNAR2 is 
associated with JAK1. The initial step is activation of the receptor associated JAK(1), 
which occurs in response to a ligand dependant rearrangement and dimerization of 
the receptor subunits. The activated receptor complex then phosphorylates STAT2 and 
from this a key type-I transcriptional complex ISG factor 3 (ISGF3) is formed. ISGF3 is 
composed of the phosphorylated (and activated) STAT1 and STAT2 along with the 
interferon regulatory factor (IRF)9. This complex binds specific elements known as IFN-
stimulated response elements (ISREs) that are present in the promotors of some ISGs. 
As well as activation of the classical JAK-STAT pathway, there is evidence that 
activation of the IFN receptor associated JAKs may regulate (directly or indirectly) 
other downstream signalling cascades such as the mitogen activated protein kinase 
p38, and phosphatidylinositol 3-kinase signalling pathways [58].  
 
 
The Post Genomics Era and its Technologies 
 
The post-genomics era refers to the period following the sequencing of the human 
genome [62-63] a milestone in genomic research. This era has seen the has seen the 
emergence of novel functional genomics techniques and the significant improvement 
in existing technologies, not least; high-throughput DNA sequencing, DNA microarrays, 
high-throughput cell based assays, improvements in mass spectrometry, the discovery 
of RNA-interference (RNAi), cap analysis gene expression (CAGE) for predicting 
transcription start sites, and two-hybrid screening. Essentially the post-genomic era 
                                                                                                       Chapter 1: Introduction 
23 
has witnessed an exponential increase in available data facilitated by the increasing 
ease of gathering genomic and other high-through-put data. Consequently the fields of 
computational-biology and bioinformatics have also grown rapidly over the years. The 
premise of post-genomic research has been the transformation medicine and drug 
discovery. To achieve this end, the challenge lies in managing, interpreting and 
integrating the different data-sets to better understand the system of interest.  
 
RNAi and gene expression microarrays are two investigative tools central to the studies 




RNA interference (RNAi) is a naturally occurring mechanism for gene regulation found 
in many eukaryotes [64]. The pathway used in this system is now exploited routinely in 
the biological sciences for investigating the role of various genes in a given cell or 
condition. The RNAi pathway involves small non-coding RNAs (e.g. exogenously 
introduced short interfering RNA (siRNA) or the endogenous microRNA (miRNA)) 
which associate with nuclease-containing regulatory complexes, then pair with 
complementary mRNA, and in doing so prevent their expression. The RNAi process 
begins with the processing of long double-stranded RNA (dsRNA) (that is endogenous 
to, or introduced into, the cell), into small RNA duplexes by a ribonuclease III (RNaseIII) 
enzyme known as Dicer (reviewed in [65-66]). These duplexes are then unwound, and 
one strand (guide strand) is preferentially loaded into a protein complex known as the 
RNA-induced silencing complex (RISC). The RISC complex complete with loaded single-
stranded RNA (ssRNA), then directs the cleavage of messenger RNAs that contain 
sequence homologous to the ssRNA [65-66]. The endonuclease responsible for this 
cleavage has been identified as an Argonaute protein [67-69].  
 
Systematic knockdown of protein function by RNAi used in combination with 
molecular and cellular phenotyping analysis is a powerful technique for elucidating 
gene function. Commonly the approach is used to explore gene function in in vitro cell 
culture and in vivo in model organisms. Synthetic siRNA or short hairpin-RNA (shRNA) 
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are used to mediate the RNAi pathway in experimental settings. shRNA (a short 
sequence of RNA that makes a tight hairpin turn), can also be synthesized in vivo from 
RNA polymerase III promoters  [70-71]. shRNA are introduced into cells using a (viral) 
vector, allowing integration of the shRNA expression cassette into the host genome, 
and are therefore preferred in studies requiring long-term stable knockdown of 
targets [72]. siRNA tend to be easier to design and transfect than shRNA and so are 
generally preferred for screening experiments [72]. Moreover the dosing of silencing 
ssRNA is better controlled with the siRNA method [72]. 
 
Application of RNAi as a therapeutic is also being considered with great interest since 
it would potentially provide a powerful method for inhibiting any gene whose 
expression and protein product may contribute to disease [73-74]. Consequently RNAi 
has unveiled the opportunity to manipulate a vast number of disease targets that are 
otherwise currently intractable to traditional small-molecule and protein based 
intervention approaches. Macrophages are particularly attractive targets for (gene) 
therapeutic interventions given their central role in a wide variety of biological 
processes and pathologies. 
 
There are however a number of obstacles to be addressed in order for siRNA use to be 
successful both in vitro as a laboratory tool and in vivo as a therapeutic [75]. These 
include challenges in siRNA delivery, immune activation and immune mediated 
toxicities, as well as non-immune off target effects. Initial studies in mammalian cells 
suggested that siRNA are specific and small enough to evade immune detection [64]. 
Others went on to report inadvertent effects such as activation of the interferon 
response at even low siRNA concentrations [76-77], and mRNA degradation mediated 
by partial sequence complementation [78-79]. A range of strategies have been 
deployed to design stable, specific synthetic siRNAs which circumvent immune 
activation and off target effects. These include computational screening of potential 
siRNA sequences to avoid use of known immuostimulatory sequences and those with 
a high potential for off target effects [80-81], as well as structural and chemical 
modifications to the siRNA [82-85]. 
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Microarrays for Gene Expression Analysis 
 
Microarrays permit the comprehensive and simultaneous analysis of nucleic acid 
sequences [86]. The most common applications of DNA microarrays are for measuring 
changes in gene expression level and for detecting or genotyping single nucleotide 
polymorphisms (SNPs).  Arrays comprise of DNA probes which are generally 
immobilised onto a solid surface (e.g. glass slide, silicon chip or microscopic beads). 
Probes are generally either spotted cDNA or commonly oligonucleotides and are 
designed to interrogate specific gene or intergenic sequences (or polymorphisms) in a 
given organism. The probes for assaying gene expression i.e. mRNA transcript 
abundance are commonly designed to detect cDNA/cRNA generated from total RNA 
samples. The general procedure for expression analysis by microarrays involves the 
fluorescent labelling of samples, which are then hybridised to the microarrays under 
specific conditions. The arrays are washed to eliminate non-specific binding to probes 
and are scanned to determine fluorescent signal at all probes. The signal strength at 
each probe position corresponds to amount of complementary target bound. Raw 
signal data from multiple microarrays (to be compared) is subjected to a normalisation 
step to make adjustments for systematic/technical errors introduced when batch 
processing arrays e.g. differences in scanning or hybridisation. 
 
The very first miniaturised microarray could assay 45 gene sequences of Arabidopsis 
thaliana [87]. Subsequent advances in microchip technology as well as the growing 
availability of sequence data for complex genomes, facilitated the development of 
more comprehensive microarrays. Current microarrays technology can interrogate all 
known and predicted genome sequences as well as individual exons.  Multiple probes 
may be used to target a given sequence. For example the Affymetrix Human 1.0 ST 
array is comprised of 764,885 distinct probes targeting 28,869 well-annotated genes.  
 
As microarray analysis developed, standards for recording information about 
microarray experiments were proposed [88]. Commercially available microarrays are 
now relatively inexpensive, robust and reproducible. Moreover, microarray data has 
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existed for over a decade; giving time for researchers to develop and debate analysis 
techniques to analyse this data. Indeed there is some debate as to whether 
microarrays will eventually become obsolete with the emergence of an alternative 
method for gene expression analysis; RNA-Seq (or Whole Transcriptome Shotgun 
Sequencing) [89]. RNA-Seq in principle can provide a more accurate measurement of 
transcript levels, makes no prior assumptions of sequences, and has become more 
affordable in recent years [90]. As with many high- throughput technologies, RNA-Seq 
analysis also faces a number of challenges, not least the computational management; 
from storage, processing, and optimal methods for data analysis.    
 
Systems Biology  
  
What is Systems Biology? 
 
 
The traditional (or reductionist) approach to biology has centred on dissecting the 
properties of individual genes/proteins and their contribution to the operation of a 
process. Systems biology is a paradigm and discipline centred on the comprehensive 
quantitative analysis of all the components of a biological system and how their 
interactions influence the properties of a given system (or process). The holistic 
systems-level approach to modelling and analysis has been fostered by technological 
advances in high throughput technologies as well as breakthroughs in functional 
genomics techniques (discussed earlier). In fact, managing, mining and interpreting the 
mountains of available data arguably requires a systems level approach.   
 
The ‘system’ in question can range from signalling networks, a cell, tissue, organ, 
organism etc. Systems are comprised of networks of interacting components. For 
example protein and gene regulatory networks are fundamental to the operation of a 
cell. The chief motivation and objective of systems biology is therefore to identify the 
components of a given system and how they interact with each other, in order to 
understand and/or predict emergent behaviour of the system; that is behaviour which 
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cannot be predicted from analysing individual components [91]. The premise of these 
endeavours is that it should eventually be possible to (i) predict the behaviour of a 
system in response to perturbation and (ii) redesign/perturb the systems-model to 
create new emergent properties [91]. If these points are eventually achieved they 
would revolutionise the fields of preventative medicine and drug discovery.  
 
In practice systems biology often refers to efforts to both model systems both in terms 
of defining the interactions between the components of a system and computationally 
modelling its activity, as well as new approaches to interpreting and mining biological 
data derived from genome-wide studies.  
  
Systems Level Analysis of Immune Signalling 
 
A ‘systems-level’ approach is particularly suited for better understanding complex 
biological systems and processes (e.g. immune signalling, neurobiology). Although it is 
becoming increasingly evident that systems based challenges permeate all areas of 
biology and medicine.  Emergence, robustness and modularity have been identified as 
three key concepts central to systems biology [91]. All of these concepts are relevant 
to our understanding of immune signalling and macrophage biology. Emergence 
relates to system properties which cannot be explained by the activity of individual 
components alone e.g. the activation status of a macrophage depends on the balance 
of activity of numerous proteins. Robustness refers to the maintenance of phenotypic 
stability in spite of perturbations. Robustness is a critical feature of the immune system 
which must be adaptable to environmental fluctuations and tolerant to errors, in order 
to contend with various challenges posed by microbes. Finally in biological systems, 
modularity describes networks of components e.g. proteins/genes that interact 
together in undertaking a common function [91].  Signalling pathways comprise 
networks of interacting proteins, and in the macrophage regulation of transcriptional 
networks is vital in defining the phenotypic properties of the cell.  
 
There are now numerous systems-based approaches to studying the immune system 
and macrophage biology which have been employed (reviewed in [92]). These include 
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a number of initiatives to collate data and investigate immune signalling systems and 
pathways; examples including  the INTERFEROME database of interferon gene targets 
[93], the Alliance for Cellular Signaling collaborations [94], the LIPID MAPS consortium 
[95], the Inflammation and Response to Injury Project [http://www.gluegrant.org/], 
the DC-ATLAS resource for interpreting high-throughput data generated from dendritic 
cells [96], and the Innate Immunity Project [www.innateimmunity-
systemsbiology.org/], to name just a few.  
 
The macrophage possesses a host of features which render it an attractive if not vital 
target for ‘systems-level’ analysis [97]. These features include; the substantial range of  
well characterised signalling pathways; the plasticity of the cell; the relative ease of 
obtaining and culturing primary macrophages (from human blood, mouse bone 
marrow and peritoneum); the availability of macrophage-like immortalised cell lines; 
and crucially the clinical significance and therapeutic appeal the macrophage holds 
[97]. Whilst the ability to perform quantitative and qualitative measurements on the 
cellular components of the macrophage has increased massively, as has knowledge on 
how they interact with each other. The challenge still remains in converting these 
observations into detailed systems-models. However, without such models we cannot 
hope to truly understand macrophages or indeed any other cell at a systems level. 
Detailed and well characterised models of the signalling pathways, disease processes 
active in the macrophage are still scarce. Other key challenges in deploying the 
systems-level approach include standardising datasets, and integrating different levels 
of data (e.g. transcription, protein expression, kinetic data) to build and inform system-
models. Defining modularity, especially the transcriptional networks activated in 
macrophage and how these relate to the phenotypic properties of the cell is essential 
in understanding the heterogeneous behaviour of this cell.   
 
Pathway Modelling  
 
Interest in ‘pathway biology’ has never been greater as we struggle to comprehend 
cellular systems from a combination of targeted studies and the deluge of data flowing 
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from ‘omics platforms. This is reflected by the escalating efforts to assemble pathway 
diagrams [98-102], develop standards for depicting pathways [103-106], software to 
support their construction [107-109] and exchange [110-112], and the development of 
approaches to model and predict pathway behaviour [113-115]. Whilst arguably there 
is no such thing as a pathway only one big integrated network of molecular 
interactions, it is still useful to think in terms of pathways as being connected modules 
of this network. As such a pathway may be considered to consist of a specific biological 
input or event that initiates a series of directional interactions between the 
components of a system leading to an appropriate shift in cellular activity. As we begin 
to appreciate the potential complexity of these molecular networks, there is increasing 
interest in modelling pathways in order to expand our understanding of biology from 
the traditional gene-centric view of life, to a systems level appreciation of biological 
function. 
 
Much of this work describing pathways and their interactions remains locked in the 
literature where specific insights into pathway function are subject to the semantic 
irregularities that come with their description by different authors. Pathways are 
understood more generally by their description in reviews and diagrams produced on 
an ad hoc basis. Whilst such diagrams are clearly useful aids to understanding specific 
cellular processes, even at their best, they are not sufficient by themselves, relying on 
extensive textual descriptions to explain what is shown pictorially. Furthermore these 
pathways are rarely available as a cohesive network with pathway diagrams usually 
focusing only on a small part of a biological system which often reflects the curator’s 
bias, such that the ‘same’ pathway described by different individuals may share little in 
common. In this sense pathway resources offer a fragmented view of systems with 
some proteins or metabolites being members of numerous pathways; the concept of 
pathway membership being a highly subjective division. Figure 1.4 shows the apoptosis 
pathway as curated by four different sources and underscores some of the issues with 
current pathway depiction.  Whatever the source of these pathways and networks 
they generally suffer from graphically poor representation with ambiguity around the 
precise identity of what is being shown and the exact nature of their interaction. 





Figure 1.4: Apoptosis pathways curated and assembled by four different sources. The ‘same’ pathway 
may share little in common in terms of layout, pathway components, standard graphical notation and 
nomenclature systems (if any used) for pathway components. (a) Apoptosis Pathway as extracted from a 
review article; Johnstone et. al 2008, Nat Rev Cancer. (b) Mitochondrial Control of Apoptosis, taken from 
www.cellsignal.com/pathways/apoptosis-signaling. (c) Apoptosis Signalling as portrayed by Ingenuity 
Systems a commercial queriable pathway resource. (d) Apoptosis as taken from KEGG (Kyoto 
Encyclopaedia of Genes and Genomes) Pathways.  In all cases these clearly highly simplified 
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In order to escape the gene-centric view of biological systems, requires the 
development of better ways to order and display our knowledge of protein 
interactions and the systems they form. Moreover the creation and developments of 
standards is essential to enhance and permit the exchange of pathway knowledge. 
Until very recently biology has lacked standardised graphical notation schemes for 
illustrating pathway information [103, 116-118], and even now these standards are still 
being developed and are far from universally applied. Formalized diagrams (i.e. those 
constructed using a graphical language) act as a visual representation of the 
interactions between cellular components and provide a valuable resource for 
modelling network structure and the dependencies between components [119]. In 
addition, pathway models are an invaluable resource for interpreting the results of 
genomics studies [120-126], for performing computational modelling of biological 
processes [115, 127-130] and fundamentally important in defining the limits of our 
existing knowledge. Large integrated diagrams of metabolic pathways have been 
available for many years, for example Gerhard Michal’s classic biochemical pathways 
wall chart first published by Boehringer-Mannheim in 1968. Such pathway diagrams 
are inevitably complex, but potentially liberate the user to explore the 
interconnectivity between what might be seen as separate pathways and get an 
overview of topology of the system as a whole. In contrast, the assembly of detailed 
diagrams of signalling pathways as integrated networks rather than a series of 
disconnected views has been little explored.  
 
To gain a better understanding of a heterogeneous cell such as macrophage will 
require characterisation of its constituents and how they interact over time. As with 
many biological systems, certain macrophage pathways are very well characterized 
whereas little is known about many others. Even where pathway domain knowledge 
does exist however, it is generally fragmentary and subjective. Chapters-2 and -3 will 
explore means of creating a macrophage pathway resource and the in silico 
representation of the biological interactions underpinning the activity of this cell.  
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Networks in Biology 
 
Visualisation and analysis of biological data as networks is now becoming a widespread 
and increasingly important approach in biological and medical research [131]. In 
classical graph theory, a network (or graph) consists of nodes connected by edges.  For 
biological networks the nodes may represent a biological entity (for examples genes, 
proteins, organisms) and the edges denote a type of relationship or interaction (for 
example protein-protein binding, metabolic coupling, genetic origin as well as 
experimentally determined similarities). Biological relationships analysed using 
networks have included; sequence similarity, protein structure, protein interactions 
and evolutionary relationships [132-134].  Most biological networks tend not to be 
random, but follow a series of basic organizing principles in their structure and 
evolution. This also applies to other natural networks, as wells as technological and 
social systems, and distinguishes them from randomly linked networks. The structure 
of such “non-random” networks can provide insight, often overlooked by other 
methods of data representation.  
 
Many biological networks show a high degree of clustering i.e. highly interlinked local 
regions in the network or topological modules [131].   A number of network-clustering 
tools, designed for identifying such modules have emerged over recent years [133, 
135-137]. The clustering technique has performed exceptionally well for analysis of 
protein-protein similarity networks [133] and demonstrated that clustering nodes 
according their graph context, rather than iterative pair-wise clustering has great 
potential for the discovery of novel aspects of biological function.  
 
 
Network Based Approach for Gene Expression Data Analysis 
 
 
Traditionally statistical methods have taken precedence for the analysis of microarray 
transcriptomics data. These pair-wise comparison methods can include fold 
change/significance analysis between two or more conditions e.g. between treatment 
vs. controls.  Whilst statistical methods are often viewed to be rigorous, there are 
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certain caveats to reliance purely on statistics for microarrays experiments, especially 
those with a large and varied number of treatment conditions. For example statistical 
methods ideally require multiple replicates of a condition to determine the significance 
threshold of a result. This can become inherently expensive and impractical for large 
scale screens or experiments with many conditions. There are also often limitations on 
the quantity of data that can be presented in an intuitive manner. In many cases the 
most changing transcripts (one condition vs. another) will be determined and much of 
the remaining data overlooked. Furthermore the individual sample by sample 
comparison approach does not take into account the relationship of all the data 
samples or arrays to each other.  Correlation based methods whereby cohorts of genes 
related in their behaviour across a data set are identified, are also a commonly applied 
approach in expression analysis. 
 
Although network analysis is proving to be valuable for the analysis of a range of 
biological data, its application for examining microarray gene expression data has until 
years recently been overlooked, possibly due to lack of supporting software tools. 
However the general quality, abundance and high-dimensional nature of expression-
data make it compatible with network analysis [138]. Typically microarray expression 
data consists of many thousands of measurements of relative transcript abundance 
and depending on the study these measurements are derived from a few to several 
thousand biological samples [139]. The collection of expression values of any given 
transcript across the samples of interest is referred to as its expression profile. The 
network paradigm for the analysis of gene expression data is based on defining the 
level of correlation (degree of similarity) between expression profiles of different 
transcripts. The basic principles of generating and analysing gene-expression networks 
are described below. 
 
Basic principles of correlation based network analysis for gene expression data 
 
For the purpose of gene expression analysis in this thesis I have applied a network 
based approach to explore the microarray data generated by this project.  Generation 
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of network graphs from gene expression data has used the Pearson correlation 
coefficient as a measure of similarity between expression profiles, where an 
expression profile is defined as the collection of numerical data values (expression 
values) of an individual probe or probe-set targeting a defined transcript, derived from 
the range of samples being investigated. Pair-wise Pearson correlation coefficients are 
calculated for every transcript represented on the array, and each calculation then 
defines the strength of a relationship between two transcripts or in essence provides a 
similarity score between their expression profiles between +1 (perfectly correlated) 
and -1 (negatively correlated). Correlation coefficients above a predefined threshold 
can be used to draw edges between genes (nodes) and generate a network graph of 
expression relationships. Figure 1.5 provides a simple worked example of a correlation 
based gene expression network.  
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Figure 1.5: Example of a network graph consisting of nodes (genes) and edges (correlation between 
the genes). (a) The network graph has not been filtered so all Pearson correlation relationships are 
displayed, therefore all nodes (genes) form connections with each other. (b) The network graph has 
been filtered so only Pearson correlations above a threshold of 0.7 are displayed. Consequently the 
network is connected by fewer edges, defining only relationships above 0.7. In this scenario Gene 5 does 
not form part of the main network, since all of its relationships with other genes fall below the 0.7 
Pearson correlation filter, indicating that its expression profile is poorly related to the other genes.   
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Expression data can be influenced by both biological variations across the samples and 
by technical artefacts. However generation of these network graphs from expression 
data makes no prior assumption of experimental variables, including design, 
normalisation method, microarray platform or even the questions being addressed by 
the study. Thus in essence this approach provides a truly unbiased view of the data.  
 
BioLayout Express3D is a software tool designed specifically for the visualization, 
clustering and analysis of large network graphs in two- and three-dimensional space 
derived primarily, but not exclusively, from biological data [138-139]. The tool had now 
been optimised so it can render graphs of approximately 45,000 nodes in size 
(connected by ~5,000,000 edges, although this is hardware dependant) and also has an 
inbuilt application for clustering graphs using the Markov clustering (MCL) algorithm 
[137]. The MCL algorithm is an unsupervised approach for sub-dividing graphs non-
subjectively into discrete sets of genes sharing similarities in their expression, 
otherwise known as clusters (or graph modules). Clusters are defined on the basis of 
node connectivity and edge weight (strength of relationships). Consequently nodes 
(transcripts) contained within clusters are in close proximity in the graph and are highly 
related in their expression profiles. The MCL algorithm can be adjusted by use of an 
MCL-inflation value, to alter the stringency of the cluster membership and 
consequently the granularity of clustering. The higher the MCL inflation value is set, 
the stronger the correlation (in pattern of expression) between the cluster members. 
Although this also reduces the size of clusters within the graph as modules are sub-
divided further based on their graph context.  
 
 
Previous Use of Network Based Approach for Interpreting Transcriptomics 
Data 
 
BioLayout Express3D is a network analysis tool that has been specifically designed for 
the analysis of gene expression data and is especially suited for large and complex data 
sets. It has now been utilized in the analysis of a number of published studies 
                                                                                                       Chapter 1: Introduction 
37 
addressing a range of biological questions [140-144].  In order to explore the network 
based approach for analysis of transcriptomics data and to gain a better understanding 
of the transcriptional profile of macrophages I have contributed to the analysis of a 
number of gene expression datasets [145-147]. This includes a large data set assaying 
gene expression across 44 purified primary mouse cell populations or untransformed 
cells and two mouse organs; the spleen and mesenteric lymph nodes [145].  The 
approach allowed the concurrent analysis of 20,346 nodes (transcripts), and their 
relationships (944,650 edges) in one network graph (Figure 1.6), a scale that would 
otherwise be unattainable using other methods or network tools. From the network 
graph it was possible to extract a number of interesting observations; firstly that some 
patterns of expression i.e. clusters of transcripts were specific to particular cell types 
(Figure 1.6), some of which may prove to be markers for those cells.  In other cases 
some of the clusters appeared to be associated not with cell lineage but with broad 
biological processes. This not only provided insight into the processes shared or 
specific to cohorts of cell types, but also demonstrated the potential to characterise as 
yet un-annotated proteins since the likely function or process in which they are 
involved can be inferred by their co-expression with genes encoding proteins of known 
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Figure 1.6: Network analysis of mouse transcriptomics atlas (extracted from Hume et al., 2010). 
Samples of 44 mouse cell populations and 2 tissues (lymph node, spleen) were collected and analysed 
on Affymetrix MOE430 2.0 arrays in duplicate, see GEO dataset: GSE10246 (www.biogps.org). Results 
were normalised using the MAS5 algorithm and the tool BioLayout Express3D used to calculate pair-wise 
Pearson correlation coefficients for every transcript represented on the array. A network graph of 
20,346 nodes (transcripts), connected by 944,650 edges was generated by filtering data to display only 
Pearson correlation relationships (between transcripts) of 0.8 or above. The resultant graph was then 
clustered using the Markov clustering algorithm with an inflation value of 2.2 resulting in 812 clusters 
containing > 4 nodes. Examples of these clusters, shown isolated from the main graph alongside the 
average expression profile of the transcripts that make up the cluster. The number of transcripts in each 
cluster is shown bottom right next to the graph of the cluster. Transcripts belonging to the five example 
clusters are largely expressed in specific cell types and/or under specific conditions i.e. LPS activation of 
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The network based approach had also been used to assess genome wide changes in 
transcript abundance in response to targeted RNA-interference induced suppression of 
the expression of a number of key genes associated with IFN signalling in murine 
macrophages prior to stimulation with mouse IFN-γ (Figure 1.7) [146].  The original 
objectives of this investigation were to further our understanding of the mechanism by 
which certain ISG’s contributed to the protective effect of IFNγ during viral infection by 
targeting the genes with siRNA. However the act of siRNA transfection itself induced a 
type-I IFN transcriptional response, thus even in the absence of IFN-γ treatment IFN 
response genes appeared to be regulated. Moreover one cluster of regulated genes 
represented transcriptional changes occurring regardless of IFN-γ treatment. This 
cluster-(d) was enriched for type-I response genes. Interestingly six siRNA treatments 
(targeting Ifnb1, Irf3, Irf5, Nfkb2, Stat1, Stat2) perturbed the transcriptional networks 
associated with IFN signalling (Figure 1.7).  Some of these siRNA targets were known to 
act within the IFN pathway. The observations made by this study formed the basis of 
the follow up experiments described in Chapter-5. 
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Figure 1.7: Clusters extracted from a transcriptional network of expression data from RNAi treated BMDMs, and the median expression profiles of transcripts within 
the clusters (Taken from Lacaze et al., 2009). A network graph filtered at a Pearson correlation r ≥ 0.9 was clustered using Markov clustering algorithm at an inflation 
value of 2.2). 4a: Five main clusters of co-expression emerged containing genes influenced most by siRNA & IFNγ treatment. A consistent disruption of transcriptional 
activity of mouse BMDM was observed using six particular siRNAs (shaded in blue) targeting Ifnb1, Irf3, Irf5, Nfkb2, Stat1 & Stat2 mRNAs. 4b: Cluster 1 – 234 genes 
whose expression is induced by IFNγ and repressed by the six active siRNAs. 4c: Cluster 2 – 179 genes repressed by IFNγ but de-repressed by six siRNAs. 4d: Cluster 3 – 
67 genes whose expression is not influenced by IFNγ at 24 hour assay point but repressed by six siRNAs. Many of these are innate immune response genes 4e: Cluster 4 
– 86 genes de-repressed by siRNAs, many of which have known functional association with cell cycle 4f: Cluster 5 – 44 genes enriched with annotation for NF-kB 
signalling.  
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Aims and Objectives 
  
The overall objective of this thesis was to gain a better understanding of the signalling 
pathways underpinning macrophage activation (particularly in response to interferons) 
by applying a ‘systems-levels’ approach to biological modelling, data analysis and 
mining. Systems biology aims to escape the traditional gene-centric, reductionist view 
of biological investigations. This necessitates the development of better ways to order, 
display, mine, and analyse biological information, from the output of high-through-put 
‘omics technologies to our growing knowledge of protein interactions and the systems 
they form. Crucially these developments are necessary if we are to improve our 
understanding of complex and dynamic biological entities.  The work described in this 
thesis is associated with three main objectives: 
 
1. A wealth of literature describing the individual interactions of signalling pathways 
active in the macrophage currently exists. The challenge lies in capturing this 
information in a format with the potential for ‘systems-level’ analyses. Therefore an 
initial objective of this work was to develop a pathway resource of the signalling 
events active in the macrophage, particularly of receptor initiated pathways and 
type-I and type-II interferon signalling. Associated with this objective was the desire 
to explore and develop a graphical notation scheme for depicting biological 
concepts i.e. a language for drawing and exchanging pathway models.   
 
2. Pathway models are a working hypothesis of how a system may operate over time 
and under given conditions. As such, models must undergo cycles of iterative 
refinement to become more accurate and detailed. In this case evaluation of the 
pathway resource created, exposed its limited coverage of transcriptional events. 
Thus a second objective of these studies was to explore the transcriptional networks 
associated with macrophage activation in response to type-I and type-II interferon, 
as well as LPS; three stimuli which are considered to prime macrophages towards 
the M1-type activation state. Traditionally statistical fold-change cut offs and lists of 
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the most differentially expressed genes are the approach applied for expression 
analyses. However the objective here was to explore the use of network-based 
analysis and presentation for transcriptomics data derived from macrophage 
activation studies.  
 
3. Previous investigations by the group revealed that transcriptional networks 
associated with type-I interferon signalling, were perturbed using siRNA targeting 
genes which may act in the same pathway. In order to expand on these findings 
there was the desire to design and optimise a cell based assay to investigate the 
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Chapter 2. Construction of Large-Scale Diagrams of 








This and the following chapter present my work on one of the central challenges in 
pathway biology: How does one construct clear concise pathway diagrams of the 
known interactions between cellular components that can be understood by and 
useful to a biologist? In our efforts to understand the signalling cascades fundamental 
to macrophage biology, I have endeavoured (as part of the group’s efforts) to generate 
large integrated graphical models of these pathways.  
In recognition of the importance of documenting pathway knowledge, many efforts 
have been made to collate pathway knowledge, together with information derived 
from large-scale interaction studies and literature mining, into public and commercial 
databases [148-157]. These offer searchable access to pathway diagrams and 
interaction data derived from a combination of manual and automated (text mining) 
extraction of primary literature, reviews and large-scale molecular interaction studies. 
Whilst invaluable and in many ways the best we have, a major problem with these 
efforts is that the information content of these diagrams is frequently limited and 
visualizations of these systems are of variable and often poor quality; Pathway 
components are often labelled using inconsistent nomenclature systems and depicted 
using a variety of shapes (glyphs) to illustrate component ‘type’ (see Chapter-3). 
Furthermore, notation schemes used for pathway diagrams to depict one molecule’s 
interactions with another are not standard and are often limited in their ability to 
convey the exact nature of the relationship between components. Finally, pathway 
diagrams are generally highly subjective reflecting the curator's bias, such that two 
diagrams depicting the ‘same’ pathway may share little in common (see Chapter-1 
Figure 1.4). Together these factors commonly result in uncertainty as to what exactly is 
being shown. The diagrams thereby fail to fulfil their basic purpose – to provide a 
comprehensive and unambiguous picture of what is known about a pathway. In an 
effort to address some of these issues, a number of groups have suggested notation 
schemes for drawing ‘wiring diagrams’ of cellular pathways [103-105, 158]. The 
evolution of one of these notation schemes, the modified Edinburgh Pathway Notation 
(mEPN) forms the basis of discussion in Chapter-3). 
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During the course of this thesis I have been engaged in constructing process diagrams 
[102, 159] of pathways important in regulating macrophage immune biology and 
known to be activated in these cells during infectious and inflammatory disease. The 
eventual aim being of these efforts would be a pathway resource that would serve to 
inform and aid the interpretation of wet-lab analyses of this cell and would also have 
the potential to be applied for computational modelling. The task of converting the 
literature into understandable, unambiguous, and useful pathways diagrams posed a 
range of challenges. Examples of these included; deciding on reliable sources for 
collecting pathway interaction data, deciding what constitutes a valid interaction, and 
how and what interaction data to store, how to arrange pathway components in a 
diagram, as well as choosing a suitable software for assembling the diagrams. In order 
to address these challenges and define a suitable protocol for constructing pathways, I 
was assigned the task of assembling a pathway diagram of apoptosis signalling (or 
programmed cell death). At the time of embarking on this task, the existing pathways 
of apoptosis were highly abstract and ambiguous (Chapter-1 Figure 1.4). Apoptosis is a 
carefully regulated process in the macrophage and is controlled by a diverse range of 
cell signals; both intrinsic (DNA damage, organelle stress) and extrinsic (cytokines, 
pathogens). 
 
In constructing a model of apoptosis signalling it was necessary to establish some 
principle rules for assembling pathways. This stage of the pathway construction effort 
is described in Phase 1 of the results section. Essentially the lessons learnt from this 
process laid the foundations for generating further pathways of interest, and in an 
effort to better understand the signalling cascades fundamental to macrophage 
activation, I then constructed an integrated framework diagram of macrophage 
signalling encompassing the TLR (Toll-Like-Receptor), IFN (interferon), NF-κB and 
apoptosis pathways. These signalling events are of central importance in defining the 
macrophages response to pathogens and do so in a highly inter-dependant manner 
[160]. The results of these labours are presented below (Phase 2) and in Raza et al., 
2008 [102]. The framework diagram comprised 295 nodes including 140 proteins and a 
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total of 272 interactions. Although this coverage was an improvement on other 
available macrophage pathways at the time this was still a very limited view of 
macrophage signalling. However the pathway proved to be a useful and a desire to 
expand this into a more comprehensive and powerful resource led the group to 
construct additional diagrams of pathways active in the macrophage including; antigen 
presentation, MAPKinase, non-TLR pathogen detection, to name just a few. These 
pathways and the framework diagram were then amalgamated to generate an 
integrated network of macrophage pathogen recognition and detection systems. 
These efforts are presented in Phase 3 of the results and in Raza et al., 2010 [159]. The 
current macrophage diagram is to our knowledge the most comprehensive network of 
signalling events in the macrophage constructed using a formalised graphical notation 
[159].  
 
The pathways described were constructed using the Edinburgh Pathway Notation 
(EPN). In doing this another objective was to road test the Edinburgh Pathway 
Notation (EPN), (see Chapter-3) for its usability in portraying pathways.  By 
constructing these graphical models which encompass a diverse range of biological 
pathways and concepts, it was found necessary to refine the Edinburgh Pathway 
Notation (EPN) scheme as previously proposed [102, 105]. The current ‘modified’ EPN 
(mEPN) scheme has been arrived at through extensive use and testing and is described 
in Chapter-3 and at http://www.mepn-pathway.org/ [116].  
 
The macrophage pathway models presented here, explores some of the challenges 
associated with meeting the various demands of a pathway diagram. The hope is the 
integrated pathway will prove to be a useful resource for macrophage biologists, as 









Phase 1: Evolution of pathway construction methodology 
 
When embarking on the task of pathway construction for the first time it was 
necessary to define a standard procedure for doing so. In fact the most time 
consuming aspect of the process was establishing the methodology of how to 
construct the pathway. Some of the crucial choices to be made were; deciding on the 
‘best’ software for the task; how to arrange pathway components; how to improve the 
aesthetics of the pathway to make it more readable; and how to adapt the notation 
where needed to better reflect the biology of the interactions; how to record the 
interaction data of the pathways. The phases of the early pathway construction efforts 





























Figure 2.1: A workflow diagram summarizing the early stage approach taken to assemble pathway 
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Some time was spent in exploring software options for constructing pathways. Initially 
pathways were constructed using a relatively new academic software; Edinburgh 
Pathway Editor (EPE) (http://epe.sourceforge.net/SourceForge/EPE.html). However at 
the time of use the EPE was still in its early phase of development and lacked a user 
friendly GUI (graphical user interface), required extensive use and testing to resolve 
software ‘bugs’ and had significant stability issues. There were also limitations on the 
spectrum of graphics available and the editing capability (such as changing size and 
colours). Essentially it would take some time before this software is capable of 
supporting the scale (and quality) of pathways we were hoping to construct. An early 
draft of an apoptosis pathway generated in EPE (Figure 2.2a), exemplifies the issues 
with visualising diagrams constructed in this editor and using the early draft of the 
EPN. Efforts were made to improve the ‘readability’ of the pathway (Figure 2.2b) for 
example by increasing text to the maximal size permitted by the software, 
standardising component sizes, and adding colour to reflect the type of component. 
However even this version appeared cluttered and complicated and the software still 
limited the graphical rendering of biological concepts. One such example being, sub-
cellular compartments could only be shown as blocks extending the width of the 
pathway. For this reason compartments such as the mitochondrion would be placed 
between the cytoplasm and nucleus. Therefore when components were shuttling 
between the cytoplasm and nucleus, edges defining this movement would also extend 
through the mitochondrion and in this way the translocation events of pathway 
components could easily be open to misinterpretation. 
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Figure 2.2: (a) Draft apoptosis pathway in Edinburgh Pathway Editor (EPE). Initial draft of the apoptosis 
pathway constructed using the original Edinburgh Pathway Notation (EPN) scheme and Edinburgh 
Pathway Editor software. The pathway runs from top (extracellular) to bottom (nuclear) with other sub-
cellular compartments shown as the background layers. Text, symbols, and arrowheads were difficult to 
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Figure 2.2: (b) An edited version of the draft apoptosis pathway in 2.2a. Text has been increased to 
maximal permitted size by the EPE software, as are notation symbols. Component sizes have been 
standardised and the use of colour is explored as a visual cue to assist with differentiation of 
components and interaction edges. Here proteins are coloured blue and protein complexes yellow. 
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Other network and pathway editing software including Cytoscape 
(www.cytoscape.org/) and Cell Designer (www.celldesigner.org/) were considered for 
the task but also suffered from a number of the following; limited graphics or 
restrictive support for notation schemes, limitations on the size of networks the 
programmes could support, unintuitive or complicated GUI’s and finally at the time of 
starting the pathway construction (2007) these software did not support automated 
layout of networks and edge routing (a very useful functionality, especially for large 
networks). Microsoft PowerPoint was also explored although for improving visual 
aesthetics of the pathway and was not appropriate as a pathway editing tool. Figure 
2.3 displays the apoptosis pathway illustrated using PowerPoint. This version 
demonstrated the pathways may benefit from running left to right rather than top to 
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Figure 2.3: The apoptosis pathway assembled in Microsoft PowerPoint. The pathway runs from left 
(extracellular) to right (nucleus) with some compartments displayed as entities within other 
compartments, e.g.  The mitochondrion and endoplasmic reticulum are placed within the cytoplasm. 
This arrangement allows for pathways to be more compact. Components can be aligned and arranged 
more precisely in this software than EPE. Although the visual aesthetics of the pathway have arguably 
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Eventually yEd (www.yworks.com), a Java2D generic graph editor was chosen for 
generating the pathway diagrams. The software was suited to the task for several 
reasons; it is available as a free download with no restrictions on its use, it is stable and 
‘bug’ tested prior to release of new versions, has an intuitive interface with exceptional 
navigation, visualisation, multiple import/export possibilities and supports large 
graphs. Additional features which made yEd particularly appealing as a pathway editor 
included its integrated data storage, various network presentation possibilities and 
numerous automated layout algorithms to assist with the arrangement of a networks 
nodes and edges. An extract of the apoptosis pathway generated using yEd (Figure 2.4) 
exemplifies the progress made in creating readable pathways (cf., initial pathways 








Figure 2.4:  Apoptosis signalling pathway constructed using the yEd graph editor. The pathway is 
arranged to flow from left to right. Components are coloured according to type (protein, complex or 
gene) and arranged within the sub-cellular compartments in which they are active. yEd grap editor 
serves as a pathway editing tool and has exceptional graphics for producing clear diagrams. This 
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Apart from helping to establish the best choice of software the process of re-
constructing the apoptosis pathway several times helped to uncover other obstacles 
with pathway construction that required addressing.  Crucially the evolving pathways 
demonstrated how basic changes to the aesthetics of the pathway could drastically 
improve its readability. The process of data collection for the apoptosis pathway raised 
a number of questions as to where to obtain ‘reliable’ sources of information of 
collecting interactions of the pathway. Extensive group discussions explored which 
repositories would be an acceptable source for pathway interaction. With a plethora of 
interaction data now available, ranging from established published interactions, 
predicted interactions based on functional associations, hits from yeast-2-hybrid 
screens, it was key to define how ‘inclusive’ the pathways should be.  Eventually it was 
agreed that only peer-reviewed published evidence, that explicitly cites an interaction 
would be used for the pathways. Although the pathways are designed to be a 
consensus of knowledge, if all sources of interaction data are included, integrity of the 
pathways is compromised and there would be the danger of creating an interaction 
network, rather than a pathways with a clear beginning and output.     
 
Another issue arising whilst collecting interaction data, was that a given protein may 
have several alias names, for example NFKB1 is also referred to as p50 in the literature. 
In terms of presenting pathway components it was therefore deemed essential to 
identify whether a protein/gene has already been captured under another alias name. 
It soon became obvious to us that a standard nomenclature scheme should be 
adopted to label pathway components. HGNC were chosen for this, given the potential 
application of the pathway for overlaying results of transcriptomics data.  
 
To summarize the main principles established during the task of constructing an 
apoptosis pathway were;  
 
(1) Pathways can be constructed to an acceptable standard using the freely 
available graphing tool yEd graph editor. 
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(2) To improve aesthetics of the pathway and in turn its readability; sizes of 
pathway components and text should be standardised.  
(3) Used carefully, the addition of colour can enhance the ‘readability’ of the 
pathways 
(4) Component layout should be performed manually or with the assistance of 
layout algorithms, however components can only be placed in their site of 
cellular activity, represented as predetermined areas (compartments) on the 
canvas. 
(5) A conventional naming scheme should be adopted for labelling pathway 
components to avoid ambiguity of what is being represented; in this case HGNC 
was chosen. 
(6) No interaction may be included within the pathway without published 
evidence. More than one paper may be used to support the same interaction 
(two or more is preferable).  
(7) Evidence of an interaction between one component and another should be 
stored in an interaction table. Evidence to support an interaction should be 
derived from the primary literature (and reviews). This must include the 
interacting partners, the direction of the interaction is inferred by order HGNC1 
-> HGNC2, the type of interaction (phosphorylation, cleavage), method, 
PubMed ID, site of specific change of state [P-Ser123].  
 
These principles now form the basis for assembling the pathway diagrams within the 
group and are described in more detail in the methods section of this Chapter. The 
process of ‘road-testing’ apoptosis pathway construction was crucial in defining some 
standard methodology for the task. However not all issues with pathway construction 
were identified at this stage. In practise some issues would only come to surface with 
greater experience of building pathways; for example when trying to model new 
biological concepts or when creating larger pathway diagrams or when combining 
diagrams of multiple but associated pathways. The next stage of the pathway mapping 
efforts was to model other pathways of interest in macrophage biology and combine 
them into one diagram by identifying links between these pathways. 
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Phase 2. Construction of a framework diagram of macrophage 
activation pathways 
 
The TLR (Toll Like Receptor), type-I and type-II IFN (interferon) signalling, NF-κB and 
apoptosis pathways are of central importance in defining the macrophages response 
to pathogens and do so in a highly inter-dependant manner [160]. In an effort to 
describe and consolidate knowledge of these signalling events, I set out to construct a 
pathway diagram based on published literature and using the EPN. Given the extensive 
cross talk between these pathways, they were combined into one integrated diagram. 
This initial framework map of macrophage activation [102] (Figure 2.5) a total of 295 
nodes of which 140 are proteins, 99 complexes, 44 genes, and 12 other components 
(pathogens, DNA, RNA etc).  A total of 272 interactions are described in the pathway 
map, of these 85 are binding events, 149 are various activation state modulations (67 
activation of gene expression, 26 phosphorylation, 7 auto-phosphorylation, 1 
dephosphoylation, 23 cleavage, 9 translocations and 16 activation by processes not 
defined). There are 10 inhibition reactions, 4 of these are inhibition of gene expression, 
3 are inhibition of cleavage, and 1 is an inhibition of translocation.  A total of 26 
translocation events occur as well as 2 protein dissociations.  282 different references 
support the interactions shown on the pathway. In many circumstances the same 
paper may describe multiple interactions, for example Chaudhary et al., (1997) report 
that both TNFRSF10A and TNFRSF10B recruit the protein FADD during apoptosis 
signalling [161]. 
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Figure 2.5: Framework integrated pathway map of signalling in the macrophage. The diagram includes 
the interferon signalling, NF-κB, apoptosis and toll-like receptor pathways, all represented as one 
integrated pathway due to their overlapping interactions. In general interactions of the interferon 
response pathway are in the top quarter of the map, with NF-κB directly below. Apoptosis is presented 
halfway down the map and toll-like receptor signalling is in the bottom quarter. 154 different protein or 
gene nodes are included in the pathway, along with 80 different complexes and 12 other molecular 
species (such as pathogens, DNA, RNA). The pathway diagram represents 272 different interactions. 
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The four signalling pathways were combined into one diagram since there is extensive 
crosstalk between them. Therefore, in order to check the integrity of the network each 
input (e.g. cytokine or pathogen molecule), was highlighted in turn and the logical flow 
of information from this input followed through the diagram.  By following the flow of 
information from each pathway input, a different but expected output was observed, 
be that the activation of transcription or a process such as apoptosis (Figure 2.6).  This 
suggests that although several signalling pathways have been integrated to form this 
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Figure 2.6: Follow through of signalling pathways stimulated by IFNG (a) and FASLG (b). The signalling 
events following the input signals of IFNG and FASLG have been highlighted on the entire map in lilac 
and orange, respectively. The nodes activated or directly affected by FASLG or IFN-gamma binding to 
their receptors are coloured and the interaction edges and gates are also highlighted. Nodes and edges 
not directly downstream of the FASLG or IFNG signalling are shown in grey. This figure demonstrates 
inputs into the pathway can clearly be followed to the expected outcome events. In the case of IFNG-
input, gene transcription is the resulting event, and in the case of FASLG, apoptosis. Furthermore these 
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Use of the Framework Pathway Diagram in the Interpretation of 
Transcriptomics Data  
 
In order to explore the utility of this framework pathway diagram in the interpretation 
of transcriptomics data, the transcriptional events following the treatment of mouse 
bone marrow derived macrophages (BMDMs) with interferon-gamma (IFN-γ) were 
examined (This data set is discussed in more detail in Chapter-4).  Using the network 
analysis tool BioLayout Express3D [162] a 3-D network of transcripts identified as being 
differentially expressed following IFN-γ stimulation was constructed. 1,491 transcripts 
were represented within the network.  Of the 154 unique proteins/genes represented 
on the pathway map, 58 of were represented within the transcriptional network.  All of 
the genes represented on the map were up-regulated in the data set.  None of the 
transcripts down-regulated in response to IFN-γ were present on the map. Clusters of 
transcripts representing genes activated at different times following treatment were 
then further collated into 3 groups of up-regulated genes; genes activated at (1) 1-2 
hours, (2) 2-4 hours and (3) 4-8 hours post-treatment.   Genes that were activated and 
included in the set of mapped genes were then highlighted on the map and the 
possible downstream consequences (assuming de novo protein synthesis and activity 
following an increase in gene transcription) were highlighted (Figure 2.7).  In this way it 
has been possible for the first time to interpret these transcriptional events in the 
context of the possible consequences of these observations. 
 
Using this data overlay approach onto the pathway it was possible to extrapolate some 
interesting observations by visualizing the changes and the possible downstream effect 
of the changes. It was also possible to appreciate the connectivity and co-dependency 
of the changes over time. Although the framework pathway at this stage did show 
much promise of being a useful resource for data interpretation the group was acutely 
aware that in its current form the diagram covered only a limited snapshot of activity 
in the macrophage. For instance only a relatively small number of the genes shown to 
be transcriptionally regulated following IFN-γ treatment were present on the diagram. 
Furthermore none of the genes shown to be down-regulated by IFN-γ are shown in the 
diagram.  




Figure 2.7:  The integrated framework pathway diagram presented at (a) 1–2 hours, (b) 2–4 hours and 
(c) 4–8 hours post-IFN-γ treatment. Differentially expressed genes are highlighted in red and the 
possible consequential downstream events resulting from the changes, (assuming de novo protein 
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The exercise of constructing the framework pathway was essential in order to define a 
process for doing so and to explore how best to graphically depict complex biological 
systems. During Phase 2 of this exercise the resulting pathway proved to be a valuable 
resource to the group and for others with an interest in macrophage signalling events 
[146, 163].  It was possible to demonstrate that despite the integration of several 
pathways the diagram still maintained integrity as to the biology being portrayed 
(Figure 2.6).   Furthermore, the pathway showed potential for being useful in the 
interpretation of transcriptomics data. However, it was apparent that the pathway 
provides just a snapshot of the processes active in the macrophage, as was evident 
from the IFN-γ-transcriptional response analysis, where only 58 of the 1,491 regulated 
transcript were represented on the map. As we explored more transcriptomics analysis 
performed on these cells it was apparent that a whole range of pathways regulated by 
different macrophage stimuli were absent from the diagram. It was also observed that 
the TLR representation was more simplistic than current knowledge, for example links 
with MAPKinase signalling were absent. Also pathways key to macrophage function, 
such as antigen presentation were not presented. 
 
In order to obtain a more comprehensive resource on macrophage signalling and to 
assist with the interpretation of genomics data derived from this cell, additional 
pathways of interest were assigned to a cohort of MSc students registered for an MSc 
in Genomics and Pathway Biology at the Division of Pathway Medicine, who were 
presented with the task of assembling the interaction networks of the following;  
detailed views of the TLR pathways, other pathogen recognition systems (RIG’s, NOD’s 
NALPS’s) , extensive view of NF-kappa-B signalling,  MAP-kinase cascades, MHC antigen 
presentation and proteasome assembly. A workflow for constructing pathways was 
established from the lessons learnt from constructing the original framework diagram 
as summarized in the schematic Figure 2.8. The pathways were then combined along 
with the framework diagram into one integrated network. I supervised the 
reconstruction of the TLR system and related pathways, oversaw the integration of the 
separate pathways into one network diagram, and participated in regular discussions 
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with other pathway constructers to assess the progress of the pathways and addressed 
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Figure 2.8: Pathway construction workflow. A workflow diagram summarizing the main stages of 
pathway assembly from concept to final diagram. Blue boxes portray the pathway construction phase. 
Each phase embodies a number of tasks (shown as lilac boxes or yellow-ellipses for data storage and 
processing), which when completed lead to progression towards the next stage of pathway construction 
(connected by green arrows). Red arrows indicate feedback to a previous construction phase. Lilac 
boxes describe the construction steps required pre-pathway assembly, whereas green boxes are linked 
to post-construction phases and describe the possible applications of the constructed and validated 
pathway diagram. 
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Phase 3. A large scale integrated map of macrophage pathogen 
recognition and effector systems 
 
The work described in this section followed in the footsteps of earlier efforts to 
construct process notation diagrams of macrophage pathways [99-100, 159]. In the 
course of phase 3, solutions were sought to issues associated with the depiction of a 
variety of different biological systems, combining diagrams from multiple curators and 
the layout and integration of a large network model of these systems. Teams of 1-2 
junior biologists (MSc students) were given a remit to describe a given pathway system 
using the mEPN scheme [116]. The signalling systems were chosen based on their 
significance to macrophage biology and/or the group’s interest in interpreting the 
results of tanscriptomics studies.  Macrophages are professional antigen presenting 
cells, however these pathways were missing entirely from the framework diagram. 
Therefore antigen processing and presentation was assigned as one remit. Closely 
linked to this pathway was unbiquitination and proteasome assembly, which also 
appeared to be regulated transcriptionally in response to a number of macrophage 
stimuli, however very few detailed pathways of these systems existed in the public 
domain. The framework diagram also lacked coverage of non-TLR-pathogen 
recognition systems, and the existing TLR system required further expansion, including 
links with other pathways such as MAPkinase signalling. The group also had a desire to 
contextualise gene expression results showing many members of the NF-κB family to 
be regulated, however the framework diagram only incorporated the most well 
characterised NF-κB members and pathways. Therefore an expansion of the NF-κB 
systems was undertaken and the results of this labour highlighted how simplistic the 
original views of this signalling system were. Once all individual pathways had been 
assembled by individual teams of curators, they underwent extensive editing in 
attempt to unify their notation usage, stylistic qualities and overall appearance. The 
original pathway diagram [102] was then used as a framework on to which the new 
pathways were connected. The final product of this labour provides what is to date the 
most comprehensive model of macrophage signalling in the public domain and one of 
the largest examples of a pathway constructed using a formalised graphical notation 
scheme. 
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Integrated Pathway Diagram 
 
The pathway diagram presented here (Figure 2.9, also available at 
http://www.macrophages.com/macrophage-pathway-resources) is a consensus view 
of a number of pathway modules assembled based on the interpretation of the 
literature describing these systems. A given interaction between components of the 
pathway may be supported by evidence derived from one or more publications and a 
publication may provide evidence supporting more than one interaction. A total of 
1,000 different interactions have been recorded, supported by 728 different original 
papers and reviews (the full list of interactions and supporting publications at 
http://www.macrophages.com/macrophage-pathway-resources). The network 
diagram is comprised of 2,170 nodes connected by 2,553 edges. The diameter of this 
network (maximum distance from one node to another) is 58 and there is an average 
node connectivity (number of inputs/outputs) of 2.37 (max 37). A detailed breakdown 
of the class (type) of the nodes that make up the diagram is shown in Figure 2.10. 
Briefly, 496 unique proteins are represented in the diagram many of which are shown 
to go on to be modified into different forms or bind together resulting in 412 different 
complexes. 81 genes are shown to be transcriptionally regulated by these pathways 
based on known associations between transcription factors and target genes. The 
interactions between these components are represented by 552 process nodes, 120 
Boolean logic operators and 158 edge annotations. The pathway is drawn using the 
mEPN scheme, a full description of which can be found in Chapter-3 and on 
www.mepn-pathway.org  and in Freeman et al., 2010 [116]. The macrophage-related 
pathways are also available through www.macrophages.com. 
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Figure 2.9: Integrated pathway diagram of innate immune and macrophage activation pathways.  
The modified Edinburgh Pathway Notation (mEPN) scheme is used to describe the interactions of 
signalling pathways active in the macrophage. A total of 2,170 components in this network are 
connected by 2,553 edges. Components include 496 unique proteins, the complexes formed between 
them (412), 181 genes/ DNA/ promotor regions, in addition to other molecular species (e.g. pathogens, 
drugs, RNA) and the nodes representing the processes in which the components are involved. 
Components are arranged to reflect the location in which they are active and background colour is used 
to distinguish between different sub-cellular locations. 
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Description of the Biological Content of the Integrated Pathway Diagram 
 
The pathway diagram presented (Figure 2.9 and 
http://www.macrophages.com/macrophage-pathway-resources) incorporates detailed 
views of some of the best characterized pathways associated with macrophage-specific 
biology, as well as some that are generic but in some way linked to the activity of these 
cells. Figure 2.10b shows the approximate location of the different pathway modules 
within the diagram. The size of the diagram requires it to be ideally viewed on a 
computer. Every effort was made to arrange modules so those with shared nodes and 
high connectivity are located in close proximity, however given the issues in depicting 
information on this scale, arriving at an ‘ideal’ arrangement of components is 
challenging. The interactions between components and limited views of the pathways 
they form have been described in detail in the literature used to construct this diagram 
(the interaction table, is available at http://www.macrophages.com/macrophage-
pathway-resources). An overview of the pathway biology depicted by the diagram 
follows. 
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Figure 2.10 (a) Breakdown of node class in the integrated pathway diagram and (b) Key to the 
pathway layout and content of the integrated diagram. (a) Components, Boolean Logic, Process Nodes 
and Edge Annotation form the category of possible nodes. A detailed breakdown of the number of each 
type of node in each category is given. (b) The key reflects the approximate location of the different 
pathway modules depicted in the integrated diagram (Figure 2.9). Ideally pathways with high 
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Macrophage Pathogen Receptor Systems 
Macrophages are equipped with a complex array of pattern recognition receptors 
(PRRs) that bind a varied assortment of pathogen-associated ligands. Perhaps the best 
studied of these are the membrane-associated toll-like receptors present on the cell’s 
surface (TLRs 1/2/4/5/6/10) and lining their endosomal compartments (TLRs 3/7/8/9) 
[164-165]. The receptors commonly form complexes comprised of 6-8 protein subunits 
which undergo a series of phosphorylation, dissociation and binding events following 
engagement of the receptor with their respective ligand class. As with all such 
receptor-ligand interactions shown in the diagram, each successive stage in the 
formation and activation of the receptor complex is explicitly shown (Figure 2.11 a&b). 
TLR’s are comprised of two functionally significant domains; one for recognizing 
specific pathogen associated molecular patterns (PAMPs) and one for recruiting 
signalling adaptor proteins following binding of an appropriate pathogen-derived 
ligand. The pathogen recognition domains of different TLR’s are structurally highly 
variable [166], thereby allowing the recognition of diverse pathogen-derived molecular 
species ranging from viral double- and single-stranded RNA [167-168] bacterial flagellin 
[169-170], lipopeptides [171-172], lipopolysaccharides [173-174], and bacterial and 
viral CpG motifs [175-176]. In contrast, the internal domains tend to be more 
conserved, reflecting the ability of different TLR’s to recruit the same adaptor proteins; 
in particular MYD88, IRAK4, IRAK1, TOLLIP, TIFA, and TRAF6 are common to most of 
the TLR receptor complexes. The use of common adaptor proteins by many of the TLR 
complexes represented a significant challenge in depiction, with many edges 
emanating out of each adaptor molecule. Much effort was therefore put into layout of 
this system so as to provide visual clarity. A comprehensive and systematic effort to 
depict TLR signalling has been reported elsewhere [100] however this was not used in 
the construction of the current view of TLR signalling. These receptors ultimately 
activate a number of downstream signalling pathways including the NF- B, IRF 
(interferon regulatory factor) [177] and MAPKinase, ERK, and JNK signalling [178]. 
Also represented here are 9 non-TLR cytoplasmic PRRs, including the NOD (nucleotide-
binding oligomerization domain)-Like Receptors and RNA helicases, whose role it is to 
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detect endogenous stress signals and intracellular pathogens. NOD-like receptors 
(NLRs) can be broadly divided into various classes, the NODS, NALPS and other types of 
NLRs, based on their protein domain structures. Bacterial associated PAMPs (e.g. 
flagellin and various classes of peptidoglycans) are recognised by NOD1, NOD2 and 
NLRC4 (IPAF1) which activate the NF- B and MAPKinase pathways. NOD1 can also lead 
to the cleavage of IL1B into its active form. The NALPS (NLRP1, NLRP2, and NLRP3) 
detect a range of stress signals such as K+ efflux, DNA, ATP or membrane damage, 
often collectively referred to as danger-associated molecular patterns (DAMPs). Once 
activated by DAMPs the receptors form oligomers with inflammatory caspases 
(CASP1/5) and in doing so activate the cleavage of the caspases [179]. The active 
complexes are known as ‘inflammasomes’ owing to their ability to cleave and activate 
interleukin proteins, and are crucial mediators of the inflammatory response. Although 
three NALP receptors have been depicted up to 14 different NALPS have been 
reported [180-181]. Finally, RNA helicases are responsible for the intracellular 
recognition of viral single stranded and double stranded RNA. The diagram shows 
DDX58 (RIG-1) and IFIH1 (MDA5) which recruit factors via their CARD domains and 
eventually initiate anti-viral gene expression by activation of the NF- B system. The 
ZBP1 protein was recently characterized as a sensor of viral DNA [182] and activates 
the IRF3 transcriptional pathway. As such the PRR systems depicted represent a 
comprehensive view of these receptors and the signalling pathways they activate. 
However the diagram still lacks other known macrophage PRRs, including the surface 
mannose receptor, secreted receptors e.g. those belonging to the complement system 
and the recently described DNA receptor AIM2 [183-186].  
Cytokine Activation Pathways 
The diagram also describes a number of the main cytokine signalling systems active in 
macrophages. These include the interferon (type-I - IFNA/IFNB and type-II IFNG), 
interleukin 1B (IL1B), TNF, TNFSF10 (TRAIL), TNFSF13B, FASLG and CD40LG signalling 
pathways. In each case these have been depicted starting from their interaction with 
their receptor complexes (Figure 2.11a) through to the activation of their downstream 
signalling and effector pathways. Interestingly, the expression of a number of these 
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ligands is activated by PRR pathways (e.g. IL1B, IFNB) producing autocrine feed-
forward loops. IFNB is perhaps one of the best studied genes in the whole genome in 
terms of its transcriptional regulation [165, 187-189]. It is also one of the primary 
targets for a number of the macrophage PRR activation pathways described above and 
we therefore constructed a detailed model of its regulation (Figure 2.11h). Part of the 
reason behind this was also to grapple with the issues with depicting transcriptional 
networks and we believe the solution arrived at should work for other systems. In the 
current diagram however, we have generally chosen not to depict the links between 
cytokine gene activation (or indeed between other genes) and their respective 
proteins (via translation). The depiction of these edges adds to the visual complexity to 
the diagram. For modelling purposes however these connections can be added. 
 
Apoptosis (Programmed cell death) 
A potential output of the innate immune response is to culminate in host cell suicide 
(apoptosis) thereby potentially limiting further reproduction of pathogenic organisms 
such as viruses. Two major routes of apoptosis execution have been identified, termed 
the intrinsic and extrinsic pathways. The intrinsic pathway is activated as a result of 
stress signals detected within the cell, for example, penetration of a viral pathogen 
into the cell or UV light induced DNA damage. Extrinsic apoptosis on the other hand is 
triggered by extracellular death-signalling ligands (FAS, TNFSF10 (TRAIL), TNF which are 
also members of the cytokine activation pathways) binding to the cell membrane 
receptors. Both intrinsic and extrinsic pathways activate a number of the caspase 
family of cysteine proteases. The initial caspases to be activated are categorized as 
initiators, (CASP2/4/6/8/9/10) and are capable of cleaving downstream executioner 
caspases, specifically CASP3 and CASP7. Caspases 3 and 7 initiate the series of events 
that directly lead to the morphological changes in a cell associated with apoptosis by 
the cleavage or inactivation of an array of molecules including, structural proteins, 
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Signal Transduction and Transcription Factor Networks   
The NF- B (nuclear factor kappa-light-chain-enhancer of activated B cells) family of 
transcription factors are pivotal in the regulation of a wide variety of biological 
processes [190-193]. This includes many aspects of the innate and adaptive immune 
response, as well as the regulation of a diverse range of stress-related stimuli [194]. 5 
different NF- B proteins (REL (c-Rel), RELB (REL), RELA (p65), NFKB2 (p100 or p52), 
NFKB1 (p105 or p50) have been identified and these form a variety of homo- or 
hetero-dimers resulting in an array of different NF- B complexes. Previously [102] the 
framework diagram described the activation of two of the best-characterized NF- B 
dimers; NFKB1:RELA (also known as p50-p65) and NFKB2 (p52):RELB, often referred to 
as the canonical and non-canonical pathways, respectively. However, it was soon 
realized that this diagram was a rather naïve view of the NF- B system and the 
students were assigned to explore the literature on this system in greater detail. These 
efforts have resulted in the depiction of 14 different NF- B dimers formed from 
combinations of the five NF- B proteins. In addition to the 14 dimers, some NF- B 
complexes form further complexes with a number of accessory proteins 
(NFKBIA/B/E/Z, BCL3, HMGA1, CREBBP, HDAC3, NCOR2) and together with their 
regulation by multiple phosphorylation events, give great diversity in the form and 
control of this important class of transcription factors. This goes someway to 
explaining the pleiotropic effects regulated by this system [195]. It is unlikely however 
that all the possible NF- B systems depicted are active in the macrophage or indeed 
any other single cell type. NF- B signalling is often cited in loose terms in literature 
with little reference to the exact NF- B complex active in any given situation. The 
pathway diagram presented here demonstrates the complexity of this system and 
underscores the need for acknowledging the range of possibilities beyond the 
canonical and non-canonical NF- B pathways.  
 
As mentioned above, phosphorylation is a key element in the activation process of 
many of the NF- B complexes. In the pathway, dimers of the core proteins may bind to 
NFKBIA, NFKBIB or NFKBIE, a group of I-kappa-B or NF- B inhibitor proteins. When 
bound to their inhibitor, the NF- B complexes are restricted to the cytoplasm. Upon 
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stimulation the I-kappa-B proteins are phosphorylated, leading to their ubiquitination 
and eventual degradation, and the release of the active NF- B complex. Dissociation of 
the inhibitors exposes the nuclear localization domain on the NF- B complex causing it 
to translocate to the nucleus where it can modulate transcriptional activity of target 
genes [196-197]. Other NF- B complexes (which are not bound to inhibitors) are 
activated following cleavage into smaller DNA-binding subunits. This is induced by 
stimuli phosphorylating the complex leading to its ubiquitination and subsequent 
processing of one or more of their subunits into smaller DNA binding peptides e.g. 
NFKB2 is processed from p100 to p52. Currently there are 34 genes shown on the 
diagram as the transcriptional targets of NF- B signalling (Figure 2.12g). In reality this 
is only a small percentage of the known NF- B targets [198]. Furthermore, the 
representation of the transcriptional regulation of these genes is almost certainly a 
gross over simplification, as there are likely to be other transcription factors acting in 
concert with NF- B to modulate gene expression.  
 
The pathway diagram presented here also includes preliminary views of some of the 
kinase signalling pathways known to be associated with macrophage activation. These 
include the MAP2K1/2 (MEK1/2)-MAPK3/1 (ERK1/2) cascade known to be activated by 
TLR signalling and the MAPK8 (JNK)-JUN (AP1) and MAPK14 (p38) (Figure 2.12e) 
cascades activated by NOD1/2 and TLR signalling. These pathways are clearly 
important to macrophage activation and are known to influence a range of different 
processes such as cell differentiation, cell cycle, phagocytosis and apoptosis. Future 
efforts will need to integrate these pathways into the overall signalling network to 
improve the predictive value of the pathway diagrams.   
 
Antigen Presentation and Related Pathways 
Antigen presentation is not exclusive to macrophage biology but equally central to it. 
We have attempted to depict the MHC class I and II pathways from either the 
degradation of cellular proteins or the phagocytosis of pathogens, to the presentation 
of cellular/pathogen peptide antigens to CD8 cytotoxic T-cells or CD4 T-helper cells, 
respectively. In order to achieve this however, it was found necessary to construct 
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diagrams of the ubiquitination pathway (due to it role in tagging cellular and pathogen 
proteins with ubiquitin) and proteasome formation (due to the role of the proteasome 
in the digestion and/or processing of ubiquitinated proteins). These latter two systems 
are also crucial to many aspects of cell biology, being responsible for the activation 
and/or degradation of many cellular and pathogen proteins alike. Depiction of these 
systems proved to be challenging. In the first instance, whilst our view of phagocytosis 
is greatly simplified, we had to find ways to show the passage of key molecules in the 
antigen presentation pathways from their assembly in the endoplasmic reticulum 
(Figure 2.12f) to their transport to the phagosome via the golgi and intermediate 
endosomal compartments. This required us to show events both at the molecular 
level, as well as the transition of compartments in which they reside from one state to 
another. In this case nodes representing pathway modules have been used to link one 
compartment to another indicating a series of vesicular transitions and fusions; 
complex processes in their own right. Another challenge was the depiction of the 
ubiquitination pathway. In short, proteins are tagged for degradation or cleavage 
through their binding to E3 ligases. Each E3 ligase or E3 ligase complex binds specific 
protein targets. We have shown a number of classes of these molecules i.e. the 
HERC/HECT, ring finger, U-box and SCF E3 ligases, encompassing over 80 proteins in 
total (Figure 2.11c). However many more proteins are thought to be associated with 
this role, perhaps as many as 500 [199-200]. To add to this complexity there are 36 
known E2 ligases and 6 E1 ligases which add further specificity to this system. Clearly it 
would be impossible to show each individual protein and their associated E3 ligase 
passing through the ubiquitin pathway (even if the details were known) and therefore 
it has been depicted as a generic process; proteins bind E3 ligases, which provide a 
scaffold for ubiquitin transfer from E2 ligases, resulting in the ubiquitinated-protein 
being presented subsequently to the proteasome for processing. When a protein in 
the pathway is ubiquitinated it is shown using a process node with the symbol Ub, 
which is essentially a short cut to showing this process. In the original framework 
pathway [102] the proteasome was depicted as a single node responsible for the 
cleavage and activation of ubiquitinated NF- B complexes. However looking further 
into the nature of the proteasome, it was then appreciated that there is not just a 
                                                                                                                             Chapter 2 
78 
single proteasome but at least 5 specific proteasome complexes; the 26S, 11S capped 
and 19S+11S capped hybrid constitutive proteasomes, and 11S and 19S+11S capped 
hybrid immunoproteasomes [201-202]. In an effort to show something of the structure 
of these large barrel-like complexes, we chose to depict the layered arrangement of 
core subunits into four stacked rings (7 subunits per ring/layer), where appropriate 
capped with other subunits that form the regulatory particles (Figure 2.11d). By linking 
the proteasomes with the generic model of the ubiquitination pathway we have also 
attempted to show each proteasome’s preference for the cleavage of a specific class of 
peptides. However in doing this, it is not possible to show whether the given output of 
a proteins ubiquitination and cleavage is an activated peptide, a peptide for antigen 
presentation or the complete destruction of the protein. Where a protein in a pathway 
is degraded the sink glyph (Ø) has been used as a short cut to indicate that the protein 
has been removed from the system by proteasomal degradation. 
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Figure 2.11 Snapshots from the integrated macrophage pathway diagram. (a) Activation of the 
interferon type-1 receptor through its interaction with interferon-α (IFNA) or interferon-β (IFNB1).   In 
each case binding of the ligand causes autophosphorylation of JAK1 which eventually leads to the type1-
interferon response (not shown). (b) Activation of TLR7 by single stranded RNA in the endosome.  This 
sequential multistep process involves binding events, autophosphorylations and dissociations steps. (c) 
E3 ligase system.  Up to 500 proteins may potentially function as E3 ligases and here the well 
documented members are shown. (d) Depiction of the proteasome.  In some cases it is useful to lay out 
the subunits of a complex to reflect the complexes known structure. Represented here are the layers of 
the proteasome’s barrel structure and cap. (e) Activation of MAPK14 (p38).   Phosphorylation of p38 is 
reversible; numerous kinases will phosphorylate p38.  p38 is dephosphorylated by DUSP1 and inhibited 
by the specific inhibitor SB203580.  (f) Combinatorial assembly of the MHC class 2 HLA-D (alpha/beta) 
complexes.  The & and OR Boolean operators indicate the combinatorial assembly of HLA-D (alpha/beta) 
complex from different classes of MHC class 2 proteins. (g) Genes activated by NFKB1 (p50):RELA (p65) 
complex. A number of genes activated by the binding of the p50:p65 complex to known NFKB elements 
in their promoter.  In each case the likely functional consequence of this activation is shown as a 
pathway output. (h) Regulation of IFNB1 expression.  Shown are the known promoter elements and 
factors that bind to them leading to IFNB1 expression. 
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Compatibility of mEPN Pathways with Other Pathway Analysis Tools  
The pathway model presented here is primarily designed to function as a computation 
resource.  Its size as well as the fact that additional information is available through 
mouse-over or hyper-linked from it, means that it is best viewed on a computer. The 
diagram has been constructed using the freely available program yEd graph editor 
(yFiles software, Tubingen, Germany), a general purpose tool designed for the 
depiction of network-based diagrams. The standard file format used with this program 
is .graphml which is also supported by other network/pathway editing tools [203-206]. 
In this format pathways are available for editing and expansion or alternatively using 
the yEd editor, can be exported from the program in a number of image (.jpeg, .png, 
.pdf) and exchange formats (.tgf, .gml, .ygf, .xml, .html). The pathway is also available 
as .pdf and .html formats (see http://www.macrophages.com/macrophage-pathway-
resources or http://www.biomedcentral.com/1752-0509/4/63). In order to enhance 
options for the display, analysis and integration of these pathways with other data 
types the group has recently implemented the import of .graphml files into Biolayout 
Express3D, a network analysis tool [206]. This program supports a range of other 
network analysis features and is suited for working with small or large networks 
derived from other data sources. A ‘layout’ file can be generated such that the diagram 
can be viewed in this tool as either a conventional 2D or 3D network diagram, in both 
cases using the node co-ordinates from the .graphml file (although polylines are not 
supported). Alternatively the diagram can be viewed in 3D using a modified 
Fructerman-Rheingold organic layout algorithm [207]. A notation system consisting of 
3-D shapes is applied in the 3-D view of the pathway [116] (also see Chapter-3 and 
www.mepn-pathway.org). With the ever increasing amounts of interaction data it 
becomes more evident that an extra dimension will be valuable for the visualisation of 
large pathways and eventually an in silico cell.  The BioLayout Express3D interface also 
supports the follow through of connectivity in pathways such that the parent or 
children nodes of a given selection can be highlighted and selected nodes hidden or 
isolated.  
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Pathway diagrams are frequently used as an aid to the interpretation of experimental 
data e.g. gene expression analyses, proteomics screens whereby the results of these 
studies are be overlaid on top of pathways to provide context to the findings. To 
facilitate these analyses the group has recently implemented an “import class-sets” 
functionality into Biolayout Express3D, allowing lists of genes of interest and/or 
annotations to be easily exported directly from the tool and identified on the pathway 
(demonstrated in Raza et al., 2010 [159]).  
 
In the ways described above, the diagram presented here represents a detailed 
consensus view of a range of pathway systems that are of interest to and the subject 
of ongoing research into macrophage biology. It has been designed to be easily 
accessible, distributable and can be modified by end users to suit their interests or 
knowledge-base. Finally software has been developed to facilitate the use of the 
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Discussion 
The studies of this Chapter set out to create a pathway resource describing the 
signalling events active in the macrophage. The pathways described here are of central 
importance to understanding macrophage biology and therefore innate immunity, and 
the diagrams provide a consensus view of these systems. This is not to say that the 
model is either viewed as complete or necessarily even correct, but only as a working 
model. Amongst the key signalling pathways yet to be incorporated into the 
macrophage model are the classical stress response, the hypoxia response, a number 
of PRRs, a range of cytokine and chemokine receptor activated pathways, and greater 
representation of transcriptional events and regulation.  The pathway has been 
designed with the idea that it will need to be modified and expanded based on new 
publications, experimental observations or deeper insight into specific systems. All of 
the pathways depicted are reasonably well characterized and as such there is a relative 
abundance of information on them from a wide variety of sources. What was lacking 
prior to this work was a way of collating our understanding of these pathways and 
integrating this view with the abundance of data generated on these cells by ourselves 
and others. A key objective has therefore been the creation of a pathway diagram that 
graphically reflects the current view of a pathway system in a visibly intuitive manner. 
In so doing the hope was to create a resource for data integration, pathway modelling 
and hypothesis generation. In order to achieve these objectives it was found necessary 
to modify both the PDN [103] and EPN schemes [105] for pathway depiction (see 
Chapter-3). The original diagram [102] (Figure 2.5) acted as a framework for the 
current effort helping to highlight the many gaps in our understanding and together 
with developing interests in macrophage biology, helped to prioritize areas for future 
modelling. Modelling of the pathways continued to be based on labour-intensive 
curation of the literature. Post-graduate students were given an area of biology to 
examine, and all the resources for researching the literature and depicting their chosen 
pathway module. Regular debates on the progress of the pathway models were held, 
and through this process deficiencies were plugged in the graphical depiction of 
events, pathway content, notation, component labelling and the recording of the 
supporting information; a process which in itself was highly informative. An important 
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point is that the diagrams can be shared and understood by all those familiar with 
notation, and as a result all the work presented here has been subjected to form of 
internal critiquing. However, each new area of biology included in the current diagram 
has presented its own problems in layout and concept representation. As a result there 
has been subtle but almost constant re-evaluation of various aspects of the notation 
scheme and as it has been necessary to deal with new issues in the depiction of 
different systems. The mEPN scheme has matured to the point where little need to 
change the majority of the notation scheme presented is foreseen (see Chapter-2 and 
Freeman et al., 2010 [116]), although clearly the modelling of other systems and ideas 
from others may present a case for further modifications.  
 
Pathway diagrams are an established tool in our effort to interpret and explain results 
from functional genomics investigations. Overlay of results, usually from studies of the 
difference between one biological state and another, on top of pathway diagrams 
allows the investigator to visualize and link observations to defined pathways. 
BioLayout Express3D, a network analysis tool developed within the group [138, 206], 
provides a powerful approach to visualize and analyze ‘omics data from a variety of 
sources [138]. Recently implemented is the import of .graphml files into BioLayout 
Express3D and the tool now supports the visualization of pathway diagrams as 3D or 2D 
networks [206].  A parser automatically converts the mEPN notation into the 
equivalent 3D notation scheme and can use the diagrams original node co-ordinates to 
layout the pathway. Also implemented is the ability to export analyses from one 
dataset e.g. clustering of microarray gene expression data and import and overlay 
these analyses on to another network. As standard gene nomenclature is used in the 
assembly of this pathway it is possible to map directly between gene identifiers from 
data to genes/proteins in the pathway. In practice any number of lists with 
annotations can be imported as class-sets onto the pathway and one can envisage how 
this would facilitate the comparison of numerous data sets in the context of the 
macrophage pathway. Although the concept of data mapping onto pathways is not 
new and is supported by other pathway resources [122, 151, 208] these pathways 
suffer from a number of issues pertaining to the lack of standard graphical notation 
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used to depict them. Furthermore the nature of the pathway presented here (in terms 
of scale, detail, formalised notation, range of pathways covered and integrated nature 
of their presentation) presents a valuable additional resource for those interested in 
macrophage biology or any of the more generic pathways included. Clearly the better 
and more extensive the pathway diagrams are the easier it will be to provide a working 
hypothesis on the interpretation of data. Increasingly, it is now experimental data that 
is helping to refine existing pathway models and observations that are yet to be fully 
understood that are now driving the groups current modelling efforts. 
 
The task of assembling this diagram has been time consuming and laborious involving 
1,000’s of hours of work. On the other hand, it summarizes the results of investigations 
that have taken many times that amount of time to perform and it is difficult to 
envisage how one could précis this body of work in any meaningful way other than as a 
diagram. To gain a systems level view of these pathways is to gain an insight into the 
molecular networks that regulate normal immune function and whose malfunction or 
manipulation underpins inflammatory and infectious disease. Greater understanding 
of the overall architecture of the immune system and its susceptibility to deregulation 
by pathogens and other disease causing agents, should ultimately lead to new 
strategies and targets for therapeutic intervention. Apart from summarizing decades of 
research, pathways depicted with formalized graphical notation schemes should aid 
the communication and comparison of biological data. During a thorough process of 
internal critiquing sections of the pathway were presented to others who were familiar 
with the notation scheme but not involved in constructing the pathway presented to 
them and asked to interpret the biology shown. This process ensured that the 
interactions of the pathway were not ambiguous in their depiction.  
 
Another major incentive for generating pathways with standard notations is to permit 
the conversion of graphical models into computationally tractable ones, suitable for 
simulation analyses. For this purpose members of the group have been exploring the 
use of signalling Petri nets (SPN) [114] for modelling “flow” in the integrated pathway 
diagram. The approach is suited to large scale models and pathways drawn using the 
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mEPN system can easily be converted into a bipartite graph of places (nodes) and 
transitions connected by arcs (edges) that are required to support this approach..  The 
SPN algorithm uses stochastic flow simulations to distribute 'tokens' representing 
quantitative estimates of activity through a network graph over time using only the 
network structure to determine outcomes. The technique has the advantage of 
offering fast computational simulations on large networks (< 1 sec for ~100 node 
networks), can support concepts of co-dependency between components and requires 
no kinetic details for interactions. In this way it should be possible to estimate the 
dynamics of information flow through a network and the effects of perturbations on 
that flow. Having developed the comprehensive pathway resource the hope was it 
would serve as a dynamic tool to aid the groups’ research in addition to being a useful 
point of reference for macrophage pathway knowledge. This is now being achieved 
with the application of the pathway for genomics data analysis, aid in informing wet-
lab investigations and now with the potential for computational modelling.    
  
The exercise of pathway construction has provided a resource for training, pathway 
modelling, literature/data interpretation, hypothesis generation and as such is now 
central to ongoing investigations of macrophage biology. Importantly however, the 
pathway model presented here also serves as a worked example of how pathways 
might be represented in a logical, unambiguous and biologist-friendly fashion, 
whatever the system of interest. What is arguably essential for the development of 
this resource is the support of the wider community in assembling and editing such 
diagrams. Such efforts are already underway [154-156] and are already providing a 
vital forum for debate on the known details of pathways in different cell systems. 
Ideally these efforts will result in detailed models of biological systems that can be 
shared and assimilated. However, in order to achieve this end pathway models clearly 
need to be assembled using standard rules and graphical languages. The hope is that 
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Conclusions 
The formalised depiction of biological pathways is increasingly recognised as a crucial 
requirement for the exchange of pathway data, modelling of their activity and systems 
level interpretation of biological data. However, there are just a handful of worked 
examples of large pathway diagrams constructed using a formalised graphical 
modelling language. The model of macrophage signalling and effector pathways 
presented here is to our knowledge the most comprehensive pathway of its kind 
published to date. As such it offers a worked example of how large pathway and has 
also proved to be a testing ground for the mEPN system [116]. When presented in this 
manner the network reflects the extensive cross-talk between pathway modules and 
transcriptional networks and high degree of feedback and feed-forward control taking 
place.  
 
Although a time consuming and laborious exercise, the act of converting literature 
derived knowledge into a formalised computational models is essential if we wish to 
truly gain a systems level understanding of any cellular system. The macrophage model 
presented here summarizes the results of years of investigations and has allowed the 
thorough testing of the notation system used to depict it. The hope is that this work 
will provide a useful resource for others interested in the macrophage and the 
pathways depicted, and will help contribute to the development of standard graphical 
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Methods and Materials 
 
Data mining, curation and organization 
Ongoing analysis of macrophage-related datasets and an interest in consolidating 
knowledge of a number of signalling pathways directed the choice of pathways to be 
mapped. Public and propriety databases were initially used as resources for data 
mining, but ultimately all molecular interaction data was sourced from published 
literature. Manual curation of the literature was performed to firstly evaluate the 
quality of the evidence supporting an interaction and secondly, to extract the 
necessary and additional pieces of information required to ‘understand’ the pathway 
and construct an interaction diagram. Pathways have been drawn based on the groups 
long term desire to model pathways active in a human macrophage and therefore all 
components have been depicted using standard human gene nomenclature (HGNC). 
However, the understanding of the pathway components and the interactions 
between them, have been drawn largely from a consensus view of literature 
knowledge. As such the pathways presented here are based on data derived from a 
range of different cellular systems and mammalian species (human and mouse). The 
following details were captured in an interaction list spreadsheet: PubMed ID (of the 
paper citing the interaction); the names and official HUGO and Entrez IDs of the 
interacting components; the nature of the interaction, an extract from the interaction 
table can be found in Figure 2.12 (and the full list is available at 
http://www.macrophages.com/macrophage-pathway-resources).  
 
Pathway construction  
Phase 1 and phase 2 of this work was carried out largely by myself.  In phase 3 of the 
work individual pathway diagrams focused on a specific area of biology were 
constructed by myself or by teams of 1 or 2 curators who were given a remit to 
describe a given pathway system using the mEPN scheme [116], over a 6 month 
period. Primary curators were junior biologists (MSc students) who were encouraged 
to use all information resources available to first build up an overall picture of these 
pathways prior to more detailed analyses and literature-based verification of 
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interactions. Great emphasis was also placed on the need to discuss and justify the 
information they were attempting to represent to others. Layout was assessed by 
several curators, as was pathway content and notation usage. Essentially, it was 
attempted to ensure that the graphical depiction of pathway/interactions was 
intelligible and unambiguous to another individual familiar with the notation scheme. 
Teams of curators were therefore encouraged to show and discuss their progress with 
other members of the group on a regular basis. 
 
All pathways have been constructed as directional networks. Interactions between 
pathway components are drawn using the principles laid down by the mEPN scheme 
[116] and diagrams assembled according to the workflow described in Figure 2.9. The 
current mEPN scheme and a detailed description of the notation scheme and rules for 
its use are provided in Chapter-3 and Freeman et al., 2010 [116] and www.mepn-
pathway.org. Individual pathway maps were drawn using the freely available program 
yEd graph editor (yFiles software, Tubingen, Germany) and later the pathways were 
integrated using the same software. In order to make these diagrams an information-
rich vehicle for conveying details about pathway components and the reactions 
between them, PubMed IDs supporting the interactions are stored on appropriate 
edges or nodes within the .graphml version of the diagram, as are URL-links to Entrez 
gene for each protein or gene component in the pathway and notes from the curators. 
Due to the nature of pathway construction edges are often moved, deleted then 
redrawn to optimise the pathway layout and for this reason annotation may also be 
linked to an appropriate process and/or edge annotation node. 
 
Pathway optimization and integration 
Following an initial development period, the focused diagrams went through extensive 
editing in attempt to unify their notation usage, stylistic qualities and overall 
appearance. All aesthetics of the pathways (component colours, text font, text size, 
edge thickness etc.) were standardized between the diagrams. The original pathway 
diagram [102] was then used as a framework on to which new pathways were joined. 
A central rule of the mEPN is that a particular component in a given state may only be 
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represented once in any sub-cellular compartment [102, 105, 116].  Thus when 
integrating the diagrams a crucial step was to identify, using the interaction and 
component lists, overlap between pathway members in the individual diagrams. 
Connections could then be built between the individual pathways based on shared 
pathway members and common interactions. For example, a number of the systems of 
interest feed into the NF-кB system including the TLR and non-TLR pathogen detection 
receptor signalling, TNF-receptor activation, apoptosis and MAPKinase signalling. If the 
representation of interactions differed between individual diagrams they were re-
examined by going back to the literature. Furthermore, annotations and curators notes 
were moved and preliminary layouts optimized. Depicting this interconnectivity 
ultimately leads to numerous challenges in arranging the layout of the diagram. This 
was particularly acute when laying out the integrated diagram. A significant leap 
forward was made with the realization that however ‘optimized’ the layout of the 
diagram it was too large to be displayed in a readable format on a single page (as had 
always been the aim when working on a smaller scale when trying to produce a 
‘publication ready’ layout). With this in mind it was possible to be more free with use 
of space and in the final layout, pathway ‘modules’ consisting of numbers of connected 
nodes involved in a similar system are separated out. This has the effect that more 
space is available to run tracks of parallel edges between modules and subsequent 
additions or editing are easier to perform. Following the integration of TLR system with 
the original diagram, the NF-кB, non-TLR and proteosome maps were added 
sequentially according to the same principles. The fully integrated map then 
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Figure 2.12: Extract from table of interaction data. For each interaction depicted on a pathway diagram it is crucial to keep a record of the supporting evidence for that 
interaction and unambiguous identifications for each interacting components. As the very minimum it is advisable to store the following information; Official Gene 
Symbol for both interactants, Gene IDs, the type of interaction, the appearance of the interactant as shown on the map (i.e. if a protein is interacting whilst it is in 
complex with other proteins then it’s full complex name/ details are shown), the type of interaction (usually corresponding to the process node involved), the location of 
the interaction and the PubMed-ID references for each interaction. Some interactions have multiple references sources shown on the line below so new interactions are 
separated by a yellow line break. Other information, such as the technique used to identify the interaction, the cell type in which the interaction was identified and 
other supporting information can also be stored. 
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Pathway overlay of the transcriptional response analysis of mouse bone 
marrow derived macrophages to interferon-γ treatment 
For details of cell culture, treatment, RNA preparation and microarray processing see 
Chapter-4. Genes that were considered transciptionally activated in response to IFN-γ 
treatment and included in the set of mapped pathway genes were manually 
highlighted on the map and the possible downstream consequences (assuming de 
novo protein synthesis and activity following an increase in gene transcription) were 
followed highlighted. 
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supported the current development; finally Prof. Tom Freeman oversaw the pathway 
construction, orchestrated the development of the mEPN scheme, has directed the 
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Chapter 3. Towards the Standardisation of the Graphical 
Representation of Biological Pathways: Development of 










Graphical Notation Schemes for Describing Pathways 
Despite having a high ratio of graphical to textual information, biology has lacked 
standard graphical notations for illustrating pathway information.  Standard notation 
for circuit diagrams has proven fundamental to the evolution of the electronics 
industry (http://www.iec.ch/; http://www.ansi.org) and in the design of computational 
network systems for example UML diagrams (http://www.uml.org/) diagrams. With 
the advent of analytical techniques able to perform genome-wide analysis of cell 
systems and the unprecedented increase in data to interpret, there is a pressing need 
in biology for formalised methods to depict molecular and cellular systems.  Moreover 
there is also a need for comprehensive pathway models to assist with the 
interpretation of the vast quantities of medium to high-throughput-data now 
available.  
 
In order to address these issues the groups of Kohn and Kitano began to devise new 
approaches to pathway notation using many ideas adopted from the electronics and 
computer industries [103-104, 209].  In particular the MIM (molecular interaction map) 
notation [209] a form of entity-relationship representation and the process description 
notation (PDN) [103], respectively. Examples of pathways that have been published 
using these notation systems include a molecular interaction map of macrophage 
signalling [210], Toll-Like-Receptor signalling [100], epidermal growth factor receptor 
signaling [101] and the RB/E2F pathway [98] which have been depicted using the PDN 
scheme; cell cycle control and DNA repair has been presented in the MIM notation 
[104]. However, in the course of our investigations it was found that the diagrams 
resulting from these elegant and pioneering efforts were not always easy to interpret 
and the notation system was a challenge to implement (Figure 3.1 provides examples 
of pathways constructed in the PDN and MIM schemes). Furthermore, it was found 
that the PDN did not support all of the concepts that are required to reflect the 
diversity of pathway components and the relationships between them. The original 
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Edinburgh Pathway Notation (EPN) scheme [105] was designed to allow the logical 
depiction of signalling pathways and is largely based on the original concepts of the 
PDN. The notation incorporated many of the ideas of the process PDN scheme but 
notably introduced the idea of using Boolean logic operators (AND/OR/NOT) nodes to 
represent co-dependencies between components. The basic objectives of the EPN 
were to create a notation scheme that was: a) flexible enough to allow the detailed 
representation of a diverse range of biological entities, interactions and pathway 
concepts; b) able to represent pathway knowledge in a semantically and visually 
unambiguous manner; c) able to the construct pathway diagrams that are 
understandable by a biologist; and d) able to produce diagrams that are sufficiently 
well defined that software tools can convert graphical models into formal models, 
suitable for analysis and simulation. Of primary importance to the EPN scheme is the 
desire to develop pathway maps that are ‘readable’ by a biologist.  Since the pathway 
maps are primarily produced as a tool for communication it is critical that they are 
easily understandable and the notation can be applied and read by biologists with 
minimal training.  Other objectives are that the notation should be computable, 
compact, show sub-cellular localization and be tolerable of incomplete knowledge. 
Whilst all of these objectives are valid, fulfilling them in practice is far from trivial and 
at the time of publication on the original EPN scheme there were few worked 
examples of large pathway diagrams depicted in standard notations, available in the 
public domain.   
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Figure 3.1: Examples of biological pathways depicted with graphical notations. Pathways depicted with 
existing notation schemes in 2006/2007 were found by our group to be complex to interpret and to 
difficult to implement at the time; this included their complicated depiction of protein-complexes; 
multiplicity of arrowheads; struggle of following pathway inputs to their outputs; and limited choice of 
software which could depict these edges and symbols (a) Extract from the Toll-like-receptor signalling 
pathway by Oda, et al. 2006 [100] depicted with the process description notation (PDN). (b) Extract from 
a map of epidermal growth factor receptor family signalling by Kohn, et al., 2006 [117] depicted using 
the molecular interaction map (MIM) notation.  
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Development of the modified Edinburgh Pathway Notation 
scheme  
The original EPN was conceived and published in 2006 [105].  During early stages of 
“road-testing” of the original EPN it became evident that further refinements were 
necessary, if the scheme was to be able to fulfil its original objectives.  Figure-3.2 
shows a sketch created using the original EPN and original pathway editing software, 
the Edinburgh Pathway Editor (EPE) and Figure 3.3 displays the original EPN scheme as 
proposed in 2006. It became apparent that changes were needed to the aesthetics of 
the notation, choice and range of symbols, pathway syntax, as well as choice of 
supporting software if the notation was to fulfil its original objectives. Chapter 2 
(Results  Phase 1) discusses how the appearance and readability of the pathways 
improved with change of supporting software. The improvement in aesthetics of the 
pathway was also heavily linked with changes made to the original notation scheme; 
from increasing size of the original symbols (see Figure 3.3), to amending symbols to 
appear more intuitive, addition of colour as a visual cue to assist with differentiating 
between components (for example complexes and proteins) and the eventual removal 
of numerous different arrow heads to depict interaction since these can easily become 
difficult to memorise. All in all changes were made where needed to improve the 
notation scheme to allow it to fulfil one of its fundamental objectives; produce 
diagrams that are easily understandable by a biologist. Hence in constructing pathway 
models of the apoptotic, NF-κB, interferon and toll-like receptor pathways [102], I have 
also been central to the group’s effort to refine this notation scheme such that it was 
fit for purpose. This pathway construction exercise initiated the huge the jump forward 
from a theoretically useable notation scheme to one that was workable in practice.  
However as the group’s pathway mapping efforts continued to develop it was 
necessary to further refine the EPN scheme from when deployed to construct a 
framework map of macrophage signalling. Changes were necessary in order to model a 
range of different pathways and biological concepts [211]. The objectives of the EPN as 
originally proposed remain preserved as do many of its original concepts [212]. 
However substantial modifications have been made to the notation system from the 
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Figure 3.2: Extract from apoptosis pathway drawn using the original Edinburgh Pathway Notation 
(EPN) scheme. The sketch was drawn using the original EPN palette and supporting software Edinburgh 
Pathway Editor (EPE). Drawn during the early phases of notation testing the sketch displays some of the 
deficiencies of the scheme prior to optimization. Some of the original symbols were not intuitive, 
supporting software did not aid layout and aesthetics, and resulting diagrams were not easy to follow.  
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Figure 3.3: The original EPN scheme. The original symbols and descriptions of the Ediburgh Pathway 
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This Chapter will describe the work which followed on from the initial publication of 
the EPN [105] and define a modified version of the EPN scheme which is aligned with 
the developing international standard, the Systems Biology Graphical Notation (SBGN), 
but has a number of important differences with this scheme as currently proposed.  
The mEPN graphical language has reached a sufficient level of maturity to now be 
formally described [212]. Arguably the mEPN has some important advantages over 
other proposed pathway notation schemes and attempts to address some of their 
shortcomings. As such we believe it is a positive contribution to the debate on 




















Definition of the modified Edinburgh Pathway Notation (mEPN) scheme 
A pathway may be considered to be a directional network of molecular interactions 
between components of a biological system that act together to regulate a cellular 
event or process. In this context a component is any physical entity involved in a 
pathway e.g. a protein, protein complex, nucleic acid (DNA, RNA), molecule, etc. 
Interactions are generally the relationships between one component and another 
where one component influences the activity of another e.g. through its binding to, 
inhibition of, catalytic conversion of, etc. Interactions between cellular components 
thereby lead to a change in the status of the system. A pathway notation scheme is a 
collection of predefined symbols (shapes, lines, figures) that represent the constituent 
parts of a graphical system for depicting the components of a biological pathway, the 
interactions between them and the cellular compartments in which they occur. A 
scheme should also include rules for the use of these symbols in depicting information. 
Glyphs are stylized graphical symbols that impart information nonverbally and are used 
to portray different classes of biological entities e.g. protein, gene, pathogen etc. and 
the nature of the relationships between them. In network terminology all glyphs are 
nodes (vertices) of a specific type and the connectivity between them is defined by 
edges (lines/arcs). The entire set of glyphs employed in the mEPN scheme are shown in 
Figure 3.4 and their detailed description and rules for use have been published in a 
published specification document [116] available at 
http://www.biomedcentral.com/1752-0509/4/65/additional/ as well as at 
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Figure 3.4: List of the glyphs used by the modified Edinburgh Pathway Notation (mEPN) scheme. Unique shapes and identifiers are used to distinguish between each 
element of the notation scheme. The notation scheme essentially consists of the following categories of nodes representing; cellular components, compartments, 
Boolean logic, edge annotations, reactions and processes. 
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Pathway Components  
The mEPN uses a set of standard shapes to represent classes of molecules 
(components) from a rounded rectangle to represent proteins and protein complexes, 
to a diamond shaped glyph to represent simple ions and molecules e.g. Na+, K+, H2O 
etc. Components play some role within the pathway and exist in one or a number of 
locations within a cell. An important rule of the mEPN is that a component may only be 
represented once in any given cellular compartment. Whilst this rule can potentially 
lead to a tangle of edges due to certain components possessing numerous connections 
to other components spread across the pathway, the benefits of the rule outweigh the 
issues in adhering to it. The number of edges leaving each node gives the reader an 
exact indication of a component’s connections to other components and hence 
potential activity, without the need for scanning the entire diagram to find other 
instances where the component is described. A notable exception to this rule is in the 
depiction of small and ubiquitously present ions and molecules which may be 
represented numerous times and be involved in numerous processes. A component 
may however be shown more than once in a given cellular compartment if it changes 
from one state to another e.g. from an inactive form to an active form, in which case 
both forms are represented as separate components.  
 
Component Annotation  
Multiple names are often available to describe any given component e.g. a number of 
different names for the same protein may be in use in the literature at any one time. 
Likewise some common names may be used to describe more than one protein or 
complex. When non-standard nomenclature is adopted to name pathway components 
it therefore frequently leads to ambiguity as to the exact identity of what is being 
depicted. Use of standard nomenclature also assists in the comparison and overlay of 
experimental data with pathway models. The mEPN recommends the use of standard 
gene nomenclature systems e.g. HGNC or MGD to name human or mouse 
genes/proteins, respectively. These nomenclature systems now provide a near 
complete annotation of all human and mouse genes and their use in the naming of 
proteins provides a direct visual link between the identity of the gene and the 
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corresponding protein. Where other names (alias’) are in common use these names 
may be shown as an addition to the label on the glyph representing the protein and 
are included as part of the node’s label after the official gene symbol in rounded ( ) 
brackets. Protein complexes are named as a concatenation of the proteins belonging 
to the complex separated by a colon. Again if the complex is commonly referred to by 
a generic name this may be shown below the constituent parts. There are no strict 
rules as to the order in which the protein names are shown in the complex and are 
often shown in the order in which proteins join the complex, in the position they are 
likely to hold relative to other members of the complex (where known) or position 
relative to cellular compartments e.g. with receptor proteins in a membrane bound 
protein complex protruding into the extra-cellular space.  
 
Where a specific protein is present multiple times within a complex, this may be 
represented by placing the number of times a protein is present within the complex in 
angle brackets < >. If the number of proteins in the complex is unknown this may be 
represented by <n>. The particular ‘state’ of an individual protein or a protein within a 
complex may be altered as a consequence of a particular process. This change in the 
component’s state is marked using square * + brackets following the component’s 
name; each modification being placed in separate brackets. This notation may be used 
to describe the whole range of protein modifications from phosphorylation [P], 
truncation [t], ubquitinisation [Ub] etc. An example of an annotated complex is shown 
in Figure 3.5. Where details of the site of modification are known this may be 
represented e.g. [P-L232] = phosphorylation at leucine 232. Alternatively the details of 
a particular modification may be placed as a note on the node visible only during 
‘mouse-over’ or when viewing a node’s properties. Where multiple sites are modified 
this may be shown using multiple brackets, each modification (state) being shown in 
separate brackets. 
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Figure 3.5: Example of a multimeric protein complex, the apoptosome depicted using the mEPN. The 
active apoptosome consists of 7 APAF1 proteins, 7 CYCS proteins, and 7 truncated CASP9 proteins. 
 
Depiction of Interactions Between Components 
Interactions are depicted by edges, sometimes referred to as lines or arcs, and signify 
the relationships between one component and another. Edges denote that an 
interaction occurs between components/processes in a pathway and convey the 
directionality of that interaction. The nature of an interaction is inferred through the 
use of edge annotation nodes, process nodes, and Boolean logic operators. Interaction 
edges may be coloured for visual emphasis but as with nodes, the definition of 
meaning is not reliant on colour. A number of edges contain an in-line annotation node 
to indicate the ‘type’ of interaction, as is sometimes depicted by the use of different 
arrowheads. An edge annotation is generally characterized as having only one input 
and one output, and functions to describe the type of activity implied by the line e.g. 
activation, inhibition, catalysis. Figure 3.6 provides an example of an interaction, as 




Figure 3.6: Depiction of a component interaction using the mEPN: BIRC2 inhibits the process of CASP3 
activation by preventing its cleavage into the truncated form of the protein. 
  
Depiction of Biological Processes  
A process is a defined event occurring between components or to a component. A 
process node in the context of this notation system can be defined as a node that 
infers an action, transformation, transition or process. They impart information on the 
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type of process that is associated with transformation of a component from one state 
to another or movement in cellular location. They also act as junctions between 
components and as such may have multiple inputs or outputs to components. In the 
mEPN all process nodes are represented by a small circular glyph and the process they 
represent is defined by a one-to-three letter code. Colour is used as a visual clue for 
quick recognition of the nature of the process depicted and group processes into ‘type’ 
but again is not necessary for inferring meaning. There are currently 31 process nodes 
recorded under the mEPN. Different process nodes generally have different 
connections. For instance a ‘binding’ node will have multiple inputs and one output, 
the opposite is true for a dissociation node.  
 
Boolean Logic Operators 
Boolean logic operators define the dependencies between components of a system 
describing the relationship between multiple inputs into a process. An ‘AND’ operator 
is used when two or more components are required to bring about a process i.e. an 
event is dependent on more than one factor being present. In modelling flow through 
networks these act in a similar manner to ‘bind’ process nodes i.e. all inputs must be 
present before a product is formed or reaction proceeds. In contrast an ‘OR’ operator 
is used when one component or another may orchestrate the same change in another 
component. For instance multiple kinases e.g. MAP2K3, MAP2K6, MAP2K7 may 
catalyze the phosphorylation of p38 (MAPK14) and therefore shown connecting with 
p38 via an OR operator. OR operators have also occasionally been used to infer that a 
component(s) has potentially multiple out comes. The Boolean ‘NOT’ operator has not 
been included in the mEPN as it would seem self evident that if an event is not 
depicted it is not occurring or at least there is no recoded evidence that it is.   
 
Other Nodes  
There are a number of glyphs that represent concepts that do not sit neatly under the 
headings of being a component, a process or logic operator. These include:  
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Energy/molecular transfer nodes are used to represent simple co-reactions associated 
with or required to drive certain processes (e.g. ATPADP, GTPGDP, 
NADPHNADP+). They are linked directly to the node representing the process in 
which they take part.  
 
Conditional gates are used where there are potentially multiple fates of a component 
and the output is dependent on other factors such as the components concentration, 
time or is associated with a cellular state. These have been used to depict events such 
as the check point controls in cell cycle where the decision to go on to the next phase 
cell replication is under the control of a number of factors and two or more outcomes 
are possible. Another example is where cholesterol, depending on its intracellular 
concentration, may be either exported out of the cell or trigger the cholesterol 
synthesis pathway. 
 
Pathway modules define complicated processes or events that are not otherwise fully 
described. Examples include signalling cascades, endocytosis, compartment fusion etc. 
They are a short-hand way of representing molecular events that are not known, not 
recorded or not shown.  
 
Pathway outputs detail the cumulative output of series of interactions or function of 
an individual component at the ‘end’ of a pathway. Pathway outputs are shown in 
order to describe the significance of those interactions in the context of a biological 
process or with respect to the cell. The input lines leading into a pathway output node 
have been coloured light blue to emphasize the end of the pathway description.  
 
Depiction of Cellular Compartments 
A cellular compartment can be a region of the cell, an organelle or cellular structure, 
dedicated to particular processes and/or hosting certain sub-sets of components e.g. 
genes are found only in the nuclear compartment. Sub-cellular compartments are 
defined by a labelled background to the pathway and arranged with spatial reference 
to cell structure. Compartments are coloured differently for emphasis and to ease 
awareness the location of components. Similar or related compartments share the 
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same fill colour but have different coloured perimeters to define internal boundaries 
within a compartment e.g. membrane vs. lumen or to define the origin of 
compartments e.g. different classes of vesicles derived from the endoplasmic 
reticulum or plasma membrane. 
 
mEPN Use of Colour 
The mEPN scheme has been designed to function in the absence of colour and no 
aspect of it is dependent on colour for its full understanding, hence avoiding issues 
variable colour recognition capabilities between individuals and issues with a poor 
reproduction of figures. However colour is a powerful visual tool and has been used in 
the deployment of the mEPN for emphasis. A proposed colour scheme is described 
below although is open for adaptation to suit the end users needs or aesthetic tastes. 
Nodes may be coloured to differentiate between different node types e.g. between a 
protein, complex or gene, to denote their cellular location or expression/activity level.  
 
IFNγ Activation of MHC Class II Gene Expression: A Worked Example of 
the mEPN in Use 
In order to demonstrate the pathway notation system in action on a scale that can be 
viewed in this format, a small part of the pathway diagram in Chapter-2 has been 
extracted for discussion. Figure 3.7 depicts the activation of MHC class II genes by 
interferon-gamma (IFNG) as described in the literature and represented here using the 
mEPN scheme. 
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Figure 3.7: Graphical representation of the Interferon-gamma pathway leading to MHC Class II Antigen Presentation. Shown here are the known events between the 
release of IFNү and the subsequent up regulation of MHC class 2 antigen presentation by macrophages using the mEPN scheme. See results for a full description of this 
pathway.
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Going through these series of events (shown in Figure 3.7) in detail: IFNγ is secreted by 
T and NK cells upon activation [213-215] (not shown). It oligomerises to form a 
homodimer which then binds of to its receptor complex situated in the plasma 
membrane of macrophages [216]. This complex is formed from IFNGR1, IFNGR2, JAK1 
and JAK2 [217-218], two copies of all proteins being present in the receptor complex. 
Binding of IFNγ causes the autophosphorylation of JAK2 [219] which in turn 
phosphorylates STAT1 [217]. The autophosphorylation of JAK2 can be inhibited by 
SOCS1 or SOCS3 [59, 220], and the activated complex dephosphorylated by PTPN2 
[221-222]. STAT1 now activated, oligomerises, is further phosphorylated by PRKCD 
[223] and translocates to the nucleus where it directly activates gene expression by 
binding to STAT sites present in the promoters of numerous genes. Shown on the 
diagram are just two of these genes, SOCS1 and IRF1 [192, 224]. These form feedback 
inhibition and feed-forward activation loops, respectively. SOCS1 blocking further 
signal propagation through the inhibition of the IFNγ receptor complex (reviewed in 
[225] and IRF1 being necessary for the activation of STAT1 expression as well as being 
a necessary component of the CIITA transcriptional initiation complex [148]. At least 
two complexes are reported to be necessary to activate the expression of CIITA 
(reviewed in [226], the first composed of STAT1, IRF1, USF1 and IRF2 which binds to 
the so called pIV element of the CIITA, the second is comprised of STAT1, CREB1, 
RUNX2/3, TCF3, SPI1 and IRF4 which binds to the pIII element of the gene. CIITA is a 
co-activator and the key missing element in the transcription of MHC class II genes. 
Once translated it binds to a preassembled transcription factor complex, including 
members of the RFX and NFY family of proteins and CREB1, thereby activating the 
expression of the MHC class II genes [226]. This class of genes includes CD74, HLA-
DPA/B, HLA-DQA/B, HLA-DRA/B [225, 227] and through combinatorial assembly form a 
wide variety of complexes denoted here generically as CD74 (li):HLA-D (alpha):HLA-D 
(beta). It is this class of complexes that is shown in the main diagram to go on through 
a long series of steps to bind peptide antigen derived from the lysosomal degradation 
of pathogen proteins and present them to T-helper cells. As such this diagram serves 
as a graphical representation of the known pathway connecting IFNγ secretion to the 
activation of MHC class II antigen presentation.  
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Efforts in developing this notation scheme have now reached a point where little need 
to change the majority of the mEPN scheme as presented here is foreseen. Clearly the 
modelling of other systems and ideas from others however may in the future present a 
case for further modifications or refinements. 
 
Visualization of Pathway Information in 3D Environments  
The reliance of the mEPN scheme on the principles of network graphs and use of 
simple node shapes, labels, edges and colour to convey pathway information has 
presented the opportunity to examine the use of other environments in which to 
visualize pathways. Layout of pathways in 3D space begins to address the issue of 
scalability associated with visualizing very large pathway diagrams and offers a little 
explored environment to visualize and interact with pathway models. Hence devised 
for the first time is a 3D translation of mEPN scheme (Figure 3.8). The scheme is 
devised to reflect the colours and where possible glyphs used in the 2D mEPN process 
diagrams converting the 2D shapes into 3D objects. The proposed notation scheme is 
currently supported by the network visualization and analysis tool BioLayout Express3D 
(see Figure 3.9) [138, 206]; http://www.biolayout.org/) which also currently supports 
the direct import of pathways as .graphml files, the main file type used by us to 
support our pathway modelling efforts. The potential of representing pathways in 3D 
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Figure 3.8: The mEPN3D scheme. Presented here is a conversion of the standard mEPN scheme into a 
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Figure 3.9: Pathway Representation in 3D Environment. Large macrophage activation pathway 
rendered in 3D environment where node shape, size and colour represents a components identity. (a) 
Nodes coloured according to type e.g. light blue - proteins, yellow - protein complexes, purple – generic 
molecular species. All process nodes are depicted as small cubes and coloured according to type. (b) 
Nodes coloured according to cellular location e.g. brown – plasma membrane, yellow – cytoplasm, 
purple – endosome, green nucleus. Process nodes/Boolean logic operators are shown as having no 
cellular location and are coloured dark blue (no class). (c) Nodes coloured according to overlay of data, 
in this case expression data. Colour of nodes represents co-expression cluster following stimulation of 
mouse macrophages with IFN-β (d) A representation of the interferon-beta signalling pathway and the 
transcriptional network it controls. The signalling network is represented using the mEPN3D notation 
with the addition of transition nodes for use in modelling studies. Connected to it are clusters of genes 
up or down regulated by IFN-β which have been stacked in at different layers depending on the their 










Models of pathways produced either as a graphical representation of known events or 
as a resource for mathematical modelling, are fundamental to our understanding the 
workings of biological systems. However the task of assimilating the large amounts of 
available data and representing this information in an intuitive manner remains a 
challenge. Accordingly there has been increasing interest in the biology community to 
develop approaches for representing biological pathways. The Molecular Interaction 
Map (MIM) and Process Description Notation (PDN) schemes were proposed by Kurt 
Kohn [104, 209] and Hiroaki Kitano (Kitano 2005), respectively, and their ideas laid the 
foundations for much of the work on pathway notation that has followed. The current 
mEPN scheme is the based on ideas from the PDN and original EPN schemes but 
importantly the experience of over four years of pathway construction, notation 
testing and discussions.  
 
The objectives of the EPN as originally proposed remain preserved, as do many of the 
original concepts of the EPN and PDN schemes [103, 105]. However substantial 
modifications have been made to the notation system from the introduction of new 
symbols to changes in the aesthetics of the scheme and pathway syntax in order to 
achieve the schemes original objectives. Firstly was the desire to develop a notation 
system that was flexible enough to allow the detailed representation of diverse 
biological entities, interactions and pathway concepts. In this respect, the mEPN as 
described here has not only been used in the construction of the large macrophage 
pathway diagram [211] detailed in Chapter-2, which in its own right covers a diverse 
range of signalling and effector pathways, but also for the depiction of cholesterol 
metabolism and the cell cycle by other students (not shown). In all of these 
endeavours the mEPN scheme has been able to depict the literature-based 
understanding of these systems and where it was formerly unable to support a 
concept, it was modified to allow it to do so. Secondly was the need for a system for 
presenting pathway knowledge in a semantically and visually unambiguous manner. To 
some degree this is down to actually labelling components in a way that is 
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unambiguous. The use of standard gene nomenclature to label genes/protein 
components, together with a formalized system to describe modifications to them, 
goes some way to achieving this. This has meant in many cases that the literature 
which describes these systems using numerous different names for the same protein 
or complex must be de-convoluted. It means however that one component is unlikely 
ever to be represented more than once but with different names. It also facilitates use 
of the diagrams in the interpretation of experimentally derived data which is usually 
annotated using standard gene nomenclature. The third aim, which is related to the 
second, is that diagrams are as simple as possible to construct and are understandable 
by a biologist. To help ensure this to be the case all the work in creating the pathway 
diagrams has been performed by relatively junior biologists (myself as a PhD student 
and MSc students). Those constructing the pathways were encouraged to discuss their 
ideas and pathways with each other so as iron out areas where the information was 
not clearly depicted. For this to happen one must be able to communicate complicated 
biological concepts using the diagrams. The readability of a diagram is not only 
dependent on the notation system but also on its layout. Although a variety of 
automated layout algorithms exist for network graphs they do not perform as well as a 
human curator with an artistic eye for the task. Pathway layout is relatively trivial for 
small diagrams, but a long time has had to be spent on optimizing the layout all of our 
large pathways so that they are easily interpreted. Finally, pathway diagrams are 
central to efforts to computationally model the observed behaviour of biological 
systems [119]. The fourth objective has therefore been to develop the mEPN such that 
the semantics of the resulting network diagrams are sufficiently well defined that 
software tools can convert graphical models into formal models, suitable for analysis 
and simulation. Whilst the primary objective behind the efforts has been to create a 
graphical model of events, the group has been mindful to construct pathway diagrams 
as directional networks that could in principle support studies on the dynamics of 
these systems. In examining various approaches to pathway modelling some are 
clearly not scalable, such as those using ordinary differential equations (ODEs) that 
require interaction parameters to be known or computed. Other approaches do not 
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support the modelling of the co-dependencies between components of a pathway or 
give quantitative outputs (reviewed in [128, 227].  
 
With the increasing interest in pathway science and depiction a community effort to 
develop a standard notation was formed, known as the Systems Biology Graphical 
Notation (SBGN)[228], and running concurrently with mEPN work has been this 
ongoing community effort to establish rules for best practice in pathway depiction. 
This effort aims to combine the strengths of the various proposed notation schemes 
and arrive to a consensus approach for representing biological pathways and only 
recently and a manuscript describing the SBGN Process Diagrams Level 1 specification 
was published [158, 228]. The mEPN scheme as described here aspires to many of the 
same goals as the SBGN and where possible we have tried to harmonize the mEPN 
scheme to the emerging SBGN specification. However, experience in building large-
scale pathway models of a variety of biological systems has required the group to 
depict concepts not currently supported by the SBGN scheme. Furthermore, a lack of 
available pathway editing tools when this work began, as well as the scale of diagrams 
produced (see Chapter-2), have both played their part in determining the mEPN 
approach to pathway depiction. As a result there are a number of important 
differences that exist between the mEPN scheme described here and the SBGN 
scheme as currently proposed. Firstly, in common with the proposed SBGN scheme, 
the mEPN uses simple shapes to define the class of a component but only a labelling 
system to define the exact identity of components (nodes). The SBGN scheme 
proposes the use of circles overlaid on nodes to depict protein modifications. This has 
been found to be a considerable overhead to implement and can interfere the clarity 
of what is depicted rather than enhancing it. Furthermore the notation scheme is not 
supported by many of the general purpose network visualization tools e.g. yEd, 
Cytoscape, BioLayout Express3D [108, 229-230] in general use, requiring instead the use 
of dedicated pathway software. Secondly, the mEPN avoids the use of different styles 
of arrowheads to depict the nature of interactions (edges) which limits the vocabulary 
of edges and is a system that can be challenging to remember. Instead where 
appropriate, inline annotation nodes are used to depict the meaning of edges; these 
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carry a visual clue (a letter symbolizing the meaning of the edge e.g. A for activation, I 
for inhibition) and can potentially support a wider range of edge meanings. Again the 
use of a wide variety of arrowheads is not supported by many pathway/network 
editing software packages. Finally, using the mEPN one can explicitly state the nature 
of interactions by the use of labelled process nodes. In the proposed SBGN scheme 
process nodes are used but generally not as a means to convey the nature of 
interactions except in the case of protein binding (association) and dissociation. When 
pathways are large and the distance between interacting species may be great, having 
a visual clue as to the nature of interactions is very important. Whilst on these and 
other points the mEPN and SBGN schemes may differ, we are fully supportive of the 
SBGN’s efforts to promote a common notation system and hope that current the work 
presented will contribute to the adoption of common notation schemes for pathway 
depiction. A full description of the differences between the SBGN level 1 notation and 
the mEPN as described here follows.  
 
Comparison of the mEPN Scheme with the current SBGN Level 1 
specification for the Depiction of Process Diagrams 
The mEPN (modified Edinburgh Pathway Notation) and SBGN (Systems Biology 
Graphical Notation) schemes provide two similar but different ways to depict process 
diagrams.  Each scheme is divided into a set of glyphs to depict different concepts 
(components, processes, relationships, cellular compartments) for the use of depicting 
what is known about a biological pathway as a network diagram. Both schemes were 
developed over roughly the same period of time the SBGN scheme by members of the 
SBGN community (which includes some of those involved with the mEPN); the mEPN 
scheme at the Division of Pathway Medicine, the Centre for Systems Biology Edinburgh 
(CSBE) and Roslin Institute, University of Edinburgh. Both schemes also aspire to fulfil 
many of the same goals. 
 
Although many of the concepts are named differently, many glyphs differ between the 
two notation systems they are similar enough to compare. Below is a comparison of 
the main features of both notation schemes and the glyphs used within them. Since 
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different naming conventions are used by the notation systems to describe glyphs, the 
most similar or conceptually equivalent nodes are compared below. Where a glyph 
exists in one notation scheme but not in the other a blank space can be found in the 
adjacent area of the table.  
Full details of the SGBN scheme can be found at (Le Novère, N. et al., The Systems 
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Table 3.1: Comparison of the mEPN and SBGN.  
 
Notes 
i Pathway Interactant Depiction 
Nodes which are the biological constituents participating in a particular metabolic or signalling pathway 
are referred to as Components in the mEPN and Entity Pool Nodes are the equivalent in the SBGN.  
ii Comparisons of observable and pathway output glyphs 
Observable and pathway output are comparable nodes; observable is used to describe a process 
affected by, or a phenotype generated as a result of pathway signalling. Pathway Output is also used for 
this purpose and always at the end of a series of directional interactions to highlight the consequence of 
a set of interactions.  
iii Energy/Phospho Transfer Depiction 
SBGN use two nodes (simple chemical) each time to show the transfer of x-tri-phosphate  x-di-
phosphate (e.g. ATP  ADP, GTP  GDP, whereas in the mEPN we have chosen to depict these 
reactions in one glyph which points to the process requiring energy/phosphate transfer. The use of a 
single glyph to depict energy/phospho-transfer was determined to be the most space efficient way to 
depict these co-reactions due their widespread occurrence in biology. 
iv Compartmentalisation 
In both notation schemes the glyphs used to contain nodes present in a given sub-cellular-compartment 
can take any geometry. The SBGN container nodes are also used for containing a complex or a submap 
(a node used to encapsulate processes within one glyph).  
  Logic Arc 
 



















Unit of information 
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v Sink Nodes 
Sink is an entity pool node in the SBGN and considered a process node in mEPN. Furthermore in mEPN 
the use of the sink node is restricted to defining the removal of a component from a system which in all 
cases to date has been by proteasomal degradation. 
vi Other Processes 
Other processes in the mEPN shown reading from left to right in the table are Activation (A), Inhibition 
(I), Oligomerisation (O), Cleavage (X), Auto-cleavage (AX), Catalysis (C), Auto-catalysis (AC), Translocation 
(T), Transcription/Translation (TL), Secretion (S), Phosphorylation (P), De-phosphorylation (-P), Auto-
phosphorylation (AP), Phospho-transfer (PT), Ubiquitination (Ub), sumoylation (Su), selenylation (Se), 
glycosylation (Gy), prenylation (Pr), methylation (Me), acetylation (Ac), palmitoylation (Pa), protonation 
(H+), sulphatation (S), pegylation (Pe), oxidation (Ox), myristoylation (My), and hydroxylation (OH). Use 
of colour is optional. The nature of processes (transitions) are not generally defined under the current 
SBGN specification. 
vii Boolean Logic Operators 
Both notation systems make use of Boolean logic commands AND / OR, however extensive use of the 
mEPN has yet to find use of the NOT command for signalling pathways and is therefore currently not 
included from the mEPN notation. Something NOT doing something would seem to be obvious by its 
omission. 
viii Edges 
The lines connecting components and process nodes are referred to as edges in mEPN or connecting 
arcs in SBGN. The mEPN does not make use of different styles of arrowheads to depict the nature of 
interactions (edges) instead where appropriate an diamond-shaped inline annotation node carrying a 
visual clue (a letter symbolising the meaning of the edge e.g. A for activation, I for inhibition) is used to 
depict the meaning of edges. 
ix Node Annotations 
No naming conventions are currently recommended by SBGN.  When non-standard nomenclature is 
adopted it frequently leads to ambiguity as to the exact identity as to what is being depicted as multiple 
component names are often available to describe a given component. Under mEPN we recommend the 
use of standard nomenclature systems for components e.g. HGNC or MGD conventions to name human 
or mouse genes/proteins, respectively. Use of standard nomenclature also assists in the comparison and 
overlay of experimental data with pathway models. Additional information about a component 
(modifications, states, numbers of given components within a complex) are referred to as annotations 
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Other Differences 
Cloning concept of SBGN 
If a component (entity pool node) is duplicated on the map it is indicated by using a 
‘clone marker’ (shading in the bottom third of the node) the purpose of this being to 
allow the reader a visual indication that the node has been duplicated elsewhere on 
the map. Whilst on a map of moderate size this maybe practical (allowing the reader to 
identify how many times the node is duplicated) on a larger scale and where multiple 
nodes are cloned it may become difficult to trace how many times the node is cloned.  
 
In contrast to the SBGN, mEPN usage rules dictate that a component node (proteins, 
complexes, etc) representing a given entity may only be represented once in the in a 
given sub-cellular compartment (this rule does not apply to ubiquitous components or 
reactions e.g. simple ions, energy transfer reaction nodes). The trade off here is that so 
called ‘hub’ nodes (those with many connections) will have many edges emanating 
from them to other components in various different locations of the map. However, 
the number of edges leaving each node gives the reader an exact indication of its 
connections and hence activity in the map without the need for scanning the entire 
diagram to find cloned nodes. Furthermore, the SBGN has laid out rules as to which 
glyphs may be cloned and which then require clone markers, adding yet another set of 
rules that map constructers must learn. Although both notation systems do not 
provide a perfect solution to dealing with highly connected nodes arguably the mEPN 
rule (biological component can be shown only once in a given sub-cellular 
compartment) is a more practical resolution for readers and constructors of the 
diagram for the reasons discussed above and also since repetition of identical nodes 
consumes more space on the map. 
 
3D Rendering of the mEPN 
One advantage of the simple node and edge based approach to pathway element 
depiction in the mEPN is that it supports the notations conversion into other software 
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environments. In particular there is a growing use of technology developed in the 
gaming and animation industries to support the visualization of data in virtual 3D 
environments. BioLayout Express3D, a network analysis tool developed at the Roslin 
Institute and EBI and employing the 3D graphics application programming interface 
(API) OpenGL, provides a powerful tool with which to visualize and analyze a variety of 
types of ‘omics data as networks [138, 206]. Recently implemented is the import of 
.graphml files into BioLayout Express3D such that the pathway diagrams can be viewed 
in 3D as well as a 2D environment. In this environment node walks can also be 
performed to identify the parents or children of any given node or set of nodes, 
thereby allowing the connectivity between components in large pathway systems to 
be explored. Interestingly and at first a surprise, was the effect of translating a 2D 
pathway layout as described in the original .graphml node co-ordinates into a 3D 
environment. In this way diagrams may be rotated, zoomed in on and generally 
explored in an environment which is quite different to that of a 2D representation. In 
the 3D environment colour is a powerful device that can be used to further overlay 
visual information on to nodes (Figures 3.9.a c). Pathways can also be visualized using 
3D organic layout algorithms (Figure 3.9. d.). This visualization of the pathways is 
engaging but is currently of limited utility. However, it is possible to imagine much 
larger models of pathway systems where the spatial layout of components in 3D space 
is based on a components cellular location and the visualization more closely 
approximating an in silico cell. With BioLayout Express3D now capable of supporting 
networks comprising of up to 45,000 node graphs there is considerable scope for 
building ever larger pathway models and further exploring the potential of 3D 
environments for pathway visualization and analysis. 
 
Conclusions  
There are significant efforts already underway to garner the support and interest of 
the wider biological community in assembling resources, information and pathway 
diagrams covering a broad spectrum of biology. Indeed, the need has never been 
greater for these resources. However, if they do not record pathways in a standardized 
way, integration of the results of these efforts will continue to be a considerable issue. 
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To this end the mEPN is fully supportive of the SGBN’s effort to promote the principles 
of standard notation systems even if as a group we cannot fully support the proposed 
SBGN specification for process diagrams. The hope is that this work in its published 
form [212] and the pathway diagrams [102, 211](and Chapter-2) will act as a positive 
contribution to the debate about how best to graphically model pathway knowledge.  
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Chapter 4. Analysis of the transcriptional networks 
induced by type I and type II interferons 
 
 




Transcriptional response of macrophages to interferons 
IFNs induce or repress the expression of hundreds of genes known to mediate a wide 
range of biological responses. Transcriptional targets of the interferon response are 
collectively referred to as Interferon Stimulated Genes (ISGs).  Presently around 2,000 
[231] ISGs have been identified by transcript profiling. However these have been 
derived from a variety of studies based on the analysis of different cell types using 
different array platforms and only a few of the genes are functionally well defined. 
Some of the best studied ISGs [232] are known to play pivotal roles in host defence 
including; the double-stranded RNA-dependent kinase “protein kinase RNA-regulated” 
(PRKR) [233], a family of  2’-5’-Oligoadenylate Synthetases (2’5’OAS) that lead to the 
activation of RNase L and degredation of cellular RNA [234], and the Mx proteins 
(these possess GTP binding and GTPase activity) and have been shown to restrict 
growth of certain viruses [235-236]. However the anti-viral effects of IFNs can only be 
partially attributed to these genes since mice triply deficient for PRKR, RNase L and Mx 
genes retain a degree of responsiveness to the antiviral effects of IFNs [237]. Hence 
alternative antiviral pathways and other ISGs yet to be (fully) functionally characterised 
may yet play role as potent antiviral effectors.   
 
Some ISG’s are regulated by both type-I and type-II IFNs i.e. there is a degree of 
overlap in the transcriptional networks they activate, whereas others are selectively 
regulated. IFITM1 for example is induced by all interferons whereas 2’-5’-
Oligoadenylate Synthetase I is induced in response to type-I interferons IFN-α and IFN-
β, and not the type-II IFN-γ [238]. IRF1 expression on the other hand is preferentially 
induced by IFN-γ [238]. Moreover the activation of MHC Class II antigen presentation 
in macrophages is only efficiently achieved by IFN-γ regulation of the CIITA gene [239-
240](depicted in Chapter-3 Figure 3.7). Selective regulation of ISGs by type-I or type-II 
IFN signalling could be attributed to the activation of different downstream signalling 
cascades, differential activation of transcription factors, and variation of promotor 
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elements in target genes; since some ISGs contain only ISRE’s and others only GAS 
elements in their promotors, whereas others have both elements. 
 
The JAK-STAT signalling cascades immediately downstream of the IFN type-I and type-II 
receptors is well characterised (and represented on our pathway model) however their 
links to other signalling pathways and the precise regulation of the transcriptional 
response is not well characterised or fully understood. 
 
Functional relevance of type I and type II signalling convergence 
The type-I and type-II signalling pathways cross-talk at multiple levels; sharing pathway 
components and overlapping in their transcriptional targets (see Chapter-1; Figure 
1.3). IFN-γ primarily signals through STAT1:STAT1 homodimers, although it also 
activates to a lesser extent the archetypal type-I transcription factor ISGF3.  ISGF3 is 
able to induce the expression type-I interferon and thereby amplify its response. 
Conversely type-I interferon can activate classical type-II signalling molecules e.g STAT1 
and thereby modulate the transcription of ISGs with GAS elements. The cross-talk and 
convergence of these signalling pathways is biologically relevant, since in vivo cells are 
not generally exposed to single cytokines but rather a cytokine cocktail [59]. 
 
It has been suggested that the two interferon systems may have evolved to 
complement each other in overlapping but non-redundant activities in order to defend 
against a broad range of pathogens [241]. IFN-γ-/- and IFNGR1-/- mice appear to 
develop a normal immune system, however they show deficiencies in natural 
resistance to bacteria, parasitic and viral infections [241]. Some viruses appear to 
require both type-I and type-II pathways [241] and others require predominantly type-I 
or type-II interferon for efficient clearing [242]. Since IFNs illicit their response by 
activating a large transcriptional cascade, the differential regulation of genes by the 
two types of interferons warrants further analysis to advance our understanding of the 
overlap and differences in functionality of the different interferons.  
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Microarray experiments examining the transcriptional changes induced by interferons 
are available [238, 243-247] however those based on the response induced in 
macrophages (and specifically mouse BMDMs) are not as comprehensive as those 
investigating the LPS response.   There are also limitations to some of the existing 
available microarray data. For example, studies conducted prior to 1995 are not 
genome wide; studies conducted before 2001 are not MIAME (minimum information 
about a microarray experiment) compliant and therefore unavailable as raw data files 
or poorly described and annotated. Other studies are not necessarily performed on 
robust platforms, for instance those conducted on spotted arrays [247]. Finally some 
experiments have a limited number of data-points (time-points analysed) and the 
overall experimental design is not conducive to exploring the temporal changes in 


















In order to further our understanding of the transcriptional events in response to 
stimulation of mouse bone marrow derived macrophages (BMDMs) by type-I and type-
II IFNs, microarray analysis was performed over a time-course of stimulation by these 
cytokines. IFNs are well known for their anti-proliferative effects.  Murine BMDMs 
(when cultured in CSF-1) are actively in cell cycle; do generally not constitutively 
express IFN-β; and are MHC Class-II negative [11]. Thus this system includes a biology 
of IFNs not easily seen in other cellular systems. In separate experiments mouse 
BMDMs were stimulated with either 10 U/ml mouse IFN-γ or 10 U/ml mouse IFN-β, 
where one U/ml is defined as the concentration required to inhibit viral replication by 
50%. In the case mouse IFN-γ and IFN-β biological activity is determined (by the 
manufacturers) by measuring the ability to induce cell resistance to infection by 
encephalomyocarditis virus (EMCV).  
 
In both experiments, cells were harvested for 1, 2, 4, 8, and 24 h post-IFN treatment or 
pre-treatment (0 h). High quality RNA was processed for labelling and hybridisation to 
the Affymetrix Mouse Exon 1.0 ST arrays.   
 
IFN-γ transcriptional network 
 
12 Affymetrix Mouse Exon 1.0 ST Arrays were processed for this study although one 
array failed due to array scanning-equipment failure. This resulted in the loss of one of 
the two, 2-hour biological replicate sample. Remaining arrays were normalised using 
RMA. Statistical filters were applied as a method for removing noisy and potentially 
un-interesting data. I,678 transcript passed this filter and a network-graph of the data 
was generated by filtering edges at a Pearson correlation threshold of 0.9 . The 
resultant network graph (Figure 4.1) of 1,474 nodes connected by 26,617 edges was 
clustered using the graph-based clustering algorithm MCL [137] set at an inflation 
value of 2.2 resulting in 40 clusters with a membership of 6 or more nodes 
(transcripts).  




Figure 4.1: Transcriptional network formed from expression data of a time-course of IFN-γ stimulation 
of mouse BMDMs. Mouse BMDMs were treated for 1, 2, 4, 8, and 24 h with IFN-γ or were not treated (0 
h). Gene expression across each time-point was measured on Affymetrix Mouse Exon ST1 Arrays and a 
network graph of the data generated using BioLayout Express3D. The network was filtered to display only 
relationships at or above a Pearson correlation threshold of 0.9, resulting in a graph 1,474 nodes 
connected by 26,617 edges. The resultant network was then clustered using the graph-based clustering 
algorithm MCL set at an inflation value of 2.2. Nodes (transcripts) belongings to same cluster share the 
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Description of clusters 
 
Each cluster in the network represents a group of genes with a related pattern of 
expression over the time-course. Some clusters represent very similar patterns of 
expression, however form separate clusters due to subtle difference in their 
expression patterns.  Individual clusters were assigned a description based on the 
expression pattern the cluster represented. Descriptions were based on a number of 
characteristics of the cluster, including;  
(i) the directionality of the change; where Up or Down defines up regulation 
or down regulation of transcripts within the cluster relative to time 0 h.  
(ii) The dynamics of the temporal change in expression; where transient 
implies the change in expression is reversible / not continuous/ occurs over 
given periods of time and then returns to basal levels. Sustained implies the 
change in expression is maintained over the time points studied. 
(iii) The time point(s) where maximal or minimal expression is reached in 
comparison to basal levels. This is denoted by the number(s) following the 
Up or Down description. 
(iv) The duration over which any change in expression is taking place; this is 
denoted by the numbers in brackets. 
(v) The original identifying cluster number is shown at the end of description. 
 
For example the following description “Ifng_transient_Up_8_(4-8)_C1” would imply 
transcripts belonging to this cluster one are up-regulated in expression, reach maximal 
expression at 8 hours, however the increase in expression is already apparent from 4 
hours and lasting until 8 hours. The same cluster naming scheme is adopted to 
describe clusters from the IFN-β time-course study.  
 
Clusters were annotated based on their gene membership and over-representation of 
cohorts of functionally associated genes. Annotation was performed using the online 
Database for Annotation, Visualization and Integrated Discovery (DAVID) which 
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identifies enriched biological themes within gene lists [248-249]. For the purpose of 
annotating these datasets GO (Gene Ontology) annotations defining both biological 
processes and metabolic function were assessed using DAVID. The most over-
represented terms (based on DAVID analysis of GO Ontology terms (GO FAT category)) 
were chosen to describe the biology of the clusters. Table 4.1 provides an overview of 
the major clusters of interest in the IFN-γ response data set, along with the number of 
transcripts within each cluster, examples of gene members and the most represented 
GO terms as determined by DAVID. The clusters are ordered in the table according to 
the temporal phase the transcripts are changing in expression; immediate early (1-2 




























































































 16 ↑ 13 Ifng_transient_Up_1_C16 Fos, Myc, 
Cxcl1 
Positive regulation of transcription; positive regulation of 
gene expression; positive regulation of RNA metabolic 
process; negative regulation of apoptosis 
28 ↑ 7 Ifng_transient_Up_1_(1-2)_C28 
Ier3, Ccl3, 
Nfkbiz 
Defence response; positive regulation of gene expression 
/transcription 
23 ↑ 9 Ifng_transient_Up_2_(1-2)_C23 Fosl2, Socs3 














Response to organic substance (nitrogen); regulation of cell 
cycle, chemokine activity. 
11 ↑ 21 Ifng_transient_Up_2-4_C11 Il17ra, Bach1 
Response to wounding; regulation of phosphoinositide 3-
kinase cascade; regulation of transcription 










22 ↓ 10 Ifng_transient_Down_4_(2-4)_C22 Kns2 Annotation Stats Unavailable 





Positive regulation of cell proliferation/ differentiation; 
regulation of mesenchymal cell proliferation; regulation of 
transcription 
24 ↓ 8 Ifng_transient_Down_4_C24 Oma1 Transcription factor binding 
36 ↓ 7 Ifng_transient_Down_4_C36 Irak3 Annotation Stats Unavailable 
37 ↓ 7 Ifng_transient_Down_4_C37 Ccdc128 Ribonucleotide binding 






positive regulation of NF-ĸB transcription factor activity; 
immune response; regulation of apoptosis; regulation of 
transcription 
4 ↓ 84 Ifng_transient_Down_4-8_C4 
Mcm2, Pole, 
Cdc2a 
DNA replication; DNA replication initiation, cell cycle, DNA 
repair, DNA packaging, DNA binding,  
5 ↓ 62 Ifng_transient_Down_4_(4-8)_C5 
Cdc6, Cep55, 
Ccne2 
Cell cycle; cell division; mitotic cell cycle; M phase of cell 
cycle; organelle fission; chromosome segregation; DNA 
replication 
30 ↓ 7 Ifng_transient_Down_4_(4-8)_C30 Fli1 Ion binding 
31 ↓ 7 Ifng_transient_Down_4_(4-8)_C31 Mvd ATP binding 
10 ↓ 24 Ifng_transient_Down_4-8_C10 Gab3, Coro1a Nucleotide receptor activity, G-protein coupled 
27 ↓ 8 Ifng_transient_Down_4-8_C27 Dusp19, Ing4 Annotation Stats Unavailable 
26 ↓ 8 
Ifng_4-min_8-max_Down_Up_4 & 
8_C26 


















(Innate) Immune Response; programmed Cell Death; 
Defence response;  
7 ↓ 39 Ifng_transient_Down_8_(4-8)_C7 
Ccdc5, Mxd4, 
Alox5 
Oxidation reduction; fatty acid metabolic process; 
coenzyme binding 
12 ↓ 21 Ifng_transient_Down_8_(4-8)_C12 Scamp5 
Lipid localization / transport; fatty acid transport; vesicle 
mediated transport 
13 ↓ 20 Ifng_transient_Down_8_(4-8)_C13 Scd2 
Organic acid catabolic/ biosynthesis process; fatty acid 
metabolic process 
14 ↓ 16 Ifng_transient_Down_8_(4-8)_C14 Aldoc Annotation Stats Unavailable 
17 ↑ 13 Ifng_Up_8_(4-8)_C17 Entpd1 
Response to extracellular stimulus; protein maturation; 
protein processing 
8 ↑ 27 Ifng_transient_Up_8_C8 Nfe2l1, Bag3 
Negative regulation of apoptosis; regulation of RNA 
metabolic process 










 18 ↓ 13 Ifng_sustained_Down_8_(4-24)_C18 Cd14 Annotation Stats Unavailable 
9 ↑ 24 Ifng_late-response_Up_24_(8-24)_C9 
Psmb9, 
Psma7 
Proteolysis; peptidase activity; MHC class I protein binding; 
protein catabolic process 
6 ↑ 47 Ifng_late-response_Up_24_C6 
H2-Ea, Il2rg, 
Ccr5 
Antigen processing and presentation of exogenous antigen; 
oxidation reduction; antigen processing and presentation of 
peptide antigen via MHC class II 
Table 4.1: Description of clusters of co-ordinately expressed transcripts in response to IFN-γ stimulation of 
mouse BMDMs. Clusters are arranged according to the timing of response they reflect.  
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During the immediate early response (1-2 hours post IFN-γ) there were relatively few 
genes changing in expression as compared to the rest of the data. During this early 
phase a positive regulation of transcription was observed including the regulation of 
many transcription factors (TFs). These TFs may control the next waves of response 
observed in the data.  Also during this immediate early phase there are indications of 
cytokine signalling regulation; for example the suppressor of cytokine signalling 3 
(Socs3) known to control the extent and duration of the interferon response, increases 
very transiently in expression. Indications of an immune response are observed 
(chemokines/defence response) in a handful of changing transcripts during the early 
phase.   
 
During the mid-response there is initially an increase in expression of genes 
contributing to a positive regulation of cell proliferation, however this closely followed 
by a strong signal to repress cell cycle (clusters-5 and 6). The mid-response stage also 
comprises the first major immune signalling response cluster (2) enriched for innate 
immune, apoptosis, and NF-kB signalling transcripts. However the largest cluster (1) 
containing the major interferon-stimulated-genes, appears from mid-late reaching 
maximal expression at 8 hours. Also during this mid-late phase fatty acid metabolism, 
lipid transport and metabolic processes are repressed. Interestingly and in contrast to 
cluster-2, there is an up-regulation during the mid-late phase of negative regulators of 
apoptosis. Finally during the late response genes involved in proteolysis and antigen 
processing and presentation are expressed. 
 
 
IFN-γ Network Architecture 
 
To better visualise the architecture of the IFN-γ transcriptional-response network, a 
hierarchical interaction network of the clusters and their relationships was generated. 
(Figure 4.2). With the aid of an automated layout algorithm the cluster relationships 
were arranged to flow from left to right and in this direction display the temporal 
changes in transcription (from early to late response). Up regulated components 
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(coloured red) form discreet clusters with distinct expression profiles and three of 
these are the largest in the data set.  The down-regulated graph component (in green) 
on the other hand is made up of comparatively smaller clusters with more intricate 
connections. The largest portion of transcriptional changes occurred during the mid-
period (taking place at 4 h post treatment).  In comparison fewer genes were regulated 
at the early (1-2 h) or late stages (24 h).  Furthermore only up-regulated clusters 
formed the immediate early response. 
 
To better visualise the temporal changes in gene expression, the average expression 
profile of all transcripts within clusters across a given time phase (immediate early, 
early, mid, mid-late and late) was plotted across the 11 arrays (Figure 4.3). Average 
expression for up and down regulated clusters was calculated separately, and the 
average maximal/ minimal expression varies across the different time phases.  
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Figure 4.2: Hierarchical interaction network of the IFN-γ transcriptional response in mouse BMDMs. 
Clusters relationships are shown by edges connecting the large red or green spheres, representing up 
(red) or down (green) regulated components of the response. Cluster membership (and relative size) is 
shown by the smaller red or green spheres connected to the larger cluster node and clusters are 
arranged to follow the order of temporal changes in expression. Transcripts within immediate-early 
clusters change in expression ~ 1-2 hours post treatment, those in early clusters ~ 2-4 hours, mid ~ 4-8 
(4>8) hours, mid to late ~ 4-8 (4<8) hours and late ~8-24 hours. 
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Figure 4.3: The average expression of transcripts stimulated (red) or suppressed (green) in response to 
IFN-γ treatment of BMDM across different temporal phases of the transcriptional response.  
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IFN-β transcriptional network 
 
12 Affymetrix Mouse Exon ST Arrays were successfully processed for this study all 
passing the QC. As with the IFN-γ-analysis raw data was normalised using RMA and 
statistical filters were applied to the normalised data as a method for removing noisy 
and potentially un-interesting data. A network graph of the filtered data was 
generated resulting in a graph of 2,045 nodes, connected by 92,947 edges at a Pearson 
correlation threshold of 0.9 or above (Figure 4.4). The resultant graph was clustered 
using the graph-based clustering algorithm MCL set at an inflation value of 2.2 
resulting in 33 clusters (with greater than 5 nodes). 18 of these clusters were 
considered to represent interesting patterns of expression. As with the IFN-γ network 
graph the IFN-β network also comprises two main graph components representing up-




























Figure 4.4: Transcriptional network formed from expression data of a time-course of IFN-β stimulation 
of mouse BMDMs. Mouse BMDMs were treated for 1, 2, 4, 8, and 24 hours with IFN-β or were not 
treated (0 hours). Gene expression across each time-point was measured on Affymetrix Mouse Exon 1.0 
ST Arrays and a Network graph of the data generated using BioLayout Express3D. The network was 
filtered to display only relationships at or above a Pearson correlation threshold of 0.9, resulting in a 
graph 2,045 nodes connected by 92,947 edges. The resultant network was then clustered using the 
graph-based clustering algorithm MCL set at an inflation value of 2.2. Nodes (transcripts) belongings to 
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Using the same cluster description process as used with the IFN-γ dataset, the clusters 
were assigned a description based on the timing and duration of the expression 
pattern they represented. The IFN-β clusters were also annotated based on their gene 
membership and over-representation of cohorts of functionally associated genes using 
DAVID analysis of GO biological and metabolic process annotations. Table 4.2 
summarizes the major clusters of interest in the IFN-β response data set arranged 
according to the temporal phase of the response they represent (early (1-2 h), early (2-
4 h), mid (4-8 h), mid to late (4-8 h) and late (24 h)).  
 
The immediate early response consisted of 16 transcripts increasing in their 
expression, including the suppressor of cytokine signalling, Socs3. The function of 
many of the genes represented within the immediate early clusters is currently poorly 
characterised and the only relevant annotation obtained from DAVID was ‘receptor 
linked signal transduction’.  Regulation of phosphorylation and transcription factor 
activity were the predominant signals during the early-phase of the IFN-β response, 
although this phase also saw the repression of genes related transcription-regulation 
and MAPKinase phosphatase activity. The mid-phase response consists of two of the 
largest clusters (clusters 1 and 2), both of similar size (379 and 376 transcripts 
respectively).  Transcripts within cluster-2 reached maximal expression around 4 h post 
IFN-β stimulation and are enriched for many of the well-known interferon-response 
genes including; Ifit1, Ifit2, Oasl1. In contrast, cluster-1 represents the repression of 
cell-cycle related activity including DNA replication, DNA repair and mitosis. By the 
mid-to-late phase only 52 transcripts are represented in the Up-regulated portion of 
the network graph and 81 transcripts in the down-regulated side. The late response 
predominantly comprises the repression of additional cell cycle related genes (cluster-
5), as well the induction of a handful of transcripts associated with T- and B-cell 


























































18 ↑ 10 Ifnb_transient_Up_1-2_C18 Socs3, Nfkbiz Annotation Stats Unavailable 









7 ↑ 75 Ifnb_transient_Up_2_(1-4)_C7 Socs1,Irf1, Nod2 
Regulation of phosphorylation, 
transcription factor activity, response to 
wounding hemopoiesis 
10 ↓ 32 Ifnb_transient_Down_2_(1-4)_C10 Mapk7, Zfp52 
Regulation of transcription; zinc ion 
binding; MAPkinase phosphatase activity. 




Zinc ion binding 
19 ↑  9 Ifnb_sustained_Up_4_(1-8)_C19 
Rab9 
Rtp4 










2 ↑ 376 Ifnb_transient_Up_4_(1-4)_C2 
Casp7, Cd40, 
Ifit1, Irf5, Nod1 
Immune response; defense response; 
cytokine activity; regulation of leukocyte 
activation; regulation of leukocyte 
proliferation; innate immune response; 
regulation of apoptosis 
3 ↑ 208 Ifnb_transient_Up_4_(2-4)_C3 
Stat1, Stat2, 
Gbp1, Psmb9 
Immune response; ribonucleotide binding; 
antigen processing and presentation 
8 ↓ 40 Ifnb_transient_Down_4_(2-4)_C8 Cdca7, Zfp60 
Regulation of transcription, DNA binding, 
zinc ion binding, chromatin organization 
1 ↓ 379 Ifnb_transient_Down_4_C1 
Brca1, Cdk2, 
Mcm2, Mdm1 
Cell cycle; DNA metabolic process; DNA 
replication; cellular response to stress; 
DNA repair; M phase; mitotic cell cycle 
4 ↓ 197 Ifnb_transient_Down_4_C4 
Dusp3, 
Mapkapk3,  
Nucleotide receptor activity-G-protein 
coupled; dephosphorylation; transcription 



















Annotation Stats Unavailable 
9 ↑ 39 Ifnb_sustained_Up_8_(1-8)_C9 Ccl5, Tlr7 
Immune response; inflammatory response; 
antigen processing and presentation; 
immune effector process; chemokine 
activity.  
6 ↓ 81 Ifnb_transient_Down_8_(4-8)_C6 Pdk1, Rak3 















Meiosis, M phase of Meiotic cell cycle, 
tRNA metabolic process 





Cell cycle; cell division, M phase, mitotic 
cell cycle, nuclear division, organelle 
fission, DNA replication 
14 ↑ 20 Ifnb_sustained_Up_8-24_C14 Fdg4, Tmem178 Annotation Stats Unavailable 
12 ↑ 30 Ifnb_sustained_Up_24_(8-24)_C12 Ccr5, Cd28, Ly9 
Positive regulation of interleukin-2 
production, T cell selection, T cell 
proliferation, positive regulation of B cell 
activation. 
Table 4.2: Description of clusters of co-ordinately expressed transcripts in response to IFN-β stimulation of 
mouse BMDMs. Clusters are arranges according to the timing of response they reflect. 




IFN-β Network Architecture 
 
In order to better visualise the structure of the transcriptional response network of 
mouse BMDMs to IFN-β stimulation a hierarchical interaction network of the clusters 
and their relationships was generated (Figure 4.5). As with the IFN-γ network (Figure 
4.2) the clusters are arranged to follow the temporal response (moving from early to 
late) and the ‘up’ and ‘down’ regulated graph components are shown in red and green 
respectively. The overall sizes of the Up and Down graph components is comparable, 
suggesting the extent of transcriptional induction is similar to the extent of 
transcriptional repression. The majority of transcriptional changes occur during the 
mid-phase, and the immediate-early response is reserved to up-regulated transcripts. 
The average expression profile of transcripts within clusters across a given time phase 
(immediate early, early, mid, mid-late and late) is shown in Figure 4.6. The average 
expression for up and down regulated clusters was calculated separately, and the 
average maximal/minimal expression varies across the different time phases.  
 
                                                                                                                             Chapter 4 
147 
 
Figure 4.5: Hierarchical interaction network of the IFN-β transcriptional response in mouse BMDMs. 
Cluster relationships are shown by edges connecting the large red or green spheres, representing up 
(red) or down (green) regulated components of the response. Cluster membership (and relative size) is 
shown by the smaller red or green spheres connected to the larger cluster node and clusters are 
arranged to follow the order of temporal changes in expression. Transcripts within immediate-early 
clusters change in expression ~ 1-2 h post treatment, those in early clusters ~ 2-4 h, mid ~ 4-8 (4>8) h, 
mid to late ~ 4-8 (4<8) h and late ~8-24 h.  
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Figure 4.6: The average expression of transcripts stimulated (red) or suppressed (green) in response to 
IFN-β treatment of BMDM across different temporal phases of the transcriptional response. 
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Comparison of transcriptional responses of BMDMs to IFN-β 
and IFN-γ 
 
The IFN-β and IFN-γ time-course experiments were originally conceived and analysed 
separately. Thus every aspect of the experimental set-up (from cell culture to 
microarray processing) was performed separately. However given our desire to 
understand the interplay between the type-I and type-II response [146], methods for 
comparing the two responses were explored. Ideally for comparative purposes the two 
experiments would have been set up and processed alongside each other. 
Nevertheless there was some legitimate reasons to believe that amalgamating the raw 
expression data from the two data sets and analysing these together would work, 
given the similarities of the experimental set up and the use of the same microarray 
platform. To explore whether the combined analysis of the two time-courses was 
viable the raw data sets were normalised together and some basic QC steps 
performed. A Pearson correlation matrix (Figure 4.7) of the normalised signal intensity 
across all 23 arrays (12 IFN-β and 11 IFN-γ) illustrated that the array samples correlate 
more strongly by the date of the experiment rather than by time post-treatment. In 
particular the 0 h IFN-β and 0 h IFN-γ pre-treatment samples do not appear closely 
correlated, as would be expected with un-treated samples of the same cell lineage, 
implying the concatenation of two datasets may not generate robust normalised data. 
This was further corroborated by plots of the average normalised expression of 
negative control probes on the arrays (Figure 4.8) where expression appeared elevated 
across the IFN-β arrays. Expression of control probes would be expected to be of 
similar intensity across all arrays but markedly different normalised values for negative 
control probes would further indicate fundamental differences between the two 
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Figure 4.7: A Pearson correlation matrix of the normalised signal intensity across 23 microarrays (12 
IFN-β and 11 IFN-γ). Raw data (CEL intensity files) from both the IFN-β and IFN-γ time-course 
experiments were normalised together using RMA. A Pearson correlation matrix of the signal intensity 
across the arrays was generated to gain an indication of which arrays were most correlated.  
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Figure 4.8: Average expression of Affymetrix negative control probes across 23 microarrays sampling 
IFN-β or IFN-γ treatment of macrophages. Raw data (CEL intensity files) from both the IFN-β an IFN-γ 
time-course experiments were normalised together using RMA. The average normalised expression of 
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The distinct differences of two sets of samples processed on different occasions 
impeded their combined analysis.  However the network analyses of the individual 
data sets can still be utilized to compare and contrast the transcription response to 
these cytokines.  Lists of co-ordinately expressed transcripts i.e clusters can be 
imported from one data-set and highlighted onto the network graph of another. 
Although absolute values of expression cannot be compared, it is possible to identify 
overlap in transcriptional activity and patterns of expression. 524 transcripts (matched 
by their unique gene-probe ID’s) were found to be common between the IFN-β and 
IFN-γ networks. DAVID analysis of GO annotations revealed the most over-represented 
biological process terms for the overlapping transcripts were ‘immune response’, ‘cell 
cycle’ and ‘intracellular signalling cascade’.   
 
In order to better visualise areas of overlap between the type-I and type-II response, 
the transcripts common to both networks were highlighted on the IFN-γ network 
according to their membership in IFN-β clusters (Figure 4.9).  Conversely the common-
transcripts were also highlighted on the IFN-β network according to their membership 
in IFN-γ clusters. 71 transcripts from the IFN-β cluster-01 (Ifnb_transient_Down_4_C1) 
were represented exclusively in the down-component of the IFN-γ network. Over half 
(201) of the transcripts within IFN-β cluster-02 were present in (only) the up-response 
of the IFN-γ network and 69% of these were represented in the mid phase of the 
response. In contrast IFN-β_cluster-03 transcripts were predominantly present during 
the mid-to-late stage of the IFN-γ-Up response. Up to half of IFN-γ cluster-05 
transcripts were common with transcripts from IFN-β cluster-05, both of which 
according to their GO annotations suggest repression of genes associated with the cell 
division and the mitotic phase of cell cycle. Four of the six transcripts (Axud1, Nfil3, 
Nfkbiz, Socs3) belonging to immediate early IFN-β-cluster-30 were also present in IFN-γ 
immediate early response. IFN-γ clusters with very little overlap of IFN-β cluster-
transcripts included cluster-06, cluster-08 and cluster-16, all representing up-regulated 
transcripts. The DAVID based annotations for these three clusters suggest their 
transcripts are associated with positive regulation of transcription (cluster-16), 
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negative regulation of apoptosis (cluster-08), and antigen processing and presentation 
(cluster-06).
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Figure 4.9: IFN-β transcript representation in the IFN-γ transcriptional network. Clusters of transcripts co-ordinately expressed in response to IFN-β stimulation of 
mouse BMDMs were imported from the IFN-β response network and highlighted on the IFN-γ network to reveal areas of overlap between the type-I and type-II 
response. 524 transcripts were common between the two data sets and these have been enlarged, elongated and coloured according to their IFN-β cluster membership. 
Transcripts that are not shared with the IFN-β network are shown as compressed, dark blue spheres. (See text for a description of the cluster overlap).   
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110 transcripts from IFN-γ cluster-01 and 122 transcripts from IFN-γ cluster 02 were 
present within the IFN-β network, and over 90% of these were within the mid-phase of 
the Up-response (see Figure 4.10 for illustration of cluster overlap). In total 57 
members of IFN-γ cluster-03 appeared within the IFN-β network, the majority were 
within the IFN-β early or mid-phase Up response. 50 transcripts belonging to IFN-γ 
cluster-04 were scattered across the different phases of the IFN-β down response. 47 
transcripts from IFN-γ cluster-05 were represented within the IFN-β network and 70% 
of these were within IFN-β cluster-05. Whereas IFN-y cluster-05 represents down 
regulation around the mid-phase, the IFN-β cluster-05 bears transcripts repressed 
during late stage of the IFN-β response. Other interesting areas of overlap include 
eight transcripts from the IFN-γ early response cluster-11 also present across the Up-
early phase of the IFN-β response. IFN-β clusters with little overlap with IFN-y network 
transcripts were the down-response clusters; cluster-08, cluster-10 and cluster 15. 
DAVID based GO annotations for these clusters suggest transcripts belonging to either 
cluster-08 or cluster-10 are associated with regulation of transcription and zinc ion 
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Figure 4.10: IFN-γ transcript representation in the IFN-β transcriptional network. Clusters of transcripts co-ordinately expressed in response to IFN-β stimulation of 
mouse BMDMs were imported from the IFN-γ response network and highlighted on the IFN-β network to reveal areas of overlap between the type-I and type-II 
response. 524 transcripts were common between the two data sets and these have been enlarged, elongated and coloured according to their IFN-γ cluster membership. 
Transcripts that are not shared with the IFN-γ network are shown as compressed, dark blue spheres. (See text for a description of the cluster overlap). 




The investigations of this Chapter set out to explore the pattern of transcriptional 
events in mouse BMDMs in response to type-I and type-II interferons. Specifically the 
objectives were twofold: (1) to gain a better understanding of the transcriptional 
events over a 24h time-course in response to IFN-β and IFN-γ respectively, and (2) to 
explore the application of network-based visualisation and analysis for the 
interpretation of the expression data generated. 
 
The Affymetrix Exon Arrays are designed for two complementary levels of analysis; 
gene expression and alternative splicing. Multiple probes (approximately four) are 
designed to target each exon and these probes can also be summarised into an 
expression value of all transcripts from the same gene.  A relatively new technology at 
the time, the arrays had many (17,000) probes un-annotated at the exon level. 
Furthermore the software support for analysing splicing events was still in its infancy. 
Exon-level analysis was explored for the data sets generated, but ultimately ‘gene-
level’ analysis was used as few if any convincing alternative-splicing events could be 
detected over the time-course of investigation. Thus having considered these caveats 
and given the original interests and objectives were not to identify alternative splicing 
events, a ‘gene-level’ analysis was more apt for this purpose. The raw expression data 
was normalised and statistical filtering applied beforehand to remove those transcripts 
with little change in expression across the arrays. A network based explorative 
approach was performed to visualise and analyse the expression data.  
 
Analysis of the individual data sets was performed first and overlap in the 
transcriptional response to the two cytokines was assessed.  Attempts were also made 
to concatenate the raw data sets to analyse them together.  In theory this was a 
feasible option since the two experiments were set up in similar formats; identical 
time-points, cell lineage, similar stimuli, and identical microarray platform. However in 
practice the data sets could not be analysed as one. This could be for several reasons 
technical reasons; the experiments were processed at different times, as were RNA 
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preparation, RNA labelling and microarray processing each factor potentially giving rise 
to systematic differences between the two data sets. Other biological reasons may 
have also influenced the differences in the two data-sets, for example the CSF-1 state 
of the cells. In the IFN-γ experiment cells were differentiated in L929-conditioned 
medium, whereas in the IFN-β experiment the cells were differentiated directly with 
recombinant CSF-1. CSF-1 was present throughout the time-course treatments in both 
experiments and is known to regulate a range of signalling pathways in macrophages 
[250]. The differences in cell culture techniques may therefore have influenced the 
concentration and action of CSF-1 on the cell and could be responsible for biological 
differences in the data sets.  
 
Network visualisation and analysis 
 
BioLayout Express3D was used to generate network graphs of the expression data 
derived from mouse BMDM stimulated with either IFN-β or IFN-γ over a time-course of 
24 h.  The network graphs generated from the data of both experiments (Figures 4.1 
and 4.4) encompassed two main graph structures, one comprising nodes (or 
transcripts) whose expression was up-regulated in response to interferon stimulation 
and the other containing transcripts whose expression was repressed. The resulting 
networks were divided into clusters of co-ordinately expressed transcripts using the 
MCL algorithm and those representing interesting patterns of expression (i.e. not 
clusters representing co-ordinately regulated but not differentially expressed 
transcripts) were retained for further analysis. The clusters derived from the IFN-β 
time course data ranged from 379 nodes to 6 nodes and IFN-γ cluster membership 
ranged from 224 nodes to 7 nodes. Total combined IFN-β cluster membership was 
greater (1,711 transcripts) than total IFN-γ cluster membership (1,038 transcripts), 
suggesting the extent of transcriptional regulation in macrophages is greater in 
response to IFN-β compared to IFN-γ. Stimulation of human PBMCs with a number of 
cytokines over a 24-hour period also revealed the extent and scale of transcriptional 
changes are greater in response to type-I interferons (IFN-α, IFN-β, and IFN-ω) 
compared to the type-II interferon IFN-γ [246].   
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Methods to automatically organise networks (otherwise known as layout algorithms) 
can enable interesting relationships and structure within data to be seen more easily. 
Automated layouts are rarely perfect (discussed Chapter-2) and most are easier to 
interpret after subsequent manual node rearrangement. To better visualise the 
structure of the IFN-β an IFN-γ response networks, cluster relationships and cluster 
membership information were extracted from the 3D-network graphs (Figures 4.1 and 
4.4) and with the aid of an automated layout algorithm in yED Graph editor [251] a 
hierarchical layout of the information was generated. With additional manual 
arrangement, clusters were arranged to flow according to the temporality of the 
transcriptional changes they represent, whereby early changes in transcription were 
placed at the left of the graph and later changes to the right. Arguably the hierarchical 
arrangement of the networks (Figures 4.2 and 4.5) facilitated the visualisation of the 
structure of the interferon response. The networks clearly illustrate, the majority of 
transcriptional changes take place during the mid-phase following IFN-β stimulation 
and across the mid and mid-to-late phase following IFN-γ stimulation. Genes of 
interest can be imported and highlighted onto to the (hierarchical) networks and their 
behaviour or annotation based on previous analyses can be contrasted to what is 
depicted in the existing network. This functionality was utilized to identify the overlap 
between the two networks and gain an appreciation how transcripts within IFN-β 
clusters behaved in the context of the IFN-γ network (and vice versa). Networks are 
well-defined mathematical objects and computational analysis of patterns within the 
network such as the use of the MCL algorithm here enables an automated and 
unbiased approach to data analysis and hypothesis generation. Nevertheless manual 
interpretation of the results is always necessary to ensure biological relevance. 
 
 
The IFN-β and IFN-γ transcriptional response in mouse BMDMs 
 
The networks generated (Figures 4.2 and 4.5) and functional annotation of clusters 
reveals both IFN-β and IFN-γ induce a complex transcriptional response, consisting of 
multiple gene sets encoding functional programmes controlling a number of different 
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processes. The structure and content of the type-I and type-II responses observed in 
this analysis concur with the previous studies [58, 238, 246].  IFN-β stimulation of 
macrophages resulted in the repression of a large number of genes associated with cell 
cycle and DNA replication around 4-8 h post treatment, including checkpoint-
associated genes; Chek1, Chek2. Another cluster of genes associated with cell cycle 
were repressed during the late phase and included Bub1, Bub1b, Mcm5, Mcm6. The 
most changing transcripts, in terms of the up-regulated response, were present in the 
major mid and mid-to-late phase of the IFN-β network and were indicative of main 
immune-related signature. Typical interferon response genes, Ifit1, Ifit2 were present 
within these clusters, as well as cytokines (Il10, Il15, Tnf, Fas), and apoptosis related 
machinery (Daxx, Casp7, Casp12). The largest proportion of changes in response to 
IFN-β treatment occurred during the mid-phase (4 h > 8 h), whereas in the IFN-γ 
response, the main body of changes were spread across the mid and mid-to-late phase 
(8 h > 4 h). This mid and mid-to late-phase of the IFN-γ up-regulated response was 
indicative of the activation macrophage anti-microbial signalling pathways and 
comprised; a number of genes encoding Toll-like-receptors (Tlr2, Tlr3, Tlr6), STAT 
proteins (Stat1, Stat2, Stat3, Stat5a and Stat5b), interferon regulatory factors (Irf5, and 
Irf8) as well as apoptosis related signalling (Tnf, Daxx, Fas, Traf1, Traf2). Ifng-cluster-01 
(of the mid-to-late phase) also comprised the gene encoding the MHC Class II 
transactivator; Ciita (the pathway depicting its activity is described in detail in Chapter-
3; Figure 3.7). As expected the late response to IFN-γ comprised the transcriptional 
activation of genes associated with MHC Class II antigen presentation (Ifng-cluster-6). 
The down regulated response induced by IFN-γ included the repression of cell cycle 
and DNA replication processes (Cdc6, Ccne2, Pole), as well as metabolic processes 
(clusters-7, 12 and 13). 
 
In comparison to the main body of the interferon response the role and significance of 
the genes regulated during the immediate early response is less well understood. The 
IFN-β immediate early response consists of 16 nodes of which five are currently un-
annotated and 29 transcripts make up the IFN-γ immediate early response (Figure 
4.11). In both IFN-β and IFN-γ networks the immediate early response comprises only 
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transcripts whose expression was induced in response to interferon stimulation. Socs3, 
Nfil3, Nfkbiz and Axud1 were present in the immediate early response to both 
cytokines. The role of the Socs (or suppressor of cytokine signalling) proteins is well 
characterised as part of a classical negative feedback loop induced to regulate the 
extent and duration of the response to cytokines [252-253]. The role of the other 
shared immediate early transcripts in the interferon response is less well understood. 
One study suggests the protein encoded by the Nfkbiz gene may positively regulate 
IFN-γ production in KG-1 cells (a human myeloid cell line)[254]. Other immediate early 
transcripts common between the two networks (although not within immediate early 
clusters in the corresponding study) included Trib3, Arid5b, Lrrc39, Ccl3 and Ccl4.  
Unique to the IFN-β network is Prdm1, which encodes a protein that is reported to act 
as a repressor of Ifnb1 gene expression [255] thereby forming another level of 
feedback regulation. A number of IFN-γ induced transcripts, including Dusp1, 
Gadd45G, Errfil and Ier3 have been implicated in some way in the cellular stress 
response [256-259]. Based on the limited annotation and studies related to these 
immediate early transcripts it is plausible their expression is induced in response to the 
stress of being exposed to the cytokines and well processes for regulating the extent of 
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Figure 4.11: The IFN-β and IFN-γ immediate early transcriptional response.  Transcripts belonging to 
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The type-I and type-II transcriptional response are known to share a number of 
transcriptional targets and such overlap in response was observed during this analysis  
(Figures 4.9 and 4.10). The role of type-I and type-II interferons is generally 
acknowledged to be non-redundant since efficient clearing of some viruses requires 
both types of interferon, whereas others require only type-I or type-II interferon. Thus 
exploration of the overlap and variation in the transcriptional response of IFN-β and 
IFN-γ may provide insight into their functional role. 524 transcripts were common to 
both the IFN-β and IFN-γ networks (Figures 4.9 and 4.10). It is probable that there are 
other shared transcripts not identified on this occasion as they may not have met the 
original network filtering thresholds. The most common GO annotations for the 
overlapping transcripts were ‘immune response’, ‘cell cycle’ and ‘intracellular signalling 
cascade’.  A number of the shared ISGs are transcription factors (including Stat1, Stat2, 
Stat3, Irf2, and Irf5) and may drive the subsequent waves of transcription response 
following initial interferon stimulation.  Network graphs highlighting the overlap 
between the IFN-β and IFN-γ data suggest the activity of the shared transcripts is on 
the whole consistent between the two responses. For example IFN-β cluster-02 and 
cluster-03 transcripts appear predominantly across the IFN-γ Up-response graph 
component around the mid- and mid-to-late phase.  Although comparison of the data 
sets is somewhat confounded the overall response observed is still typical of the type-I 
and type-II response reported elsewhere [58, 238, 246]. For example the IFN-γ cluster-
06 comprising transcripts associated with MHC class II antigen presentation and 
processing (a process regulated efficiently by type-II interferon [239-240]) shared very 
little overlap with the IFN-β network. 
 
Conclusions & Further Work 
The transcriptional changes observed in response to IFN-γ and IFN-β were fitting with 
the well known and documented activities of these cytokines, for examples; MHC Class 
II activation by IFN-γ, the anti-proliferative signature induced by the IFNs, as well as the 
classical anti-microbial response. The network based analysis of the gene-expression 
data illustrated clear structure in the transcriptional response generated by the two 
cytokines. Moreover the analyses also revealed a complex network of co-ordinately 
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expressed transcripts, many of aspects of which are currently poorly characterised and 
understood (e.g. the immediate early response genes). Future efforts may seek to 
unravel the significance of these genes in the type-I and type-II IFN responses.  
 
The comparison of the IFN-β and IFN-γ response in mouse BMDM was limited by 
experimental differences in the generation and processing of samples for the two 
micro-array studies. For a more rigorous comparison the two time-course studies 
would be conducted on the same days on samples derived from the same culture of 
cells. Processing of the samples for hybridisation to microarrays (from RNA extraction 
to labelling) would also be conducted simultaneously as well as the all aspects of the 
microarray processing (for example use of scanners).   
 
To further explore and validate the transcriptional responses observed, it would be 
valuable to follow up these findings using appropriate techniques. For example the 
IFN-β network analysis revealed a large response associated with the repression of 
cell-cycle related transcripts, suggesting cell division is being halted. FACS analysis 
could corroborate this suggestion as well as provide insight into the exact cell cycle 
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Methods and Materials 
 
 
Generation of type I and type II interferon response data sets  
 
During the course of these investigations I had two separate opportunities to run 12 
Affymetrix Mouse Exon arrays as part of the Wellcome Trust Advanced Course (WTAC) 
series in Functional Genomics and Systems Biology, where I was participating as an 
assistant. Given the interest in better understanding the transcriptional response of 
macrophages to IFN, a time-course of IFN-γ stimulation of mouse BMDM was 
generated during the 2007 WTAC.  Twelve microarrays were used to analyse 6 time-
points in duplicate (0, 1, 2, 4, 8 and 24 hours); the final MIAME compliant dataset is 
available in Array Express (record E-MEXP-1490). During the 2009 WTAC the 12 
microarrays were utilized to examine transcriptional events following IFN-β stimulation 
of mouse BMDMs at the same time points as the IFN-γ study and is available in the 
Gene Expression Omnibus (GEO accession: GSE20403).     
 
During the interim period between the two courses I moved from the Division of 
Pathway Medicine (UoE) to the Roslin Institute (UoE) where a slightly different 
macrophage cell culture technique was adopted (see Methods) to that used in the 
previous lab. Thus the two time-course experiments were performed on different 
years and in different laboratories with slightly different cell culturing techniques. 
However, even if this compromised cross-comparison of experiments, the individual 





Cell culture and treatment 
Primary mouse bone marrow derived monocytes were prepared from male BALB/c 
mice 10–12 weeks old. Cells were washed, resuspended in DMEM-F12/10% FCS/L929 
medium and counted before being plated in a 24-well plate at a concentration of 5 × 
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105 cells/well. To differentiate the cells from monocytes into primary macrophages, 
cells were then incubated for 7 days in DMEM-F12 growth media supplemented with 
10% L929 cell suspension releasing the MCP-1 macrophage stimulating factor, with 
media changes on days 3 and 5. On day 7 the growth medium was replaced with 
DMEM-12/10%FCS medium containing 10 U/ml recombinant mouse interferon gamma 
(Pierce-Thermofisher Scientific, Rockford US) and harvested 1, 2, 4 & 8 h following 
treatment or collected pre-treatment (0 h).  
 
RNA extraction, QC and labelling for arrays 
Total RNA was harvested from the cells using an RNeasy Plus kit (Qiagen) according to 
manufacturer's instructions. RNA was quantified and quality controlled using a 
NanoDrop spectrophotometer (Nano-Drop Technologies) and BioAnalyser 2100 
(Agilent). Replicate 150 ng samples of total RNA derived from two separate wells per 
time point were labelled using the Affymetrix whole transcript labelling protocol and 
hybridized for 16 h at 45°C to Affymetrix mouse exon 1.0 ST arrays. They were then 
washed and scanned according to manufacturer's recommendations. 
 
Data processing and network analysis 
Data (ArrayExpress Ac. No: E-MEXP-1490) was normalized using the RMA package 
within the Affymetrix Expression Console software and annotated. Transcripts which 
might be considered to be differentially expressed were identified using either the 
Empirical Bayes function within Bioconductor (http://www.bioconductor.org/) or using 
the annova function within GeneSpring (Agilent Technologies, Stockport, Cheshire) 
with a 1.6 fold cut-off. In total 1,678 transcripts were identified by one or both of these 
filters. The data corresponding to this list was then loaded into the network 
visualization tool BioLayout Express3D [23] using a Pearson correlation cut-off of 0.9 to 
filter edges. The resultant network graph (Figure 4.1) of 1,474 nodes was clustered 
using the graph-based clustering algorithm MCL [137] set at an inflation value of 2.2 
resulting in 40 clusters with a membership of 6 or more nodes (transcripts).  
 




Cell culture and treatment 
Bone marrow derived macrophages (BMDM) were prepared from femurs of 8-9 week 
old male BALB/c mice. RPMI 1640 medium (Sigma-Aldrich, Gillingham, UK) 
supplemented with 10% heat inactivated foetal bovine serum (FBS) (Sigma-Aldrich 
Gillingham, UK), 25 U/ml penicillin (Invitrogen, Paisley, UK), 25 µg/ml streptomycin 
(Invitrogen, Paisley, UK), and 2 mM L-glutamine (Invitrogen) (complete medium) was 
used for culture of the BMDM. Briefly, bone marrow cells were cultured for 6 days in 
complete medium in the presence of 10,000 U/ml CSF1 (a gift from Professor David 
Hume) on 10 cm square bacteriological plastic plates, with a re-supplement of CSF1 on 
day 5. On day 6 cells were harvested, counted, re-suspended in complete medium with 
10,000 U/ml CSF1 and plated out onto 6-well tissue culture plates at a density of 1 x 
106 cells per well and cultured for a further 24 h. Cells were maintained in a 37°C 
incubator containing 5% CO2. On day 7 cells were treated with 10 U/ml recombinant 
mouse interferon-beta (IFN-β) (PBL Interferon Source, New Jersey, USA) and harvested 
1, 2, 4, 8 and 24 h following treatment or collected pre-treatment (0 h).  RNA 
extraction, QC and labelling for arrays was performed as for the IFN-γ study with the 
exception that 300 ng of RNA was used instead of 150 ng. 
 
Data processing and network analysis 
Data (GEO accession no GSE20403) was normalized using the RMA package within the 
Affymetrix Expression Console software and annotated. Transcripts which might be 
considered to be differentially expressed at each time point compared to 0 h were 
identified using the Empirical Bayes function within the Bioconductor 
(http://www.bioconductor.org/) package of the R statistical programme using a 1.5 
fold cut-off and a p-value of 0.05. According to this analysis 2,300 transcripts were 
considered to be differentially expressed. Data corresponding to these transcripts was 
then loaded into the network visualization tool BioLayout Express3D [138, 206] using a 
Pearson correlation cut-off of 0.9 to filter edges. The resultant network graph (Figure 
4.4) of 2,045 nodes (connected by 92,947 edges) was clustered using the graph-based 
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clustering algorithm MCL [137] set at an inflation value of 2.2 resulting in 33 clusters 
(with greater than 5 nodes). Manual inspection of the clusters revealed 21 clusters of 
interest i.e. their expression profile was consistent with the genes being regulated by 
IFN-β. Resulting clusters represent patterns of co-expression amongst transcripts in the 
network graph. The clustered data was then exported as “class-sets” for overlaying 
onto other datasets (including the IFN-γ response network) as well as the macrophage 
pathway diagram. 
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this Chapter has been performed by me under the supervision of Prof. Tom Freeman. 



















































This page has been left intentionally blank
                                                                                                                             Chapter 5 
170 












Chapters 2 & 3 described the assembly of an in silico model of receptor-initiated 
signalling pathways in the macrophage, including type-I and type-II interferon 
signalling cascades. The analyses included in Chapter-4 attempted to characterise the 
transcriptional response of BMDMs to IFN-β and IFN-γ using a network based approach 
to analyse microarray data. Leading on from these studies (in Chapters-2 to 4) and 
other investigations within the group [146] was the desire to study the contribution of 
individual pathway components to the interferon response. Based on previous 
investigations we found the siRNA induced knockdown of certain genes, perturbed 
transcriptional networks associated with type-I interferon signalling [146] and using 
the pathway model it was possible to hypothesise a rational explanation for these 
observations. The investigations described in this Chapter-(5) aimed to reproduce our 
previous findings [146] and extend these investigations to other genes known or 
hypothesised to modulate type-I interferon signalling. In order to begin to perform 
such an analysis it was first necessary to optimise an in vitro assay for using siRNA-
based screening in mouse primary BMDMs. Therefore the major focus of the work 
described here was to define and optimise an in vitro screening assay to study the 
effect of gene knockdowns on the interferon response. The secondary focus was to 
then use (and test) the optimised screening protocol to the study the role of genes of 
interest in type-I interferon signalling.   
 
Modulation of type-I interferon signalling by targeted siRNA induced 
gene knockdown - Prior work 
 
Previous data generated by our group suggested targeted knockdown of certain genes 
by siRNA in mouse BMDMs perturbs siRNA-lipofection induced type-I interferon 
signalling [146]. Specifically the siRNA’s resulting in this marked shift in the 
macrophage transcriptome, targeted the Ifnb1, Irf3, Irf5, Stat1, Stat2 and Nfkb2 
transcripts. Transfection of other siRNA’s (in this case targeting the Casp4, Ifi47, Lyn, 
Sod2, Traf1 transcripts), resulted in the activation of transcriptional networks typically 
                                                                                                                             Chapter 5 
172 
associated with interferon signalling to a similar degree to control non-targeting siRNA 
(Chapter-1; Figure 1.7). A simplified schematic describing the expected outcome (in 
terms of ISG expression) to treatment with non-targeting siRNA or with siRNA 
targeting a gene which acts as a positive regulator of type-I signalling is shown in 
Figure 5.1.  
 
Certain macrophage PRRs (TLR3, TLR7, TRL8, RIG-like-receptors) are thought to be 
sensitive to synthetic siRNA resulting in activation of the immune system in 
mammalian cells [260-263]. Engagement of these receptors with viral RNA or in this 
case the synthetic siRNA leads to the eventual assembly and activation of the IFN-β 
enhancesome. Four (Irf3, Ifnb1, Stat1, Stat2) of the six gene targets which perturbed 
transcriptional networks associated with type-I IFN signalling [146] are known to act 
within the same (IFN-β) pathway [189, 264-265].  
 
The role of the Irf5 and Nfkb2 transcription factors in the IFN response is less well 
characterised and/or established, particularly at the pathway level. There is evidence 
to implicate these proteins in the immune and IFN response [266-271]. The most 
compelling of this evidence suggests high IRF5 expression (in mice and humans) is 
characteristic of the M1 phenotype of macrophages in which it directly activates the 
transcription of certain genes encoding inflammatory mediators [272]. 
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Figure 5.1: Predicted response of primary mouse macrophages to siRNA tranfection using a lipid delivery vector. Macrophages not exposed to siRNA/lipid are 
expected to express low/ basal levels of interferon stimulated genes. Transfection of a siRNA-lipid complex is expected to induce autocrine IFN-β production in the 
macrophage, as the siRNA/ lipid are detected by pattern recognition receptors. If the siRNA transfected into the macrophage happens to target a key component of IFN-
β/ type-I signalling (such as the Ifnb1 gene itself), it would be expected that level of autocrine IFN-β production and subsequent ISG expression would be lower relative 
to cells transfected with control-Non-Targeting siRNA or siRNA targeting genes not critical in the propagation of the interferon response.  
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Further studies are required to understand how and at what level the Irf5 and Nfkb2 
proteins are acting in the (type-I) interferon pathway. Other members of the group are 
currently investigating the role of Nfkb2 in macrophage signalling to follow up the 
observed effects of siRNA/ type-I response study [146] and to gain a better 
understanding of its action on macrophage signalling. Preceding these investigations 
was the desire to develop methods of studying the effects of siRNA mediated 
knockdown of the Nfkb2 gene, as well as other genes, with the objectives of:  
 
(i) Investigating whether it was possible to replicate the observations of the 
previous siRNA screen [146] (under new laboratory settings). 
(ii) Exploring whether other genes (not considered during the original study 
[146]) might also be implicated in mediating the type-I response in mouse 
macrophages.  
(iii) Optimising an experimental assay for screening genes by siRNA knockdown 
and thereby assessing their contribution to the type-I response or other 
macrophage activation pathways. 
 
Requirement for a new in vitro assay to study the role of other GOI in 
the type-I interferon response and a preliminary assay design  
 
The experimental setup of the previous study was not specifically designed to assay 
the effects of the gene knockdowns in the siRNA-induced type-I response. In fact the 
original study was designed to understand the role of the genes of interest in the 
context of the type-II interferon response (see Chapter-1 and [146]). The discovery 
that siRNA’s targeting the six genes (described above) perturbed transcriptional 
networks associated with type-I interferon signalling was to some extent 
serendipitous. For the investigations in this Chapter a new in vitro assay was designed 
to test the role of genes in the type-I response using siRNA.  One of the major reasons 
for the design of a new assay, as opposed to keeping entirely with the methodology of 
the previous screen was that the system of studying type-I response perturbation 
using a method (siRNA lipofection) that induces the signalling of interest may 
complicate the analysis of the role of the GOI. For example, it is possible the act of 
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siRNA transfection may induce Ifnb1 expression before the siRNA has had sufficient 
time to knockdown the GOI, therefore masking any influence the GOI may have in 
Ifnb1 regulation.  Alternatively by allowing sufficient time for gene KD, then using 
another (exogenous) stimulator of Ifnb1 expression in macrophages it may be possible 
to better attribute the contribution of the GOI to Ifnb1 production and/or subsequent 
type-I response. An exogenous stimulator of IFN-β signalling in macrophages is 
Lipopolysaccharide (LPS). LPS is the major component of the outer membrane of 
Gram-negative bacteria. It causes monocytes, macrophages and neutrophils to up-
regulate phagocytic functions and to release inflammatory mediators, including 
interleukins (IL-1, IL-6, IL-12), TNF, nitric oxide (NO) and interferons [273-274]. In 
macrophages, LPS stimulation induces the rapid transcription of IFN-β mRNA and 
protein secretion [275].  In turn IFN-β signalling forms a key portion of the LPS 
transcriptional response and LPS induced lethality [276-277]. Studying the effect of 
GOI knockdown in the context of the LPS response could be valuable not only because 
LPS serves as a stimulator of Ifnb1 expression, but also to further explore the 
contribution of IFN-β signalling in the LPS response. Thus another motivation to 
develop a novel in vitro assay was the interest in studying the role of the GOIs in the 
context of the LPS (induced-type-I) response. 
 
Figure 5.2 describes how LPS stimulation of macrophages could be incorporated to 
study the role of the GOI in the type-I interferon signalling response. The basic design 
of the assay was firstly to knockdown the genes using siRNA and measure any 
consequential change in Ifnb1 and type-I gene expression, and secondly challenge the 
cells with LPS to determine variability in Ifnb1 and type-I gene expression induction. 
Given this analysis was based on the desire to replicate and expand on observations in 
the previous siRNA screen [146] some consistency between the previous screen were 
maintained, including the supply of siRNA used (Dharmacon (Thermo Scientific) ON-
TARGET plus SMARTpool), and the choice of transfection method and reagent 
(Lipofectamine 2000). Previous data from the group suggested BMDMs are sensitive to 
Lipofectamine, but less so than Lipofectamine in combination with siRNA [146]. Others 
have optimised siRNA delivery by electroporation in primary BMDMs and suggested 
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this method does not affect macrophage function and phenotype [278]. However the 
study of lipid based siRNA delivery to macrophages warrants investigation in itself 
since it is argued to be the most tractable form of siRNA delivery in in vivo settings 
where electroporation is not viable. Furthermore synthetic non-viral, lipid-based 
vectors are considered the most feasible method for delivering DNA/RNA therapeutic 
agents since they are regarded to be safer than their viral counterparts and 
improvements in their chemistry and formulation are beginning to position them as 












Figure 5.2: Preliminary work flow for investigating the role of genes of interest (GOI) in the IFN-β 
signalling pathway. GOI knocked down in mouse bone marrow derived macrophages using siRNA, and 
then challenged with LPS. Subsequent Ifnb1 and type-I gene expression was measured, and some of the 
possible outcomes are shown. If a GOI knockdown results in either a reduced or augmented type-I 
response and Ifnb1 expression compared to controls, it could be plausible the GOI is either a positive or 
negative regulator respectively, of type-I response signalling. Other outcomes (not shown) are possible; 
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Questions to be addressed in the design of an assay to study the role of 
genes of interest in the type I response in BMDMs 
 
Despite the advances in siRNA design to improve potency and reduce off-target 
effects, siRNA effectiveness can still vary across different cell types [280]. Furthermore 
conditions for optimal siRNA efficacy may need to be altered depending experimental 
design factors, for example the scale of throughput (screening in 6/24/96/384 well 
plates), method of siRNA delivery, other treatments the cells are exposed to, and the 
cellular environment [281].  Ultimately each experimental scenario requires careful 
optimisation to find a balance between siRNA induced knockdown potency and off-
target effects. Some of the specific questions that were to be addressed during the 
assay optimisation included: 
 
 What is the ‘ideal’ siRNA concentration to use for screens in mouse BMDMs? 
To explore this point the following parameters were investigated: 
o Uptake of increasing concentrations of siRNA in mouse BMDMs  
o Knockdown efficiency of increasing concentrations of siRNA targeting a gene of 
interest 
o Assessment of type-I response gene induction with increasing concentrations of 
siRNA 
o Changes in cell morphology with increasing concentrations of siRNA combined 
with LPS treatment. 
 
 What concentration of LPS should be used in the in vitro assay?  
To explore this point the following parameters were investigated:  
o Comparison of type-I response induced by LPS, IFN-β and NT-siRNA 
o Analysis of macrophage response to combined siRNA and LPS treatment 
o Analysis of macrophage response to 5 ng/ml LPS and 20 nM siRNA 
(concentrations which were chosen for the in vitro assay). The individual 
response and combined response to these stimuli was studied.  
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 What is the ideal siRNA-treatment time for obtaining optimal gene knockdown 
and type-I repression following LPS stimulation?  
To explore this point the following parameters were investigated: 
o Analysis of protein level knockdown over time 
o Analysis of gene-level knockdown and efficacy of downstream response 24 h or 
48 h post-siRNA transfection 
In addressing the above points the optimal time for measuring Ifnb1 expression in 
response to siRNA transfection as well as following LPS stimulation in mouse BMDMs 
was determined. Finally using the parameters established in the optimisation process 
(siRNA concentration, LPS dose, time of siRNA treatment), an in vitro assay for studying 
the role of GOI in the type-I and LPS response using siRNA was finalised. To test the 
assay as well as the potential role of the GOI in LPS signalling, a siRNA screen targeted 
a number of genes was performed and type-I signalling levels assayed by QPCR as well 
























Optimisation of an in vitro assay for screening the role of gene 
knockdowns in the interferon-β response and LPS response 
 
 
(1) Determination of ‘ideal’ siRNA concentration to use for screens in 
mouse BMDMs 
 
Previous data generated within the group relied on a final concentration of 20 nM 
siRNA when transfecting primary mouse BMDMs [146]. This concentration was not 
previously optimized.  I therefore examined the dose-dependence of siRNA actions in 
mouse BMDMs. 5, 20, 50 and 100 nM final concentrations of siRNA were transfected 
(using Lipofectamine 2000) into mouse BMDMs and cell morphology, siRNA 
transfection efficiency, target gene knockdown levels and immune activation were 
assessed.  
 
(1.1) Uptake of increasing concentrations of siRNA in mouse BMDMs  
 
Fluorescently labelled siRNA, siGLO Green, is a RISC-independent non-targeting control 
intended as a qualitative indicator of delivery, especially lipid-mediated transfection. In 
order to gauge the extent and dynamics of lipid-based siRNA delivery, the uptake of 20 
nM or 50 nM final concentration of siGLO in mouse BMDMs was monitored over time 
by confocal microscopy and cell images taken at 4, 7 and 24 h post transfection. This 
process was first performed at a cell seeding density suited for confocal imagery, (that 
is 50,000 cells per glass slide placed in a well of 24-well tissue culture plate) and was 
then repeated closer to a seeding density used in 24-well tissue culture experiment.  
 
At 50,000 cells per slide and challenged with 50 nM final concentration siRNA, almost 
every cell contained the fluorescently labelled siRNA (Figure 5.3a&b). At 4 h post-
transfection, cells contained granular clusters of green fluorescence, as well as staining 
overlapping with the nuclear dye DAPI. By 7 h this staining was more diffuse and even 
more so by 24 h. Furthermore by 24 h patches of staining were observed in areas not 
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overlapping with cells. Subsequent observations suggested this may be residual stain 
from cellular debris arising from cell death (Figure 5.3.a&b). When 50,000 cells were 
treated at a final siGLO concentration of 20 nM, every cell appeared to overlap with 
fluorescent staining. Although at 4 h there appeared to be fewer granules of 
fluorescence compared to the 50 nM siRNA treatment, by 24 h there were large and 
clearly visible pools of staining overlapping or surrounding the DAPI staining (Figure 
5.4). Hence even with 20 nM siRNA every cell appeared to be transfected by 24 h of 
treatment. To determine if the extent of transfection was changed at a seeding density 
closer to that normally used in a well of 24 well plate, 163,000 cells per glass slide were 
exposed to a final concentration of 20 nM siRNA. Over the time-course of treatment 
the intensity of the staining increased and by 24 h the fluorescence overlapped or 
surrounded all nuclear staining, suggesting that even at a higher seeding density the 









Figure 5.3. (a) Time-course of uptake of 50 nM fluorescently labelled siRNA (siGLO) in mouse bone 
marrow derived macrophages. Mouse BMDMs were seeded at a density of 50,000 cells per glass cover 
slip placed in a well of a 24-well tissue culture plate. Lipofectamine 2000 was used to transfect the 
BMDMs with siGLO (fluorescent siRNA) at a final concentration of 50 nM and cells were fixed at 4, 7 and 
24 hours post-transfection. Nuclei were stained with DAPI. siGLO is chemically labelled with a 6-FAM 
fluorophore. Cell images were captured using confocal microscopy. No fluorescence was visible in the 
FITC channel of control (untreated) cells.  
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Figure 5.3. (b) Detailed cell images extracted from figure 5.3a showing uptake of 50 nM fluorescently 
labelled siRNA (siGLO) in mouse bone marrow derived macrophages over time. Mouse BMDMs were 
seeded at a density of 50,000 cells per glass slide place in a well of a 24-well tissue culture plate. 
Lipofectamine 2000 was used to transfect the BMDMs with siGLO (fluorescent siRNA) at a final 
concentration of 50 nM and cells were fixed at 4, 7 and 24 hours post transfection. Nuclei were stained 
with DAPI. siGLO is chemically labelled with a 6-FAM fluorophore. Cell images were captured using 
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Figure 5.4: Time-course of uptake of 20 nM fluorescently labelled siRNA (siGLO) in mouse bone 
marrow derived macrophages. Mouse BMDMs were seeded at a density of 50,000 cells per glass slide 
place in a well of a 24-well tissue culture plate. Lipofectamine 2000 was used to transfect the BMDMs 
with siGLO (fluorescent siRNA) at a final concentration of 20 nM and cells were fixed at 4, 7 and 24 
hours post transfection. Nuclei were stained with DAPI. siGLO is chemically labelled with a 6-FAM 
fluorophore. Cell images were captured using confocal microscopy. No fluorescence was visible in the 
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Figure 5.5: Time-course of uptake of 20 nM fluorescently labelled siRNA (siGLO) in mouse bone 
marrow derived macrophages. Mouse BMDMs were seeded at a density of 163,000 cells per glass slide 
placed in a well of a 24-well tissue culture plate. Lipofectamine 2000 was used to transfect the BMDMs 
with siGLO (fluorescent siRNA) at a final concentration of 20 nM and cells were fixed at 4, 7 and 24 
hours post transfection. Nuclei were stained with DAPI. siGLO is chemically labelled with a 6-FAM 
fluorophore. Cell images were captured using confocal microscopy. No fluorescence was visible in the 
FITC channel of control (untreated) cells.  
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1.2 Knockdown efficiency of increasing concentrations of siRNA targeting gene of 
 interest 
 
Having established that lipofection results in an efficient uptake of siRNA into 
macrophages at concentrations previously used, was the desire to then determine how 
the extent of gene knockdown would vary with differing siRNA concentrations. It might 
be expected that increasing concentrations of siRNA may achieve higher levels of gene 
KD, nevertheless any increase in efficiency of gene or protein knockdown should be 
evaluated alongside other variable factors including; the increase in cost of reagents, 
extent of immune activation, changes in cell morphology and cell toxicity. 
 
siRNA targeting either Nfkb2 or Irf7 genes was transfected into mouse BMDMs at 5, 
20, 50 or 100 nM final concentration for 24 h and expression of the target genes 
assayed by QPCR.  To control for any transfection induced changes in expression of the 
genes, non-targeting (NT) siRNA and a negative control designed to lack identity with 
known gene targets, were also transfected at the same concentrations into mouse 
BMDMs for 24 h. The data generated (Figure 5.6) several observations of interest; (1) 
Nfkb2 expression was suppressed beyond basal levels in samples treated with siRNA 
targeting Nfkb2, however Irf7 expression, even if lower than NT-siRNA treated 
samples, was slightly elevated compared to basal levels;  (2) regardless of the siRNA 
concentration used the expression levels of the GOI in the target-siRNA (Nfkb2 or Irf7)  
treated cells was similar (3) however increasing concentrations of NT-siRNA resulted in 
an almost exponential increase in GOI expression. Thus in terms of knockdown 
efficiency, comparing target gene expression at 100 nM NT siRNA treated cells vs. 100 
nM siRNA targeting the GOI, would appear to give the largest percentage knockdown. 
However, when transfected with 100 nM NT-siRNA the target genes are induced well 
beyond their basal expression level and this may have consequential downstream 
effects on macrophage signalling.   
 
Nfkb2 protein expression was also induced by tranfection of NT-siRNA, and to a 
greater extent with higher doses of siRNA (≥50 nM) (Figure 5.7), substantiating the 
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observations at the transcriptional level. In cells transfected with increasing 
concentrations of siRNA targeting the Nfkb2 gene, protein expression was supressed 
relative to cells transfected with the corresponding concentrations of NT-siRNA.  
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Figure 5.6: Assessment of gene knockdown efficiency 24 hours post treatment with increasing 
concentrations of siRNA. (a) Mouse BMDMs were transfected with four different concentrations of 
siRNA targeting the Nfkb2 gene or four different concentrations of non-targeting siRNA, or cells were 
untreated (control). Following 24 hours of treatment Nfkb2 expression was assayed in all samples. (b) 
Mouse BMDMs were transfected with four different concentrations of siRNA targeting the Irf7 gene or 
four different concentrations of non-targeting siRNA, or cells were untreated (control). Following 










Figure 5.7: Assessment of Nfkb2 protein knockdown efficiency 48 hours post treatment with 
increasing concentrations of siRNA targeting the Nfkb2 gene. Mouse BMDMs were transfected with 
four different concentrations of siRNA targeting the Nfkb2 gene or four different concentrations of non-
targeting siRNA, or cells were untreated (control). Following 48 hours following siRNA transfection cell 
were harvested and Western blot analysis performed on protein extracts from the cells using an Nfkb2 
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1.3 Assessment of type-I response gene induction with increasing concentrations 
 of siRNA 
 
The gene knockdown results (Figure 5.6) suggested similar levels of knockdown are 
achievable with a range of siRNA concentrations, however GOI expression (Irf7, and 
Nfkb2) is induced by transfecting increasing concentrations of NT-siRNA. To better 
understand how type-I response signalling could be affected by increasing 
concentrations of siRNA, expression of Oasl1 and Ifit1 was measured in the 24 h gene 
knockdown samples (Figure 5.8). Measurement of these classical type-I response 
genes across the screen of siRNA concentrations suggests different patterns of 
concentration dependant expression. An exponential increase of Oasl1 and Ifit1 was 
observed in response to increasing concentrations of NT-siRNA; the response genes 
were induced to similar levels in samples treated with increasing concentrations of 
siRNA targeting the Irf7 gene, with the exception of 100 nM Irf7-siRNA, and finally; 
decreasing expression of Oasl1 and Ifit1 were observed with increasing concentration 

















Figure 5.8: Type-I response gene expression in response to increasing concentrations of siRNA 
transfected into mouse BMDMs. (a) expression of Oasl1 or (b) Ifit1 was measured by QPCR in samples 
treated with four different concentrations of siRNA targeting either Irf7 gene or Nfkb2 gene or non-
targeting for 24 hours.  
(a) 
(b) 
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1.4 Changes in cell morphology with increasing concentrations of siRNA 
combined with  LPS treatment. 
 
A key aspect of the assay design was to incorporate LPS stimulation of the 
macrophages in order to better understand how siRNA induced knockdown of the GOI 
may perturb the (interferon component of the) LPS response. Consequently the cells 
would be exposed to two waves of immune activation, firstly by the process of siRNA 
lipofection and secondly by LPS stimulation.  Results suggest different concentrations 
of siRNA stimulate type-I response to varying extents (Figure 5.8), although the effects 
of subsequent LPS stimulation of the macrophages is unknown. In order to better 
understand the effects of the double stimulation of macrophages, cell morphology was 
monitored in BMDMs pre-treated with NT-siRNA at four different concentrations and 
then stimulated with modest concentrations of LPS (5ng/mL). Distinct changes in cell 
morphology in response to LPS stimulation were observed in cells treated pre-treated 
for 24 h with 50 nM or 100 nM NT-siRNA; the cells appeared highly granular, irregular 
in shape, with evidence of apoptotic bodies (Figure 5.9). These observations suggested 
the phenotype of the LPS stimulated macrophages pre-treated with 50 nM to 100 nM 
siRNA are considerably different from those stimulated with LPS alone or LPS in 
combination with lower doses of siRNA. The combination of results (Figures 5.3 – 5.9) 
indicate 50 – 100 nM does not enhance target gene knockdown levels, induces 
stronger immune signalling than lower concentrations, and in combination with LPS 
drives the phenotype of the cells to one indicative of cell death.  
 
Variability between the actions of 5 and 20 nM final concentration of siRNA was less 
distinguishable, and arguably the use of 5 nM concentration could have been 
investigated further. Given the effect of siRNA is transient and may wear off over time, 
and also since the previous siRNA screen was performed using 20 nM, this 
concentration was chosen over any lower dose for the remainder of the assay 
optimisation.     
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Figure 5.9: Changes in cell morphology with increasing concentration of siRNA and in combination 
with LPS. Mouse BMDMs were transfected with 5nM, 20 nM, 50 nM or 100 nM non-targeting siRNA for 
24 hours and subsequently challenged with 5ng/mL of LPS (Salmonella Minnesota rough strain) for 7 
hours. Cell morphology was assessed using a Nikon Diaphot inverted microscope and images captured at 
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(2) Analysis of LPS response in mouse bone marrow derived 
macrophages 
 
To assess the ideal concentration of LPS to use following siRNA treatment of BMDMs 
the LPS response in these cells was examined. Specific questions explored included; 
how the LPS response compares with IFN-β stimulation of BMDMs; the concentration 
of LPS required to induce IFN-β mRNA detectable by QPCR; and the effects of 
stimulating macrophages that have already undergone siRNA lipofection with LPS. 
 
2.1 Comparison of type-I response induced by LPS, IFN-β and NT-siRNA 
 
To compare the extent of (type-I) activation of macrophages by 100 ng/ml LPS with 
IFN-β at a concentration (10 U/ml) previously studied (Chapter-4) and the intended 
final concentration of siRNA to be used (20 nM), BMDMs were treated with the three 
stimuli for 24 h and type-I gene expression assessed by QPCR (Figure 5.10). At this 
time-point the expression of the Oasl1 response gene was 13 to 30 fold more potent in 
100 ng/ml LPS treated cells compared to IFN-β treated or NT-siRNA treated cells 
respectively. To further compare type-I response activation following IFN-β or LPS 
treatment, Oasl1 expression was assayed at 24 h post treatment in response to a range 
of concentrations of IFN-β and LPS. The most comparable induction of Oasl1 was 








                                                                                                                             Chapter 5 
195 
 
Figure 5.10: Oasl1 gene expression in mouse bone marrow derived macrophages 24 hours following 
stimulation with mouse Ifn-β or non-targeting siRNA or LPS.  Mouse BMDMs were treated with either 
10 U/ml mouse Ifn-β, or 100 ng/ml LPS, or with 20 nM final concentration siRNA for 24 hours, or were 
untreated (control). Expression of the type-I response gene Oasl1 was measured by QPCR and is shown 
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Figure 5.11: Oasl1 gene expression in response to increasing concentrations of mouse IFN-β or LPS 
stimulation of mouse bone marrow derived macrophages. Mouse BMDMs were stimulated with either 
IFN-β at concentrations of 20 U/ml, 50 U/ml or 100 U/ml, or with LPS at doses of 10 ng/ml, 20 ng/ml, or 
100 ng/ml for 24 hours, or were untreated (control). The relative expression of the type-I response gene 


















                                                                                                                             Chapter 5 
197 
In the context of this assay, LPS would be used to stimulate IFN-β production and type-
I response gene expression. Although the contribution of IFN-β signalling in the overall 
LPS response is acknowledged, few studies have dissected the precise differences 
between LPS and IFN-β response.  To grasp some of the differences in the expression 
and dynamics of gene induction by LPS and IFN-β, the expression of a selection of 
interferon response genes was measured by semi-quantitative PCR over time in 
response to stimulation by a range of LPS or IFN-β doses (Figure 5.13). Also performed 
in parallel for comparative purposes was the stimulation of BMDMs with 20 nM NT-
siRNA. Finally, in order to determine the extent of IFN-β production in response to 
varying doses of LPS and in response to the NT-siRNA , Ifnb1 gene expression was 
measured by QPCR in the early time-point samples (1 and 2 h) (Figure 5.12).  
 
In agreement with previous results Ifnb1 expression was induced in a dose responsive 
manner following LPS stimulation (Figure 5.12). When contrasting equivalent LPS 
doses, Ifnb1 expression was in general twofold higher 2 h post LPS stimulation 
compared to 1 hour post stimulation. At 1 hour and 2 h post-NT-siRNA transfection, 
Ifnb1 gene expression was not detectable. As expected Ifnb1 expression was not 
induced in BMDMs stimulated with IFN-β.  




Figure 5.12: Ifnb1 gene expression in mouse bone marrow derived macrophages following treatment with non-targeting siRNA, or varying doses of LPS, or varying 
concentrations mouse IFN-β cytokine. Mouse BMDMs were stimulated with any of; 20 nM NT-siRNA; LPS at 50ng/ml, 20ng/ml, 10ng/ml, 5ng/ml or 2.5ng/ml; or mouse 
IFN-β at 100U/ml, 50U/ml, 10U/ml, 1U/ml, or 0.5U/ml for 1 hour or 2 hours. Expression of the Ifnb1 gene was measured by QPCR and is shown relative to Ifnb1 
expression in 0 hour (untreated) control sample. 
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Of the response genes assayed by semi-quantitative PCR, Tnf was preferentially 
induced by LPS, Il1b expression was exclusive to LPS, and both genes were induced as 
early as 1 hour post-stimulation (Figure 5.13). Mx2 and Socs1 genes were induced 
earlier by IFN-β and later by LPS, possibly reflecting the time-lag between LPS 
stimulation and autocrine IFN-β production. Oasl1 was induced marginally earlier in 
response to IFN-β (1 h) compared to LPS treatment (2 h). However by 7 h both LPS 
stimulated cells and cells treated at 100 U/ml to 10 U/ml expressed comparable levels 
of Oasl1.  Irf5 was induced by both LPS and IFN-β. The response genes analysed were 
not induced at 1 hour or 2 hour post NT-siRNA transfection, however by 7 h Irf1, Irf5, 
Tnf, Mx2, Socs1 and Oasl1 were expressed in cells transfected with NT-siRNA. Since 
Socs1, Mx2 are expressed early in response to IFN-β stimulation, this might suggest 
that IFN-β is produced some hours after siRNA transfection and may explain the 
absence of Ifnb1 expression at 1 h and 2 h post transfection. 
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Figure 5.13: Time-course of expression of selected immune response genes in mouse bone marrow derived macrophages following treatment with non-targeting 
siRNA, or varying doses of LPS, or varying concentrations mouse IFN-β cytokine. Mouse BMDMs were stimulated with any of; 20 nM NT-siRNA; LPS at 50, 20, 10, 5 or 
2.5 ng/ml; or mouse IFN-β at 100, 50, 10, 1, or 0.5 U/ml for 1 hour, 2 hours or 7 hours. Expression of the selected immune response gene was measured by semi-
quantitative PCR. Expression of the macrophage cell surface marker (CD14), serves as an indicator of cDNA loading.  
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2.2 Analysis of macrophage response to combined siRNA and LPS treatment 
 
Clearly detectable levels of Ifnb1 and type-I response expression was induced at the 
LPS doses examined (50 to 2.5 ng/ml) (Figure 5.12). However the effects of combining 
LPS and siRNA treatment on Ifnb1 and type-I expression were unknown. Preliminary 
experiments, suggested treating BMDMs with 20 ng/ml LPS after they have undergone 
prior siRNA transfection is toxic to the cells (data not shown) and resulted in apoptosis 
and reduced yields of RNA, compared to cell cultures treated with siRNA or LPS alone. 
It was possible that using lower concentrations of LPS could circumvent this issue of 
toxicity, given the correlation between LPS dose and type-I response induction. 
Therefore the effect of combining siRNA transfection with subsequent LPS treatment 
was examined using lower concentrations of LPS (10 to 0.02 ng/ml) than previously 
employed (Figure 5.14). Ifnb1 expression was measured at 2 and 7 h post-LPS 
treatment in BMDMs with and without 24 h prior NT-siRNA transfection.  Also in 
parallel with the LPS treatment additional BMDMs were transfected with NT-siRNA 
and cells harvested at 2 or 7 h post-treatment. Once again a dose responsive induction 
of Ifnb1 expression was observed in response to increasing doses of LPS (Figure 5.14). 
Furthermore the results indicate Ifnb1 expression in response to LPS stimulation is 
amplified in cells pre-treated with siRNA. In cells treated with NT-siNA alone, Ifnb1 
expression was clearly evident at 7 h post-transfection. This suggests the optimal time 
to detect Ifnb1 expression in response to siRNA transfection is some h later than the 
transfection time and not 1 or 2 h post treatment as is suited to detecting Ifnb1 
expression in response to pathogen challenge. The results also showed slightly 
elevated levels of Ifnb1 expression in cells treated with NT-siRNA for 24 h compared to 
control untreated. On this occasion the combination of lower doses of LPS with prior 
siRNA treatment did not appear to induce cell death and consistent yields of RNA were 
extracted from all samples.   
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Figure 5.14: Ifnb1 expression in mouse bone marrow derived macrophages stimulated with varying concentrations of LPS, in the presence and absence of prior non-
targeting–siRNA transfection. Mouse BMDMs were transfected with 20 nM final concentration NT-siRNA or were untreated. 24 hours later both cells that had been 
transfected with siRNA or left untreated were further challenged with varying doses of LPS (10ng/ml, 2ng/ml, 05.ng/ml, 1ng/ml and 0.02 ng/ml) for 2 hours and 7 hours. 
Running parallel with the LPS treatment, additional mouse BMDMs were transfected with NT-siRNA for 2 hours and 7 hours. Ifnb1 expression was determined by QPCR 
and is shown relative to its expression in the 0 hours control sample. 
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2.2.1 Analysis of macrophage response to 5 ng/ml LPS and 20 nM siRNA (i.e. 
 concentrations chosen for the in vitro assay) 
 
A dose of LPS (5ng/ml) falling within the range of low doses examined (10 – 0.02 
ng/ml) was chosen as a potential concentration to be used in the final assay design. To 
compare the dynamics of Ifnb1 induction in response to 5ng/ml LPS or 20 nM siRNA, 
BMDMs were treated with LPS or siRNA and the expression of Ifnb1 assayed by QPCR 
over a time-course. Following 5ng/ml LPS treatment maximal Ifnb1 expression was 
reached 2-4 h post treatment (Figure 5.15). In response to 20 nM NT-siRNA Ifnb1 












Figure 5.15: Time-course of Ifnb1 expression in bone marrow derived macrophages following 
stimulation by LPS, or non-targeting siRNA. Mouse BMDMs were stimulated with 5ng/ml LPS, or 20 nM 
NT-siRNA, and the cells harvested at 1, 2, 4, 6, 8, and 24 hours post stimulation. Untreated (control) cells 
were also harvested at the same time-points and at time 0 hours. Ifnb1 gene expression was measured 
in the samples by QPCR and is shown relative to its expression at 0 hours (control).  
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To further validate the use of 5ng/ml LPS, BMDMs were transfected with siRNA 
targeting the Irf3 gene, or the Nfkb2 gene or with non-targeting-siRNA, and after 24 h 
cells were treated with 5ng/ml LPS (Figure 5.16). Ifnb1 expression was assayed at 0, 1, 
2, 4, 6, and 8 h post-LPS treatment, where 0 h equates to the 24 h time-point of siRNA 
treatment. Irf3 is a transcription factor known to bind to the Ifnb1 enhancesome [282], 
and could serve as a positive control when monitoring the effects of targeted gene 
knockdown on Ifnb1 expression and the type-I response. Ifnb1 expression was 
suppressed below basal levels in cells treated with Irf3 siRNA alone for 24 h (i.e. 0 h 
post LPS treatment) (Figure 5.16). Ifnb1 expression was also suppressed in cells treated 
with siRNA targeting the Nfkb2 gene (for 24 h), relative to cells treated with NT-siRNA 
for 24 h (Figure 5.16).   Furthermore for every comparable time-point post-LPS 
treatment, Ifnb1 expression was lower in those cells treated with siRNA targeting 
either Irf3 or Nfkb2 expression compared to those treated with NT-siRNA. In contrast 
to earlier observations (Figure 5.13) combining siRNA transfection with subsequent LPS 
treatment resulted in lower levels of Ifnb1 expression, compared to LPS treatment 
alone (Figure 5.16). The data also suggested maximal Ifnb1 expression is obtained 
around 2 h post-LPS treatment (with or without prior siRNA transfection). Finally, the 
cells appeared viable in response to 5ng/ml LPS treatment regardless of prior siRNA 
transfection and the phenotype of the cells was not altered compared to those 
untreated or treated only with LPS (data not shown).   
 
Based on the range of observations, 5ng/ml was chosen as the concentration of LPS to 
stimulate the BMDMs, following siRNA mediated knockdown of the GOI. The results 
also suggested that ~7 h post-siRNA transfection was the optimal time to detect siRNA 
lipofection induced Ifnb1 expression. Whereas LPS induced Ifnb1 expression was best 
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Figure 5.16: Time-course of Ifnb1 expression in bone marrow derived macrophages following stimulation by LPS, with and without prior siRNA transfection targeting 
the Irf3 or Nfkb2 genes or non-targeting. Mouse BMDMs were transfected with siRNA targeting the Irf3 or Nfkb2 genes or with non-targeting siRNA. 24 hours post 
siRNA lipofection, the cells were stimulated with 5ng/ml LPS, and the cells harvested at 1, 2, 4, 6, 8, and 24 hours post stimulation. Untreated (control) cells were also 
harvested at the same time-points and at time 0 hours. Ifnb1 gene expression was measured in the samples by QPCR and is shown relative to its expression at 0 hours 
(control). 
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(3) Determination of ideal siRNA treatment time for obtaining optimal 
 gene knockdown and type-I repression following LPS stimulation. 
 
3.1 Analysis of protein level knockdown over time 
Typical time-points for detecting optimal knockdown of target genes by siRNA at the 
transcriptional level (as recommended by the manufacturer (Dharmacon Thermo 
Scientific) range from 24 to 48 h. Knockdown at the protein level is typically observed 
around 48 h. To understand the dynamics of protein expression as well as suppression 
by siRNA, BMDMs were stimulated with NT-siRNA, LPS, or siRNA targeting Nfkb2 for 4, 
8, 24, and 48 h and Western blot analysis performed on protein extracts.  Nfkb2 
protein expression was induced by LPS to a greater extent than NT-siRNA transfection 
(Figure 5.17a). Expression of the p100 and p52 isoforms peaked at 24 h post LPS or NT-
siRNA treatment. Knockdown of Nfkb2 protein was apparent at 24 h post transfection 
with siRNA targeting Nfkb2, and was further reduced at 48 h (Figure 5.17a). Successful 
knockdown of Irf5 (relative to NT-siRNA transfected samples) at the protein level, was 
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Figure 5.17: (a) Time-course of Nfkb2 p100 and p52 protein subunit expression in mouse BMDMs 
following treatment with NT-siRNA, Nfkb2 siRNA or LPS (20ng/ml). Mouse BMDMs were treated with 
20 nM NT-siRNA, or 20 nM of siRNA targeting Nfkb2, or 20ng/ml LPS. Following 4, 8, 24 or 48 hours or 
treatment cells were harvested and western blot analysis performed on protein extracts from the cells 
using an Nfkb2 antibody targeting the p100 and p52 isoforms of the Nfkb2 protein. 20ng/ml LPS was the 
most potent inducer of Nfkb2 p100 and p52 subunit expression. NT-siRNA also induced p100 and p52 
expression following 24 hours of treatment. Nfkb2-siRNA was effective at knocking down p100 and p52 
expression by 24 and 48 hours of treatment.   
 
 
Figure 5.17: (b) Expression of Irf5 protein in BMDMs following treatment with siRNA targeting the Ifr5 
gene or NT-siRNA. Mouse BMDMs were transfected with 20 nM siRNA targeting the Irf5 gene or NT-
siRNA. 48 hours post transfection cells were harvested and western blot analysis performed on protein 
extracts from the cells using an Irf5 antibody. Ifn5 expression was induced in cells treated with NT-sRNA, 








3.2 Analysis of gene-level knockdown and efficacy of downstream response 24 h 
or 48 h post siRNA transfection 
 
Up until this stage all experiments exploring the role of GOIs in the type-I/LPS 
response, were based on 24 h of prior treatment with siRNA. The efficacy of GOI 
knock-down achieved at different time-points post-siRNA transfection had not been 
explored. Given knockdown at the protein level is apparent later than that at gene 
level there could be variability in the effect of GOI knockdown in the LPS response as 
monitored after different times of treatment with siRNA. Therefore to examine the 
efficacy of gene knockdown over time as well as determine the optimal time post-
siRNA to obtain the most efficacious response to GOI knock-down in the context of the 
LPS response, mouse BMDMs were transfected with siRNA targeting Nfkb2, and 24 or 
48 h post transfection cells were challenged with 5ng/ml LPS. At both 24 h and 48 h 
post siRNA transfection Nfkb2 expression was knocked down at the message level (~ 
40 – 50%) relative to NT-siRNA tranfected cells (Figure 5.18). In response to 
subsequent LPS stimulation, Nfkb2 expression followed a similar pattern of expression 
regardless of whether cells had been treated for 24 h or 48 h of prior siRNA (5.19).  In 
both cases Nfkb2 expression was induced by LPS stimulation alone and in combination 
with siRNA, and to a lesser extent in cells treated with prior siRNA targeting the Nfkb2 
transcript.   
 
Type-I expression was also assayed in response to LPS stimulation in cells with 24 or 48 
h prior siRNA targeting Nfkb2, Ifnb1, or Sod2 transcripts or non-targeting siRNA.  Ifit1 
expression was induced in a similar fashion and extent in response to pre-treatment 
with the different siRNAs at both 24 and 48 h (Figure 5.20).  LPS challenge in cells pre-
treated with NT-siRNA and siRNA targeting Sod2 induced Ifit1 expression to a greater 
extent than siRNA targeting Nfkb2 or Ifnb1, regardless of the duration of prior-siRNA 
treatment.   
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Taken together the data suggested there was not a major difference at the message 
level (in terms of knockdown efficiency and type-1 response) of treating with siRNA for 
24 or 48 h. Considering this and the fact our previous investigations [146] were based 
on 24 h of treatment with siRNA, this duration was chosen for the final assay design.  
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Figure 5.18: Nfkb2 expression in mouse bone marrow derived macrophages 24 hours or 48 hours post 
transfection with siRNA targeting the Nfkb2 gene.  Mouse BMDMs were transfected with siRNA 
targeting the Nfkb2 gene or non-targeting siRNA for 24 or 48 hours, or cells were left untreated for the 
duration (control). Expression of the Nfkb2 gene was then assessed by QPCR in all samples. 
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5.19: Nfkb2 expression in mouse bone marrow derived macrophages stimulated with LPS following 24 hours or 48 hours of treatment with siRNA targeting the Nfkb2 
gene. Mouse BMDMs were transfected with siRNA targeting the Nfkb2 gene or non-targeting siRNA for 24 or 48 hours, or cells were left untreated for the duration 
(control). Subsequently cells were stimulated with 5ng/ml LPS for 2 hours or 8 hours. Expression of the Nfkb2 gene was then assessed by QPCR in all samples, having 
undergone siRNA transfection and/or LPS stimulation, or no treatment (control).   
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Figure 5.20: Ifit1expression in mouse bone marrow derived macrophages in response to 2 hours of LPS stimulation, with and without 24 hours or 48 hours of 
treatment with siRNA targeting the Ifnb1 or Nfkb2 or Sod2 genes. Mouse BMDMs were transfected with siRNA targeting the Nfkb2 gene, or the Ifnb1, or Sod2 gene or 
with non-targeting siRNA. Cells were also left untreated (control). Following 24 hours or 48 hours incubation with the siRNA the cells were stimulated with 5ng/ml LPS 
for 8 hours. Expression of the Ifit1 gene was then assessed by QPCR in all samples, having undergone siRNA transfection and/or LPS stimulation, or no treatment 
(control).   
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Optimised work-flow for studying the role of Genes of Interest in the 
macrophage response to type-I interferons signalling stimulation 
 
Based on the series of questions addressed in results sections 1-3, the work-flow for 
assessing the role of GOI in the type-1 and LPS response was finalised as illustrated in 
Figure 5.21.  Mouse BMDMs were to be cultured from femurs of 7-10 week old male 
BALB/c mice with recombinant CSF-1. Although the assay optimisation process was 
performed on macrophages derived from the C57BL/6 strain of mice, the decision was 
taken to use BALB/c macrophages for the in vitro screen. The reasons for this change in 
mouse strain is discussed in greater detail and justified in the Discussion section. The 
siRNA and LPS induced effects on macrophages derived from the two mice strains 
were examined (data not shown). Similar levels of gene knockdown were achieved and 
similar patterns of type-I expression were observed in both strains. The major 
difference was the extent of type-I gene expression, which was higher in macrophages 
derived from C57BL/6 and has been observed by others [283].  
 
Following seven days of differentiation the cells were to be transfected with 20 nM 
final concentration of siRNA for a total of 24 h. However a portion of cells would be 
harvested at 7 h post transfection to monitor levels of Ifnb1 gene expression in 
response to the transfection process, since this was found to be the optimal time to 
monitor Ifnb1 expression following siRNA lipofection. Cells would also be harvested at 
24 h post siRNA transfection in order to assay type-I response stimulation. The 
remaining transfected cells would be stimulated with 5 ng/ml LPS and cells harvested 
at 2 h and 7 h post LPS to assay Ifnb1 expression and ISG expression respectively.  
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Figure 5.21: Finalised work flow for studying the role of gene of interests in the type-I response. Bone 
marrow derived macrophages are cultured by obtaining cells from 7-10 week old BALB/c male mice and 
differentiating using CSF-1. Following 7 days of differentiation cells are transfected with siRNA at a final 
concentration of 20 nM (siRNA) for 24hours before proceeding to the next stage of the experiment. 
However samples of siRNA treatment alone are taken at 7 hours and 24 hours post transfection to 
obtain RNA for assaying Ifnb1 production and type-I response activation respectively. The 24 hour 
samples can also be used to determine target gene knockdown. Remaining siRNA transfected samples 
are treated with 5ng/ml concentration of LPS and samples harvested at 2hours and 7hours post 
treatment to obtain RNA for assaying Ifnb1 production and type-I response activation respectively. 
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(4) Screen of siRNAs targeting genes of interest and their effect on the 
macrophage response to siRNA lipofection and LPS stimulation 
 
Having established and optimised a workflow for testing the effect of siRNA mediated 
gene knockdown in mouse BMDMs, the desire was to now (a) test the assay on a 
medium-throughput scale and (b) test the contribution of genes of interest (GOI) in 
type-I interferon signalling. The rationale behind the choice of genes selected is 
discussed below.  
 
Genes of interest (GOI) potentially implicated in IFN-β signalling 
To validate and extend the observations of previous investigation [146], genes that are 
either known or could potentially play a role in IFN-β signalling were chosen for 
analsysis in the in vitro assay (Table 5.1).  Some of the selected targets have well 
established roles in IFN-β signalling (Ifnb1, Irf3, Nfkb1, Rela and Irf7) [282] and were 
therefore expected to repress LPS induced type-I signalling. Conversely non-targeting 
siRNA, or siRNA targeting the Sod2 gene, would not be expected to repress the 
transfection or LPS induced type-I response; therefore if other gene knock-downs 
generate similar levels of ISG expression it may suggest they also are not crucial for 
type-I signalling. To validate previous observations, Irf5 and Nfkb2 were also selected 
for the in vitro screens.  According to the macrophage pathway model (Chapter-2), 
Nfkb2 can form a homodimer with itself or form heterodimers with Rel, Rela, Relb, as 
well other complexes along with Bcl3 and Nfkb1. Thus the transcriptional partners of 
Nfkb2 were also chosen as genes of interest for further investigation. Finally Nfkbia 
and Socs3 which serve as inhibitory proteins of NF-ĸB and cytokine signalling 
respectively were chosen to expore whether their knockdown would result in 



































Table 5.1. Predicted effects of targeting different genes with siRNA in mouse bone marrow derived 
macrophages. 13 genes of Interest (GOI) and the control Non-Targeting siRNA (NT-siRNA) to be 
transfected into primary bone marrow derived macrophages. Knock-down of genes associated with 
positive regulation of IFN-β message production or the type-I response is expected to repress type-I 
signalling relative to transfection of NT-siRNA or siRNA targeting of a negative control gene. Knockdown 
of genes associated with the negative regulation of cytokine activation pathways are expected to 
















1  Ifnb1  Interferon / Cytokine  Repress  
2  Irf3  Interferon regulatory factor  Repress  
3  Irf5  Interferon regulatory factor  Repress*  
4  Irf7  Interferon regulatory factor  Repress  
5  Nfkb1  Nfĸb transcription factor  Repress  
6  Nfkb2  Nfĸb transcription factor  Repress*  
7  Rela  Nfĸb transcription factor  Repress  
8  Relb  Nfĸb transcription factor  ?  
9  Rel  Nfĸb transcription factor  ?  
10  Nfkbia  Inhibitor of Nfĸb complex  Exacerbate  
11  Bcl3  Transcriptional co-activator 
(assoc NfĸB)  
?  
12  Socs3  Suppressor of cytokine 
signalling  
Exacerbate  
13  Sod2  Superoxide dismutase. 
Mitochondrial protein  
Induce type-I response (No 
Effect)  
14  Non-Targeting  N/A (siRNA that does not 
target any known/ predicted 
sequence)  
Induce type-I response (No 
Effect)  
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(4.1) Screen of Ifnb1 and type-I gene expression by QPCR following targeted gene 
knockdown of GOI in mouse BMDMs  
 
Two independent screens targeting the selected GOI were conducted.  Ifnb1 and type-I 
expression in response to siRNA lipofection are shown in Figure 5.22 and 5.23 
respectively and the targeted genes are ordered according to least-to-most-
immunostimulatory response (from left to right). The scale of Ifnb1 expression in 
response to siRNA transfection was ≈ 25 fold different between the two screens. 
Furthermore the order of least-to-most stimulatory gene targets was variable between 
the two screens; for example siRNA targeting Relb stimulated the greatest Ifnb1 
expression in one screen (5.22a), and was the least stimulatory gene target in the 
other screen (5.22b). Surprisingly in one screen (b) siRNA targeting Ifnb1 resulted in 
one the highest levels of Ifnb1 expression 7 h post transfection.  
 
Bcl3 and Relb were the gene targets resulting in the lowest levels Oasl1 expression 24 
h post-siRNA transfection in both screens (Figure 5.23). Cells treated with NT-siRNA or 
siRNA targeting Sod2 were amongst the samples with the highest levels of Oasl1 
expression. Contrary to the predicted response, targeting the Socs3 gene did not 
exacerbate the transfection induced type-I response (Figure 5.23), or indeed Ifnb1 
expression 2 h following LPS stimulation (Figure 5.24). Socs3, Blc3, Nfkbia and Irf3 were 
amongst the gene targets that resulted in the lowest levels of Ifnb1 expression in 
response to LPS stimulation in both screens. Cells treated with siRNA targeting the Rela 
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Figure 5.22: Ifnb1 gene expression in two independent screens of targeted RNA-interference in mouse 
BMDMs. BMDMs were transfected with siRNA using lipofecamine 2000 (L2K), targeting any of 13 
different genes (as identified in the graphs), NT-siRNA, L2K alone or were untreated (control). Following 
7 hours of treatment cells were harvested, and RNA extracted to determine Ifnb1 expression by QPCR. 
Two independent screens were performed (a and b). The bar graph is arranged to place to most 




























































7 hours post siRNA transfection
Screen- (a) 
Screen- (b) 




Figure 5.23: Oasl1 gene expression in two independent screens of targeted RNA-interference in mouse 
BMDMs. BMDMs were transfected with siRNA using lipofecamine 2000 (L2K), targeting any of 13 
different genes (as identified in the graphs), NT-siRNA, L2K alone or were untreated (control). Following 
24 hours of treatment cells were harvested, and RNA extracted to determine Oasl1 expression by QPCR. 
Two independent screens were performed (a and b). The bar graph is arranged to place to most 






























































24 hours post siRNA transfection
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Figure 5.24: Ifnb1 gene expression in response to LPS stimulation in two independent screens of 
targeted RNA-interference in mouse BMDMs. BMDMs were transfected with 20 nM siRNA using 
lipofecamine 2000 (L2K), targeting any of 13 different genes (as identified in the graphs), NT-siRNA, L2K 
alone or were untreated (control - No prior siRNA). 24 hours post siRNA treatment cells were treated 
with 5ng/ml LPS, and 2 hours post LPS treatment the cells were harvested and RNA extracted to 
determine Ifnb1 expression by QPCR. Two independent screens were performed (a and b). The bar 
































































2 hours post LPS treatment with 24 hours prior siRNA 
Screen- (a) 
Screen- (b) 
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The QPCR results of the two screens were on the whole inconclusive as to the effect of 
individual gene knock-downs on IFN-β signalling. Interpreting the contribution of the 
targeted genes was complicated by both the lack of reproducibility between screens, 
and contradictory action of gene-KDs within the screen.  However some of the siRNA 
targets were more consistent in their action between screens (including Socs3, Bcl3, 
Rela) than others. Ultimately it was difficult to abstract a convincing argument as to 
what effect the gene knockdowns have on the type-I and LPS response, based on QPCR 
data for the two genes (Ifnb1 and Oasl1) alone. Therefore to further elucidate if and 
how the GOI knockdowns had influenced the macrophage transcriptome in the context 
of the LPS response, genome wide expression was assayed by microarrays in selected 
samples from screen-b.  
 
4.2 Genome-wide microarray analysis of the LPS response following targeted 
 knockdown of genes of interest 
 
Eight siRNA treatments (from screen-b) were chosen for follow up analysis by 
microarrays; NT-siRNA (would serve as a control); Nfkb2 and Irf5 were chosen based 
on their activity in previous screens [146]. Soc3, Bcl3 and Rela were selected given 
their activity in the QPCR screens was generally more consistent than the other 
targeted genes; namely cells treated with siRNA targeting Socs3 or Bcl3 generally 
expressed lower levels of type-I genes (Ifnb1 and Oasl1), whereas those targeting Rela 
expressed Ifnb1 to a greater extent than many of the other genes targeted following 
LPS stimulation in both screen-a and screen-b.  Rela along with Nfkb1 are known to 
bind to the IFN-β enhancesome so logically it might be expected that their knock-down 
should repress type-I induction. Relb was also chosen for further analysis.  
 
In addition to the siRNA targeted samples, a timecourse of (NT)-siRNA treatment of 
mouse BMDMs was also examined alongside the data. The samples examined by 
microarray analysis are summarised in Table 5.2. 
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Stimulus Concentration Pre-treatment? Time-points (hours) 
None  N/A No 2h post experiment start 
LPS   5 ng/ml No 2h post LPS 
LPS   5 ng/ml 24 hours of 20 nM Non-targeting siRNA 2h post LPS 
LPS   5 ng/ml 24 hours of 20 nM siRNA targeting Nfkb2 2h post LPS 
LPS   5 ng/ml 24 hours of 20 nM siRNA targeting Irf5 2h post LPS 
LPS   5 ng/ml 24 hours of 20 nM siRNA targeting Socs3 2h post LPS 
LPS   5 ng/ml 24 hours of 20 nM siRNA targeting Relb 2h post LPS 
LPS   5 ng/ml 24 hours of 20 nM siRNA targeting Bcl3 2h post LPS 
LPS   5 ng/ml 24 hours of 20 nM siRNA targeting Rela 2h post LPS 
LPS   5 ng/ml 24 hours of 20 nM siRNA targeting Nfkb1 2h post LPS 
None  N/A No 7h post experiment start 
LPS   5 ng/ml No 7h post LPS 
LPS   5 ng/ml 24 hours of 20 nM Non-targeting siRNA 7h post LPS 
LPS   5 ng/ml 24 hours of 20 nM siRNA targeting Nfkb2 7h post LPS 
LPS   5 ng/ml 24 hours of 20 nM siRNA targeting Irf5 7h post LPS 
LPS   5 ng/ml 24 hours of 20 nM siRNA targeting Socs3 7h post LPS 
LPS   5 ng/ml 24 hours of 20 nM siRNA targeting Relb 7h post LPS 
LPS   5 ng/ml 24 hours of 20 nM siRNA targeting Bcl3 7h post LPS 
LPS   5 ng/ml 24 hours of 20 nM siRNA targeting Rela 7h post LPS 
LPS   5 ng/ml 24 hours of 20 nM siRNA targeting Nfkb1 7h post LPS 
NT-siRNA 20 nM No 0 h (pre-treatment) * 
NT-siRNA 20 nM No 1 h post transfection * 
NT-siRNA 20 nM No 2 h post transfection * 
NT-siRNA 20 nM No 4 h post transfection * 
NT-siRNA 20 nM No 8 h post transfection * 
NT-siRNA 20 nM No 24 h post transfection * 
 
Table 5.2: Description of macrophage samples chosen for follow up analysis by genome wide 
expression profiling using microarrays. Mouse BMDMs were treated with 5 ng/ml LPS for either 2 or 7 
hours following 24 hours of prior targeted siRNA treatment. In a separate experiment a time course of 
NT-siRNA treatment was performed in mouse BMDMs;  with samples taken at 1, 2, 4, 8, 24 hours post-
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32 RNA samples were processed for hybridisation to Affymetrix Mouse Gene 1.1. ST 
Arrays. These arrays were obtained as part of a 96-Array plate format, which enables 
the simultaneous high-throughput profiling of 96 samples, using the same content as 
the individual Mouse Gene 1.1 ST cartridge arrays. The remaining 64 arrays on the 96-
Array plate were used to process samples from experiments exploring other questions 
of interest to this thesis and are discussed accordingly in other Chapters (6).   
 
A network graph of the normalised data for the 32 microarrays pertaining to the 
investigations into targeted siRNA knockdown in mouse BMDMs was generated in 
BioLayout Express3D, by filtering for nodes with relationships across the arrays at a 
Pearson correlation of 0.85 or above. This resulted in a graph of 12,619 nodes, 
connected by 505,590 edges, which was was then clustered at an MCL inflation value 
of 2.2. After filtering to remove un-interesting clusters and those representing 
technical artefacts, the remaining graph comprised 4,674 nodes connected by 433,761 
edges (Figure 5.25). There were four main structures evident in the filtered graph; one 
representing up-regulated components, another, down-regulated components, and 
the remaining two were specific to changes during the NT-siRNA time-course.    
 
To determine whether the targeted siRNA treatment was effective at suppressing GOI 
expression following LPS challenge, GOI expression in the knockdown samples was 
compared to the untreated controls, LPS-only treated and LPS treated with prior-NT-
siRNA (Figure 5.26). All seven GOI’s were induced by LPS treatment alone (at 2 and 7 h) 
and LPS treatment in combination with 24 h prior NT-siRNA.  Relative to their 
expression in the LPS-with-prior-NT-siRNA samples, Nfkb2, Socs3, and Relb were all 
knocked down when treated with their specific targeting siRNA. Nfkb1 and Bcl3 were 
knocked down to their basal (control-untreated) levels of expression, and Rela and Irf5 
were further knocked down beyond their basal levels of expression. Therefore at the 
message-level all seven GOIs were convincingly repressed when targeted with the 
corresponding siRNA.  
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Figure 5.25: A network graph of the transcriptional changes occurring in response to siRNA treatment 
of mouse BMDMs A network graph of the normalised data for the 32 microarrays pertaining to the 
investigations into targeted siRNA knockdown in mouse BMDMs was generated in BioLayout Express3D, 
by filtering for nodes with relationships across the arrays at a Pearson Correlation of 0.85 or above. The 
resultant graph of 12,619 nodes connected by 505,590 edges was clustered at an MCL inflation value of 
2.2 to identify groups of co-ordinately expressed transcripts. Un-interesting clusters and those 
representing technical artefacts were removed from the graph leaving 4,674 nodes connected by 
433,761 edges (above). This filtered graph comprised three main components; transcripts up-regulated 
in response to LPS/ NT-siRNA treatment, transcripts down-regulated in response to LPS or NT-siRNA 
treatment and transcripts specifically regulated in the NT-siRNA timecourse. 
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Figure 5.26: Transcriptional expression and repression of genes of interest in response to LPS stimulation of BMDMS with/without prior targeted siRNA treatment. 
Mouse BMDMs were treated with specific targeting siRNA or control NT-siRNA for 24 hours, and subsequently treated with 5ng/ml LPS for 2 and 7 hours. Expression 
levels of the targeted genes (as measured by microarrays) is shown above for seven genes of interest in cells with no-treatment, LPS-treated only, NT-siRNA treated with 
subsequent LPS, and those treated with the specific targeting siRNA followed by LPS.   
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To explore the main transcriptional signatures associated with the data set as well as 
establish whether any of the targeted gene KDs had perturbed this signalling, the 
expression patterns associated with the clusters in the filtered network graph were 
examined. Despite clear indication of target gene knockdown (Figure 5.26), there was 
no evidence of transcriptional signatures associated with any of the specific knock-
downs; instead the majority of clusters were an outcome of LPS stimulation of 
macrophages and unaffected by the suppressed expression of any of the GOIs. The 
average expression of co-ordinately expressed transcripts was plotted across the 
siRNA-KD data set (Figure 5.27) for the major clusters within the data set which are 






























Go Terms/ associated processes 
Cluster-a 1,248 Repressed 7 h 
post LPS 
treatment. 
Repressed at 4 h 
in NT-siRNA time-
course 
Cell-cycle progression (e.g Cdc6, Cdca2/3/4/5/7/8), 
cyclins, (e.g Ccna2, Ccnb1, Ccnb2, Ccnd1, Ccne1/2), DNA 
polymerase subunits (Pola1, Pola2, Pole, Pole2). 
Cluster-b 1,029 Up-regulated 7 h 
post-LPS, and at 8 
h in the NT-siRNA 
time-course 
Regulation of immune signalling, leukocyte activation and 
cytokine production. (e.g Cxcl3/9/10/11, Ifit1/2/3), Il6, Il7, 
Il12a, Il15, Oasl1, Oasl1a, Oasl2, Oas2, Tlr1, Tlr3, Tlr6, Tlr8, 
Myd88)  
Cluster-c 351 Represses 7 h 
post LPS 
treatment. 
Repressed 8 h in 
the NT-siRNA 
time-course 
Membrane organisation and endocytosis 
Cluster-d 223 Upregulated 2 
and 7 h post LPS 
and from 4-8 
hours in the NT-
siRNA 
timecourse. 
Cytokine production and regulation (e.g. Ccl2, Cxcl1, 
Cxcl2, Cxcl16, Irf1, Il1a). Apoptosis signalling (Cflar, Fas, 
Tnf).   
 
Cluster-e 138 Upregulated 8h in 
NT-siRNA 
timecouse only. 
Response to virus exposure, regulation of kinase activity.   
Cluster-f 100 Upregulated 2 h 
post-LPS and 4-8 
hours in NT-siRNA 
timecourse 
Signalling cascades, and lymphocyte activation.    
Table 5.3: Overview of the main clusters of co-ordinatley expressed genes in the screen of siRNA 
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If knockdown of certain genes specifically perturb type-I signalling it was possible this 
effect was obscured if the ISGs are members of clusters with transcripts whose 
expression was not affected by the gene KDs. Therefore to further verify the GOI-
knock-downs had not had an effect, the expression of genes regulated in response to 
IFN-β stimulation of macrophages, (as determined in Chapter-4) was examined in this 
array study. 1,639 of the IFN-β study genes mapped back to the data-set here. Cohorts 
of genes which were regulated across different temporal phases of the IFN-β response 
(as determined in Chapter-4) were identified and their average expression in this array 
study was plotted (Figure 5.28). However the expression of these IFN-β response genes 
was consistent across all of the LPS treated samples, regardless of any prior targeted 
gene KD. The data would therefore suggest on this occasion the gene knockdowns 












Figure 5.27: Average expression profile of cohorts co-ordinately expressed transcripts (clusters), 
generated from a network analysis of transcriptional changes in BMDM stimulated with LPS or NT-
siRNA. BMDMs were transfected with 20 nM siRNA using lipofectamine 2000 (L2K), targeting any of 
Nfkb2, Irf5, Socs3, Relb, Bcl3, Rela, Nfkb1 or Non-targeting-siRNA (control). 24 hours post siRNA 
treatment cells were treated with 5ng/ml LPS, and were then harvested at both 2 and 7 hours post 
treatment for microarray-expression analysis on RNA extracts. In a separate experiment a timecourse of 
NT-siRNA treatment of macrophages was performed. Network based analysis was of the entire data-set 
was performed and clusters of co-ordinately expressed transcripts identified. Six examples of clusters 
representing changes associated with LPS and/NTsiRNA treatment are shown. Data points are not 
continuous, but represented as such to ease interpretation.  




Figure 5.27 (continued): Average expression profile of cohorts co-ordinately expressed transcripts 
(clusters), generated from a network analysis of transcriptional changes in BMDM stimulated with LPS 
or NT-siRNA. BMDMs were transfected with 20 nM siRNA using lipofectamine 2000 (L2K), targeting any 
of Nfkb2, Irf5, Socs3, Relb, Bcl3, Rela, Nfkb1 or Non-targeting-siRNA (control). 24 hours post siRNA 
treatment cells were treated with 5ng/ml LPS, and were then harvested at both 2 and 7 hours post 
treatment for microarray-expression analysis on RNA extracts. In a separate experiment a timecourse of 
NT-siRNA treatment of macrophages was performed. Network based analysis was of the entire data-set 
was performed and clusters of co-ordinately expressed transcripts identified. Six examples of clusters 
representing changes associated with LPS and/NTsiRNA treatment are shown. Data points are not 
continuous, but represented as such to ease interpretation. 
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Figure 5.28: Expression of IFN-β regulated transcripts (as determined in Chapter-4) in the siRNA-LPS-
screen and NT-siNRA time-course study.  The average expression of cohorts of transcripts regulated at 
specific temporal phases in response to IFN-β stimulation of macrophage was plotted based on their 
expression values in the current analysis described in Figure 5.27. 




Figure 5.28: (continued) Expression of IFN-β regulated transcripts (as determined in Chapter-4) in the 
siRNA-LPS-screen and NT-siNRA time-course study.  The average expression of cohorts of transcripts 
regulated at specific temporal phases in response to IFN-β stimulation of macrophage was plotted based 
on their expression values in the current analysis described in Figure 5.27. 




The investigations of this Chapter set out to optimise an in vitro assay to test the role 
of selected genes in the type-I response using targeted RNA-interference, QPRC and 
genome-wide expression profiling. Study of the type-I response using siRNAs is 
inherently complicated by the fact IFN-β and type-I response signalling is induced by 
the transfection of the siRNA itself. To contend with this, as well as better understand 
the macrophage response to stimulation with siRNA and/or LPS, a host of fundamental 
questions pertaining to the use of siRNA and LPS in mouse macrophages were 
examined, including;  
 The dose dependant effects of siRNA.  
 The dose dependant effects of LPS alone and in combination with prior siRNA 
treatment.  
 The timing of siRNA treatment to achieve efficient gene knockdown as well the 
most efficacious downstream response to knockdown.  
This optimisation process highlighted the issues surrounding the use of siRNA as a 
study tool in macrophages, and helped inform the design of an assay to study the roles 
of the selected GOI in the type-I and LPS response. The assay incorporated 5 ng/ml of 
LPS treatment in mouse BMDMs which had been transfected with siRNA targeting the 
selected GOI 24 h earlier.  Network analysis of genome-wide transcriptional data 
revealed there were no patterns of expression specifically associated with any of the 
prior gene knockdowns. These results would suggest that the LPS response was not 
sensitive to knockdown of any of the GOI.  
 
Factors explored during the assay optimisation process but not discussed as part of 
these results included the possibility of siRNA sequence specific effects on type-I 
responsiveness and the effect of using macrophages derived from different strains of 
mice (BALB/c and C57BL/6). Assay optimisation screens were at first performed on 
macrophages derived from C57BL/6 mice strain. The strain was later changed to the 
BALB/c since (i) the original study forming the basis of these investigations was 
performed in BALB/c derived BMDMs [146], (ii) other data generated in this thesis 
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(Chapters 4 and 6) is based on BALB/c derived BMDMs, (iii) C57BL/6 macrophages are 
more sensitive to DNA induced death and are hyper-responsive to LPS compared with 
BALB/c macrophages [283]. With respect to the latter point, during the course of these 
investigations it was found that C57BL/6 macrophages on some occasions but not 
others would be prone to siRNA-induced cell death (data not shown). In contrast 
viability of BALB/c macrophages following siRNA treatment was more consistent from 
week to week. BALB/c unlike C57BL/6, do not possess basal levels autocrine interferon 
signalling [283] this factor along with the greater sensitivity of C57BL/6 to nucleic acid 
induced cell death may have contributed to the observed differences. The effect of 
mice strain on the downstream response to siRNA could have been further explored. 
In essence this would form a study in itself, over and above the optimisation process 
given the vast number of variables that could be investigated.  
 
Also explored but not discussed in the context of these results was the presence and 
variability in possible immunostimulatory sequences across the panel of siRNAs used in 
these investigations.  It is possible the differences in the abundance of these 
sequences across the different siRNA’s may account for variability in their ability to 
induce a type-I response. The sequences implicated in siRNA immunostimulatory 
capacity include; GUCCUUCAA [284], UGUGU [285], UGGC [85], and GU [286].  Others 
have also found a correlation between the uradine content of the U-rich strand and 
the immunostimulatory activity of the siRNA duplex as well as the number of CG/ GC 
clamps interspersed along the length of the siRNA [287]. Attributing the contribution 
of individual sequences to the immunostimulatory capacity of the siRNAs is inherently 
complex. Ultimately the genome-wide transcriptional analysis revealed that the 
expression of type-I response genes following LPS stimulation was uniform across all 
samples regardless of the target of the siRNA (i.e. sequence of the siRNA duplexes) 
(Figure 5.27).  
 
Effect of increasing concentrations of siRNA in BMDMs 
Whilst lipofection of 50 to 100 nM has been recommended for stable knockdown in 
RAW cells [288], the data here indicated these concentrations were toxic to primary 
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macrophages and distorted their phenotype considerably from the control-untreated 
state, and more so when subsequently treated with LPS (Figures 5.9).  
 
Uptake of fluorescently labelled siRNA (siGLO) was observed as early as 4 h post-
transfection at both 20 and 50 nM concentrations and by 24 h post-transfection the 
siGLO staining was indicative of almost all cells having been successfully transfected 
(Figures 5.3-5.5). siGLO is intended as a qualitative indicator of siRNA transfection 
efficiency and in this respect it was apparent the cells were being transfected. 
Counterstaining with a cytoskeletal dye (e.g. actin) may have provided a more accurate 
indication of uptake of siRNA and the dynamics of uptake of siGLO (for example 
numbers of transfected vs. non-transfected cells).  
 
Efficient transfection does not necessarily correspond with efficient gene knock-down, 
in every cell type, as a cells proliferative rate [289] and capacity for degrading 
(exogenously introduced) nucleic acid may influence the potency of the siRNA KD. 
Hence also examined was the level of target gene repression by siRNA at a range of 
final concentrations. For the two genes tested (Irf7 and Nfkb2), their message level of 
expression was suppressed to the same extent regardless of the concentration of 
targeting siRNA used (Figure 5.6). However expression of Irf7 and Nfkb2 was induced in 
an exponential manner by non-targeting siRNA, as was expression of Oasl1 and Ifit1 
(type-I response genes). Interestingly the dynamics of Oasl1 and Ifit1 expression with 
increasing concentrations of siRNA varied across the three siRNAs tested (non-
targeting, Irf7 or Nfkb2-siRNA) (Figure 5.8). The results here indicate increasing the 
concentration of the siRNA (targeting key IFN-β signalling genes) does not necessarily 
correlate with enhanced repression of the type-I response. Ultimately there are likely a 
number of factors that influence the type-I induction for a given siRNA at a given 
concentration. These could be the kinetics of target gene repression, as well as that of 
protein knockdown, half-life and turnover.  
 
Others have also observed a dose responsive increase in Oasl1 and Ifit1 expression 
when transfecting RCC1 renal cell carcinoma cells with 10, 20, 50 and 100 nM of siRNA 
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targeting GAPDH. The study suggests that the IFN system is activated in response to all 
concentrations of siRNA tested, however some ISGs are only induced in a 
concentration-dependent manner [77]. The results here (Figure 5.8) suggested that 
although type-I responsiveness increases in a dose dependant manner to NT-siRNA, 
this does not necessarily hold true for other siRNAs, possibly given their known or 
potential role in interferon signalling. 
 
Examination of cell morphology suggested the phenotype of the LPS stimulated 
macrophages pre-treated with 50 nM to 100 nM siRNA are considerably distorted from 
those stimulated with LPS alone or LPS in combination with lower doses of siRNA 
(Figure 5.9). Further examination, for example an annexin-V apoptosis assay would 
provide a better indication of the extent of apoptosis the macrophages were 
undergoing.  
 
Ultimately a balance had to be achieved between using enough siRNA to achieve 
knockdown at the transcriptional and protein level, yet not causing toxicity and 
overriding the effect of any gene knockdown due to high levels of siRNA-dose 
dependant type-I expression. 20 nM siRNA (final) concentration was chosen for use in 
the screens in BMDMs for the remainder of the investigations. Knock-down of targets 
genes was achieved at both the message and protein level with this concentration of 
siRNA. 
 
Macrophage response to LPS and combining siRNA transfection with LPS 
treatment 
Type-I expression in response to a range of LPS doses was examined. Essentially a 
balance had to be drawn between using enough LPS to efficiently induce detectable 
levels of Ifnb1 and type-I expression yet avoiding causing toxicity to the cells as 
observed previously (due to the combinatorial use siRNA and LPS) (Figure 5.9).  
 
Initial investigations comparing the potency of type-I induction in response to IFN-β 
and LPS indicated a 12-fold difference between the extent of Oasl1 induction in 
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response to 10 U/ml IFN-β or 100ng/ml LPS (Figure 5.10). Given the extent of 
difference in type-I response activation by 100 ng/ml LPS and 10 U/ml IFN-β, the 
following investigations set out to determine how the type-I response varied in 
response to different concentrations of IFN-β and LPS. Macrophages induced Oasl1 
expression in a dose responsive manner in response to increasing concentrations of 
IFN-β and increasing doses of LPS respectively, 24 h post-treatment (Figure 5.11). The 
results indicated the extent of Oasl1 induction was far greater with doses of LPS used 
(10, 20, or 100 ng/ml), compared to doses of IFN-β examined (20, 50 or 100 U/ml) 
(Figure 5.11). 
  
Given the potency of type-I induction at 100 ng/ml LPS, a lower range of LPS doses 
were examined (50, 20, 10, 5, and 2.5 ng/ml). A dose dependant induction of Ifnb1 
expression was observed following 1 and 2 h of LPS treatment (alone) (Figure 5.12). By 
7 h post-LPS treatment type-I response gene induction was evident at all doses of LPS 
examined (as measured using semi-quantitative PCR) (Figure 5.13). Attempts were also 
made here to define the overlap in the transcriptional targets of LPS and IFN-β, 
however this analysis was very limited by the number of genes which were analysed by 
semi-quantitative PCR (Figure 5.13). Amongst the genes tested the results did 
demonstrate Il1b expression (and to a lesser extent Tnf expression) was exclusive to 
LPS treatment. There was also a time-lag between the induction of the interferon 
inducible genes in the LPS treated samples, possibly due to time taken for autocrine 
IFN-β signalling to initiate in LPS treated cells. Ultimately a better understanding of the 
overlap and differences in the LPS and IFN-β, may have aided the assay design. 
 
Although the investigations of this Chapter did not set out to specifically explore 
macrophage responsiveness to LPS following siRNA-lipofection, a better understanding 
of the cells response under these circumstances would have been valuable given the 
design of the assay. During the optimisation process, it was found that treatment of 
BMDMs with 20 ng/ml LPS after 24 h pre-exposure to siRNA, resulted in cell toxicity 
(data not shown). However at lower doses of LPS treatment, the cells were viable and 
in some experiments (Figure 5.14) generated higher levels of Ifnb1 in cells pre-treated 
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with NT-siRNA, compared to those treated with LPS alone. On other occasions Ifnb1 
expression was higher in cells which had not undergone prior siRNA transfection 
(Figure 5.16). Eventually a dose of 5ng/ml LPS was chosen for the assay, since 
detectable levels of Ifnb1 expression were induced at this concentration and cell 
viability did not appear compromised when 5 ng/ml LPS was used in combination with 
24 h prior siRNA. In a preliminary screen, Ifnb1 expression was lower at all measured 
time-points following 5 ng/ml LPS treatment in cells which had been pre-treated with 
siRNA targeting either Irf3 or Nfkb2 expression compared to those pre-treated with 
NT-siRNA (Figure 5.16). This observation was fitting with the original hypothesis that 
siRNA mediated knock-down of genes known to positively regulate type-I signalling will 
repress the LPS induced type-I response. Of the two genes tested, Irf3 is known to 
form part of the Ifnb1 enhancesome and Nfkb2 is suspected to play a role in type-I 
signalling regulation based on our previous observations [146]. 
 
The use of siRNA to investigate components of LPS signalling in primary and 
immortalised macrophages is not novel [290-291]. However the possibility that pre-
treatment with siRNA may in-itself modulate responsiveness to LPS in immune cells 
has broadly been overlooked.  Pre-exposure to immunological stimuli can make 
macrophages hyper-responsive or tolerant to subsequent LPS treatment. For example 
macrophages primed with IFN-γ display enhanced sensitivity to endotoxin, and in vivo 
IFN-γ pre-treatment followed by even subclinical endotoxin exposure is toxic [292-
293]. Viral infection induced type-I interferon also heightens sensitivity to LPS 
challenge as measured by increased lethality in vivo and augmented TNF-α serum 
levels [294]. In contrast, pre-exposure to low doses of LPS results in tolerance to 
subsequent LPS stimulation as determined by down-regulation of cytokine production 
in vivo [295-296] and in primary macrophage cultures [297-300]. The mechanism of 
endotoxin tolerance has been linked to the MyD88-dependent signalling, up-regulation 
of negative regulators of the TLR pathway, and transcriptional re-programming 
whereby proinflammatory cytokine expression is suppressed and anti-inflammatory 
cytokines are over-expressed [301].  
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The collection of data here strongly suggests siRNA trasfection in macrophages results 
in their activation by IFN-β stimulation, therefore the cells are type-I interferon primed 
prior to any subsequent LPS treatment.  In RAW264 macrophages, the sustained 
activation response to different TLR agonists has been found to be perfectly additive 
[302]; so that the response to activation of TLR4 by LPS was additive with that of 
TLR2/6 (but not with TLR4). Similarly LPS stimulation of macrophages which have been 
exposed to a lipid-based transfection reagent and siRNA, is likely to result in the 
activation of different TLR’s, the consequence of which is unclear.  
 
Determination of ideal siRNA treatment time for optimal KD and type-I 
repression following LPS stimulation 
 
Given knockdown at the protein level is apparent later than that at gene level there 
could be variability in the effect of GOI knockdown in the LPS response as monitored 
after different times of treatment with siRNA. For example one possibility is that by 48 
h post transfection the siRNA may have had more time to take effect at the protein 
level. Thus if the targeted GOI’s activity at the protein level is key to the LPS or type-I 
response then this could be better observed after 48 h following siRNA transfection. 
Conversely since the effect of siRNA is transient, it is possible the potency of the 
effects of knocking down a GOI may wear off over time following siRNA transfection.  
 
Protein level analysis of Nfkb2 expression indicated the peak induction of Nfkb2 by NT-
siRNA is achieved at 24 h post treatment (Figure 5.17a). Nfkb2 protein expression was 
repressed from 24 h post treatment in samples treated with siRNA targeting the Nfkb2 
gene, and to a greater extent by 48 h. At the message level, Nfkb2 expression was 
knocked-down to a similar extent at both 24 and 48 h post siRNA transfection (Figure 
5.18). Furthermore type-I response gene expression following LPS challenge presented 
a similar pattern of expression in cells pre-treated with siRNA for either 24 or 48 h 
(Figure 5.19). Thus the siRNA treatment time of 24 h was maintained for the remainder 
of the investigations. Knockdown analysis of GOI in the genome-wide microarray 
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screen revealed effective message level knockdown of the targets at both 2 and 7 h 
post LPS, when cells had been treated with 24 h prior siRNA (Figure 5.26). 
 
Studies of targeted gene knockdown in mouse BMDMs 
The purpose of the siRNA optimisation process was to aid the design an in vitro assay 
to study the role of GOI in the type-I response. LPS stimulation of macrophages 
induces the potent expression of IFN-β message and protein [275]. Consequently type-
I signalling forms a significant portion of the response to LPS [277, 303-304]. Therefore 
to measure the effect of gene knock-downs LPS was chosen as a stimulus of type-I 
signalling.  
 
BMDMs were transfected with siRNA targeting specific GOI, and 24 h later were 
treated with 5ng/ml LPS. Analysis of Ifnb1 expression demonstrated a great deal of 
variability in the level of Ifnb1 induction (following both lipid-transfection of the siRNA 
and the subsequent LPS stimulation), across the different knockdown samples. The 
magnitude of Ifnb1 induction also varied between the two screens performed. 
Furthermore reproducibility within and between screens was for many of the genes 
tested inconsistent, with respect to Ifnb1 expression (Figures 5.22 & 5.24). The siRNA 
targets which were more consistent in their action between the two screens included 
Socs3, Bcl3, and Rela. The discrepancies witnessed during these screens, and to some 
extent throughout the optimization process could be attributed to the innate 
variability of primary macrophage cell cultures. The variability in Ifnb1 expression 
observed between the two screens could partly be attributed to the very transient 
expression of Ifnb1, the peak induction of which may have been induced at slightly 
different times between the two screens and also between target-genes in a given 
screen. QPCR, semi-quantitative PCR and microarray data all suggest Ifnb1 is maximally 
expressed ~6-8 hours post-siRNA transfection (Figures 5.15, 5.16). Microarray analysis 
of a timecourse of NT-siRNA treatment in mouse BMDMs revealed the predominant 
transcriptional activity occurs at 8 h and later following transfection, with negligible 
changes at the earlier time-points analysed (1, 2 and 4 h) (Figure 5.27). These results 
underscore the importance of sample timing when trying to deduce levels of Ifnb1 
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expression in response to siRNA transfection. Moreover reproducibility of results in 
primary macrophage cultures is often unwieldy, as epitomised by the findings of the 
RNAi screen in BMDMs [146] where three biological replicates would yield variable 
outputs in terms of gene expression. To garner a more convincing view of the effects 
of the gene knockdowns on the IFN-β signaling, genome-wide analysis of the 
downstream response was performed.  
 
Efficient gene knockdown of the selected GOIs was observed relative to NT-siRNA 
(Figure 5.26). However the network based analysis of the results showed that the gene 
KDs did not perturb transcriptional signalling networks associated with the LPS and 
type-I interferon response (Figures 5.27, 5.28). One possibility is that some of the 
tested genes might be dispensable for eliciting the type-I response. Some of the GOIs 
have been shown elsewhere to play a role in type-I signalling. Interestingly in a 
recently published study Krausgruber et al, demonstrated high IRF5 expression in M1-
type human and mouse macrophages and argues that IRF5 directly activates the 
transcription of certain M1-characteristic imflammatory mediators [272]. In contrast to 
the experiments here, the authors differentiated the mouse BMDMs with GM-CSF 
rather than M-CSF (CSF-1) and found cells differentiated with GM-CSF had higher 
expression of IRF5 protein than M-CSF-derived BMDMs. Furthermore in human 
macrophages inhibition of  endogenous IRF5 via RNA-interference resulted in lower 
mRNA expression for a number of LPS induced inflammatory mediators [272].  
 
Knockdown of members of the classical/canonical NfĸB transcription factor, Nfkb1 and 
Rela also failed to distort type-I or LPS signalling based on the microarray analysis in 
this Chapter. Nfkb1:Rela are established to bind to the Ifnb1 enhancesome, but some 
have reported these proteins to be largely dispensable for the RIG-like-receptor 
triggered IFN-β induction [305-306]. Others found that Rela controls autocrine IFN-β 
and basal ISG expression [307] but is only required for a small subset of inducible ISGs . 
Despite this the authors argue Rela is critical in the interferon response as the absence 
of  Rela results in the delayed induction of IFN-β and subsequent ISG expression as well 
as increased susceptibility to viral infection [307]. It could therefore be possible that 
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although the knockdown of the GOI tested in the screen were not critical enough to 
abrogate IFN-β and ISG expression they may have influenced the timing of their onset; 
a factor not explored in these investigations.  
 
The screens in this Chapter suggest the LPS response is not sensitive to changes in 
expression of any of the GOIs. Such resilience to perturbation has been described as 
‘robustness’ in biological networks [308], a property allowing a given system to 
maintain its function despite internal and/or external assaults. IFN-β signalling is one of 
several pathways activated in response to LPS treatment of macrophages; the cells are 
also stimulated by the autocrine production of TNF-α, TGF-β, a number of interleukins 
as well as the differentiation factors CSF-1 and CSF-2 (reviewed in [309]). Activation of 
the downstream MAPKinase, PKC (protein kinase C), and heterotrimeric G-protein 
pathways are all recognised in response to LPS stimulation [309]. It is therefore 
plausible that activation of these various pathways contributed to the resistance of the 
overall transcriptional network to the gene knockdowns. A better understanding of the 
overlap and differences in the transcriptional response of macrophages to LPS and IFN-
β is required to further elucidate why the gene knockdowns were ineffective at 
perturbing the transcriptional signatures associated with LPS and type-I signalling.  
 
 
Conclusions and Further Work 
 
The work described in this Chapter has highlighted the issue that the optimisation and 
use of siRNA in macrophages is complex, requires many considerations, and is often 
confounded given the highly attuned pattern recognition machinery of these cells. At 
the same time exploring the use siRNA in macrophages remains imperative given its 
power as a tool for functional genomics screening and also since macrophages are 
attractive targets for siRNA-based therapeutics.  
 
One of the predominant issues during these investigations was the lack of 
reproducibility between experiments, which most likely could be attributed to the 
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plasticity and adaptability of primary macrophages. Arguably reproducibility may have 
been improved if the optimization process was performed in a macrophage-like cell 
lines (e.g. RAW macrophage). However the phenotype of immortalized macrophage-
like myeloid cell lines is often very different from primary tissue-derived macrophages. 
Thus to understand the immunobiology of macrophages one needs to analyse primary 
cells.  
 
There are a range of factors which could be further explored to improve the assay 
design including; testing of other lipid-based transfection vectors to determine if there 
was a difference in the immunostimulatory capacity of different transfection reagents; 
the inclusion of cell toxicity assays (for example annexin V apoptosis assays) would 
have given a more accurate indication of the levels of apoptosis induced by different 
variables (e.g. siRNA concentration; siRNA combination with LPS treatment; target 
gene of the siRNA).  In the assays described in this Chapter, IFN-β expression was 
measured at the message level by QPCR, however mRNA expression does not always 
correspond with protein expression therefore it would have been desirable to also 
measure IFN-β expression by ELISA’s.  
 
One possibility why the genome wide transcriptional profiling following the siRNA 
screens did not reveal a difference if type-I responsiveness could be because the LPS 
stimulation compensated for the lack of individual signalling components (siRNA target 
genes). Therefore a better understanding and comparison of the LPS and IFN-β 
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Methods and Materials 
 
Cell culture 
Bone marrow derived macrophages were prepared from the femurs of 7-10 week old 
male BALB/c or C57BL/6, in the presence of CSF-1. Full cell culture technique is as 
described in Chapter-4 Methods and Materials – (IFN-β study). For Western Blot 
analysis cells were plated out in 6-well tissue culture plates on day six of differentiation 
at a density of 1,000,000 cells / well. For all other experiments cells were seeded in 24-
well tissue culture plates, on day six of differentiation at a density of 200,000-210,000 
cells/ well, which is equivalent to the seeding density (cell/ over given surface area) of 
6-well plates.  
 
LPS treatment 
LPS from Salmonella Minnesota (Sigma, Poole, UK) was used at a range of 
concentrations as indicated throughout the text of the Results section in cell culture 
experiments, and diluted in culture medium.   
 
siRNA transfections  
siRNAs (SMARTpools, Thermo Scientific, MA, USA) were purchased at a 5 nmol scale 
and redissolved in 1× siRNA buffer (Thermo Fisher Inc, MA, USA) to a final 
concentration of 10 μM. Each siRNA pool comprises a mixture of four siRNA duplexes 
targeting different sequences of the same mRNA, combined into one reagent. The 
SMARTpool siRNAs are selected (by the manufacturers) using a weighted algorithm 
which incorporates a number of criteria (including sequence specific and 
thermodynamic parameters) and is thought to improve identification of potent, 
functional siRNAs [310]. The ON-TARGET plus design of these reagents incorporates 
modifications to both the sense and anti-sense strands of the siRNA duplexes to 
destabilise off-target activity and enhance target specificity [311-312]. 
Details of the siRNA used in this Chapter are summarised in Table 5.4 
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Murine Target Gene Thermo Scientific SMARTpools ID 
Rela ON-TARGETplus SMARTpool L-040776-00-0005 NM_009045 
Nfkb1 ON-TARGETplus SMARTpool L-047764-00-0005 NM_008689 
Rel ON-TARGETplus SMARTpool L-047122-00-0005 NM_009044 
Socs3 ON-TARGETplus SMARTpool L-040626-01-0005 NM_007707 
Irf5 ON-TARGETplus SMARTpool L-041093-01-0005 NM_012057 
Sod2 ON-TARGETplus SMARTpool L-062893-00-0005 NM_013671 
Nfkb2 ON-TARGETplus SMARTpool L-046030-01-0005 NM_019408 
Relb ON-TARGETplus SMARTpool L-040784-01-0005 NM_009046 
Bcl3 ON-TARGETplus SMARTpool L-045102-01-0005 NM_033601 
Irf3 ON-TARGETplus SMARTpool L-041095-00-0005 NM_016849 
Ifnb1 ON-TARGETplus SMARTpool L-043699-00-0005 NM_010510 
Irf7 ON-TARGETplus SMARTpool L-041094-00-0005 NM_016850 
Nfkbia ON-TARGETplus SMARTpool L-044170-01-0005 NM_010907 
Non-Targeting ON-TARGETplus Non-targeting pool D-001810-10-05 
Table 5.4: Details of siRNA SMARTpool purchased to target murine genes.  
 
To transfect at a final concentration of 20 nM in a 6-well format the redissolved siRNA 
(10 μM) was diluted in nuclease free water to working concentration of 2 μM. For each 
treatment-well 10 μl of siRNA SMARTpool was combined with 90 μl of Optimem 
Reduced Serum Medium (Invitrogen, Paisley, UK) solution while 5 μl of Lipofectamine 
2000 (Invitrogen, Paisley, UK) was mixed with 95 μl Optimem. Following incubation for 
5 min, the siRNA mix was added to the L2K mix and incubated for a further 30 min, 
after which 800 μl of complete medium (+CSF-1) but lacking antibiotics was added to 
the siRNA:L2K complexes. The growth medium on the cells was removed and replaced 
with 1000 μl of the siRNA:L2K liposome medium. Cells were then incubated for a given 
period of time depending on the study (as denoted in the results section) at 37°C, 5% 
CO2. 
 
To transfect at a final concentration of 20 nM in a 24-well format the redissolved siRNA 
(10 μM) was diluted in nuclease free water to a working concentration 2 μM. For each 
treatment-well 5 μl of siRNA SMARTpool was combined with 45 μl of Optimem 
(Invitrogen, Paisley, UK) solution while 2.5 μl of Lipofectamine 2000 (L2K, Invitrogen, 
Paisley, UK) was mixed with 47.5 μl Optimem. Following incubation for 5 min, the 
siRNA mix was added to the L2K mix and incubated for a further 30 min, after which 
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400 μl of complete medium (+CSF-1) but lacking antibiotics was added to the 
siRNA:L2K complexes. The growth medium on the cells was removed and replaced 
with 500 μl of the siRNA:L2K liposome medium. Incubation conditions are as described 
above. Each biological sample was generated by pooling cells from three separate 
wells.  
 
For siRNA experiments performed at final concentrations other 20nM, the working 
concentration of the siRNA pools was adjusted and all other conditions remained the 
same. For example to treat at a final concentration of 50nM the redissolved siRNA (10 
μM) was diluted in nuclease free water to a working concentration 5 μM and the 
standard protocol followed as above.  
 
RNA extraction, quantification and quality control 
 
Procedures for RNA extraction, quantification, and QC are as described in Chapter-4 or 
Chapter-6 Methods. RNA integrity was screened across all (RNA-based) experiments 
described to ensure only high-quality RNA was used for QPCR and microarray 
procedures.  
 
mRNA analysis by genome wide Microarray profiling 
 
Full details of microarray processing are described in Chapter-6. The 32 RNA samples 
analysed in this Chapter were processed for hybridisation to Affymetrix Mouse Gene 
1.1. ST Arrays. These Arrays were obtained as part of a 96-Array plate format, which 
enables the simultaneous high-throughput profiling of 96 samples, using the same 
content as the individual Mouse Gene 1.1 ST cartridge arrays. The remaining 64 arrays 
on the 96-Array plate were used to process samples from experiments exploring other 
questions of interest to this thesis and are discussed accordingly in other Chapters (6).  
 
A network graph of the normalised data expression data was generated in BioLayout 
Express3D, by filtering for nodes with relationships across the arrays at a Pearson 
Correlation of 0.85 or above. This resulted in a graph of 12619 nodes, connected by 
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505590 edges. The graph was then clustered at an MCL inflation value of 2.2 and the 
expression profiles of the clusters were analysed to: (1) identify and remove un-
interesting clusters i.e. those representing technical artefacts or unchanged expression 
profiles, and (2) to identify clusters of interest i.e. those representing changes related 
treatment parameters. The filtered graph comprised 4674 nodes connected by 433761 
edges (Figure 5.25). 
 
mRNA analysis by QPCR 
 
Methodology for QPCR has been described previously [146, 313]. The following 
Taqman Primer probe sets (below) were purchased from Applied Biosystems, 
Warrington, UK.   
 



















Prior to proceeding with expression analysis, primers were tested on range of 
concentrations of murine BMDM RNA to determine PCR efficiency. Only an efficiency 
of 97% or > was accepted. An example, of primer efficiency test is shown below for the 
TaqMan primer designed for Gapdh detection.  
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Figure 5.29: Standard Curve for the Taqman Gapdh Primer-probe. Ct values for Gapdh were 
determined at six different concentrations of input RNA (200, 100, 50, 25, 12.5, and 6.25 ng), and each 
input RNA was tested in duplicate. The RSq value (between 0 and 1) is an indicator of the quality of the 
fit of the standard curve to the Standard data points plotted. The closer the value is to 1, the better the 
fit of the line. The slope of the curve is directly related to the average amplification efficiency 
throughout the cycling reaction. PCR Efficiency (calculated from the slope of the curve) corresponds to 
the proportion of template molecules that are doubled every cycle.  
 
 
Individual reactions (for each RNA sample against a given primer probe set) were 
performed in 20 µl volumes using MicroAmp Optical 96-well reaction plates and 
MicroAmp Optical Caps (Applied Biosystems). For each reaction 2 µl of RNA (≈100 ng 
total RNA) was added to 10 µl of 2× Brilliant® II QRT-PCR Master Mix, 1-Step (Agilent 
Technologies, Stockport, UK), 1 µl of a Taqman primer/probe set for the gene of 
interest at the recommended concentration, 6.9 µl of nuclease free double-distilled 
H20, and 0.1 RT Enzyme (Agilent Technologies, Stockport, UK). At least two technical 
















GAPDH, Y = -3.363*LOG(X) + 27.58, Eff. = 98.3%
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The reaction mixture were then incubated at the following conditions on the 
MXPRO3000P instrument (Stratagene, CA, USA): an initial step at 50°C for 30 min, 
followed by 95°C for 10 min after which the samples were then subject to 40 cycles 
under Taqman standard conditions of 95°C for 30 s and then a combined annealing 
and primer extension phase at 60°C for 1 min and a short denaturation at 72°C for 30 
s. Stratagene MXPro software (Stratagene, CA, USA) was then used to analyze the 
data. Threshold determinations were automatically performed by the instrument for 
each reaction. Gapdh was used as a loading control, for normalisation purposes. 
Nomalised CT values were exported into Microsoft Excel and relative quantification of 
marker gene mRNA expression was calculated with the comparative CT method. 
Standard error is calculated for technical PCR replicates.  
 
 




PCR primers of 20 bp in length with a 45-60 % GC content and TM of 57.3 – 61.4 °C 
were selected using Primer Designer (Scientific and Educational Software 3.0) to 
amplify products of 107-228 bp in length.  TM was calculated by the primer 
manufacturer (Eurofins MWG Operon) using the following formula: TM [°C] = 69.3 + 
[41(nG + nC) / s – (650 / s)], where n = number of nucleosides of type X and s = number 
of all nucleosides per sequence. Primers were pre-screened to determine the optimal 
conditions for specific cDNA amplification on cDNA derived from mouse macrophage 
RNA. They were tested using a range of PCR cycles (between 25 and 30) at 55oC 
annealing temperature under standard assay conditions (see below), to ensure only a 
single band of the predicted size was generated. If the latter was not achieved then 
primers were redesigned.   
 
 
Semi-Quantitative (Cresol Red and sucrose) RT-PCR  
 
First strand cDNA was generated from 5 µg of RNA using random hexamers as primers 
in a final reaction volume of 30 µl. cDNA synthesis was performed in the presence and 
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absence of superscript reverse transcriptase (Invitrogen, Paisley, UK) and RNA. PCR 
amplification of cDNA equivalent of 10 ng of total RNA was carried out in 20 μl 
reactions containing the cDNA in a 4 μl volume and; 1x Reaction/PCR buffer (3.5 mM 
MgCl2), 12.46% sucrose, 0.1 mM cresol red (Sigma, Gillingham, uk (#114480)), 12 mM 
beta-mercaptoethanol, 0.5 mM dNTPs (Invitrogen, Paisley UK (#10297018)), 0.6 U Taq 
DNA polymerase (Invitrogen, Paisley UK (#18038-026)), and primers were used at 100 
ng/reaction. The inclusion of cresol red and sucrose in the reaction mixture allows 
direct loading of the product onto an agarose gel without addition of loading buffer. 
Amplifications were carried out on DNA Engine Tetrad PTC-225 Peltier Thermal cycler 
(Tetrad, MJ Research, US). This process involved an initial 2 min denaturing step (92 
°C), after which each PCR cycle consisted of 30 sec denaturing (92 °C), 90 sec annealing 
(55 or 60 °C), and 60 sec elongation (72 °C). For each given primer pair-set an 
appropriate number of PCR cycles were chosen to allow termination of amplification in 
the linear phase of the PCR reaction. Otherwise all assays were conducted under 
identical conditions and only the number of cycles or annealing temperature varied. 
After the final PCR cycle, the reaction was held for 10 min at 72 °C. The PCR products 
were then separated on a 2.5% agarose gel, stained with SYBR safe DNA gel stain 
(Invitrogen, Paisley UK) in 1 X TBE and imaged on Syngene G:Box gel documentation 
system.  
 
The primer sequences and optimized number of PCR cycles for the genes analyzed by 
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107 55oC 27 
Irf5 For-GAGAAGAATGGCCTGATGTC 
Rev-GATGCTGTCTGCCGACCAAG 
125 55oC 25 
Tnf For-GGACAGTGACCTGGACTGTG 
Rev-GAGGCAACCTGACCACTCTC 
127 55oC Less than 25 
Il1b For-GAAAGCTCTCCACCTCAATG 
Rev-GTATTGCTTGGGATCCACAC 
193 55oC 25 
Mx2 For-CTGGATTGTGATTCAGGGAC 
Rev-GCTAAATGGTGGGCAAGAAG 
228 55oC 27 
Socs1 For-TGGTTGTAGCAGCTTGTGTC 
Rev-AATGAAGCCAGAGACCCTCC 
118 55oC Less than 25 
Oasl1 For-TGGCAGAAGGCTACAGATGG 
Rev-GCACGGTCACCTGGATATCG 




175 55oC Less than 25 
 
Table 5.5 Primer sequences used in semi-quantitative PCR analysis.  
 
 
siGlo uptake analysis by confocal microscopy 
 
Cell culture for the purpose of preparing slides for confocal imaging was performed as 
described in the cell culture section with the following exceptions: sterilized (in 70% 
EtOH), dry, round glass coverslips were placed into wells of 24-well tissue culture 
plates. On day 6 of macrophage differentiation, cells were harvested from the 10 cm 
square bacteriological plates and counted. 100 μL of cell suspension containing 50,000 
or 163,000 cells (as stated in the text of the results sections) was added directly onto 
each glass coverslip and after 20 minutes (to allow the cells to adhere to the glass 
slides) 400 μL of culture medium (containing CSF-1) was added to the wells.  
 
Transfection of fluorescent siRNA (siGLO) did not differ from the standard siRNA 
transfection protocol (See siRNA transfection). (siGLO siRNA is chemically labelled with 
a 6-FAM fluorophore, which is visible/ excited under the FITC channel). At appropriate 
times post siGLO-transfection (see results) the culture medium was removed from the 
glass slides of BMDM which were then fixed in 4% PFA for 5 min at room temperature 
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and rinsed with 0.5ml PBS (with 0.1%Triton X-100). The cells were then treated with a 
blocking solution containing 1% goat serum in PBS for 10 min. The glass coverslips 
were mounted using Vectorshield HardSet Mounting Medium with DAPI at 1.5 µg/ml 
(Vector Laboratories, Peterborough, UK) onto frost-free slides.  
 
Fluorescence images were captured on a Nikon EC-1 confocal scanning laser 
microscope (Nikon Instruments, Surrey, UK). 2-D optical sections were acquired using 
Nikon EZ-C1 software (Nikon Instruments, Surrey, UK) with sequential acquisition 
(Frame Channel Mode) to give separate image files for each channel with minimal 
spectral overlap. The following stains and laser/filter combinations were used: DAPI 
nuclear stain (excitation 405 nm, emission BandPass460/50nm), 6-FAM fluorophore 
(siGLO), excitation 488nm, emission BandPass530/30nm). 
 
Protein analysis by western blotting 
BMDMs were washed with PBS and resuspended in a whole cell lysis buffer (50 mM 
HEPES, pH 7.5, 1% Triton X-100, 50 mM NaCl containing protease inhibitors (Roche 
Complete #11 697 498 001), phosphatase inhibitor cocktails I and II( Sigma P2850 and 
P5726)) at appropriate times (see results) post treatment or siRNA transfection. Cell 
lysates were centrifuged at 13000 rpm for ~ 1 min (at 4 °C) and the supernatants 
collected. Protein concentrations were determined by Lowry assays using the the Bio-
Rad Dc Protein assay (Bio-Rad Laboratories) and the NanoDrop Spectrophotometer as 
per manufacturer’s instructions. Western Blot analysis was performed by loading 10 µg 
of each protein sample onto a lane of a 10% polyacrylamide gel with a 4% stacking gel 
and separating proteins by SDS-PAGE. The proteins were then transferred to 
nitrocellulose membranes, and stained with Amido Black (Sigma, Gillingham, UK) to 
confirm equal loading of protein. Blots were then incubated in 1X TBS-triton for an 
hour at room temperature with gentle agitation followed by incubation with the 
primary antibody (anti-Nfkb2 (Cell Signalling Technology #4882) at 1:1000; or anti-Irf5 
(Cell Signalling Technology #4950) at 1:100) in immunomedium (DMEM (Invitrogen, 
Paisley, UK)) overnight at 4 °C. The following day the membrane was washed three 
times for 10 min each in TBS-Triton, before being placed in secondary antibodies in 
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immunomedium (anti-rabbit HRP at 1:7000 (Sigma, Gillingham, UK) (A9169)), coupled 
to horse raddish peroxidase for 1-2 h at room temperature. Proteins were visualized 
using ECL reagents (Pierce, Rockford, IL) and Amersham Hyperfilm ECL (GE Healthcare) 
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Chapter 6. Analysis of the transcriptional networks of 
mouse bone marrow derived macrophages in response 








The primary objectives of the work described in this Chapter were to examine the 
transcriptional signatures arising in response to three stimuli known to activate or 
contribute towards the M1 polarisation of macrophages; IFN-γ, IFN-β, and LPS. 
Previous attempts in this thesis to compare the type-I and type-II interferon response 
were confounded by the fact the two treatments (IFN-γ, IFN-β) and microarray 
processing were performed on separate occasions. As described in Chapter-4, one of 
the key interests in comparing and contrasting the transcriptional response to type-I 
and type-II interferon lies in the fact that at the functional level these cytokines have 
evolved to complement each other in overlapping but non-redundant activities [241]. 
A recent clinically relevant example of this non-redundancy was demonstrated in 
monocytes and macrophages cultured from patients with complete IFN-γR deficiency 
[314]. These patients are prone to severe infections with even weakly virulent 
Mycobacteria and type-I interferon has been proposed as a treatment. However the 
authors demonstrated IFN-α was deficient at priming for certain LPS inducible 
cytokines (such as IL-23 and TNF), as well as killing of M. smegmatis [314]. Thus 
distinguishing what is common and unique in the transcriptional signatures of the two 
classes of interferons may aid the understanding of why one class of interferon cannot 
substitute for the lack of another in response to certain pathogens.  
 
As reflected in its original name, “macrophage activating factor”, one the key functions 
of IFN-γ is to sensitise macrophages to activation by pathogen challenge. Indeed the 
classical activation of macrophages arises from IFN-γ stimulation in combination with 
TLR ligation [44, 315]. The TLR4 agonist LPS, is arguably one of the best studied and 
most potent activators of macrophages [11, 316], and the priming of macrophages 
with IFN-γ is known to have a significant effect on the cells response to LPS (reviewed 
in [317]). IFN-γ and LPS signals synergise at a number of levels, from signal recognition 
to target gene regulation [317]. For example IFN-γ positively regulates TLR signalling 
components (including TLR2, TLR4, MYD88 and the CD14 co-receptor), thereby 
amplifying sensitivity to TLR signals [317]. In contrast LPS induces the SOCS (suppressor 
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of cytokine signalling) proteins, known to negatively regulate interferon-receptor 
activation [318]. Signals also converge at key transcription factors, such as LPS 
mediated phosphorylation of STAT1, a crucial cytosolic factor for IFN-γ-dependant 
gene regulation [317]. IFN-γ priming of RAW264.7 cells and monocytes have shown to 
potentiate NF-ĸB (NFKB1:RELA) activation in response to subsequent LPS stimulation 
[319].  
 
Also acknowledged in the literature is the extent of crosstalk and synergy between LPS 
and type-I interferon signalling. In macrophages, LPS stimulation induces the rapid 
transcription of IFN-β mRNA and protein secretion [275]. In turn IFN-β signalling forms 
a key portion of the LPS transcriptional response and LPS-induced lethality [276-277]. 
In Chapter-5 LPS-induced IFN-β production formed the basis of the assay design to 
study the role of selected genes of interest in type-I signalling. However these 
investigations underscored the need to better understand the overlap between the 
type-I and LPS response. For example, are all IFN-β regulated transcripts also regulated 
by LPS?  
 
The pathway construction efforts of Chapter-2 depicted the signalling pathways 
activated in response to these three stimuli (IFN-γ, IFN-β and LPS). A simplified 
schematic extracted from the larger integrated pathway (Figure 6.1) also illustrates the 
receptor activation and downstream signalling.  As discussed in previous Chapters, 
although type-I and type-II interferons are structurally distinct and bind to different 
receptors, the signalling pathways employed by the two cytokines are inter-related 
(Figure 6.1), and this is reflected in their overlapping target genes (Chapter-4). There is 
also overlap in the transcriptional targets of interferon and LPS signalling, given the 
induction of type-I interferon by LPS stimulation.  Recognition of LPS in mammalian 
cells involves a series of interactions with several proteins including the LBP (LPS 
binding protein), CD14, LY96 (MD-2) and TLR4 (reviewed in [320-321]) (Figure 6.1). 
TLR4 signal transduction is often divided into the MYD88 dependant and MYD88-
independant pathways. The latter pathway relies on TICAM1 an adaptor protein which 
plays a key role in the activation of the IRF3 transcription factor and subsequent type-I 
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interferon regulation. The MYD88 dependant pathway is the main protagonist in the 
activation of the MAPKinase and NF-ĸB signalling pathways which result in pro-
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Figure 6.1: Type-I interferon, Type-II interferon and LPS activation of their respective receptor 
complexes. Type-I (IFN-α/ IFN-β) and type-II interferon (IFN-γ) bind to their respective receptor 
complexes. Both signalling pathways share the transcription factor STAT1 and overlap I in the 
transcriptional response induced. TLR4 signalling is commonly divided into the MYD88-dependent and 
independent pathways; whereby the independent pathway leads to IRF3 activation subsequent 
regulation of IFN-β enhansesome, and the dependent pathway activates MAPKinase and NFκB signalling 
cascades. Type-I interferon, type-II interferon and LPS signalling overlap in their transcriptional targets, 
and are also expected to induce unique sets of genes.  
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Therefore based on the existing literature and the pathway models of these signalling 
systems it would be expected that IFN-β, IFN-γ and LPS overlap in their transcriptional 
profiles. However given there are also key differences in the downstream signalling, 
there are likely to be unique sets of genes induced in response to the three inputs. The 
transcriptional response to LPS might be expected to be broader ranging than that of 
interferon alone. This assumption is based on the fact that LPS stimulation of TLR4 will 
activate type-I interferon signalling (via the MYD88 independent pathway) as well 
additional signalling systems through via the MYD88-dependant pathway. Moreover, 
given this autocrine type-I signalling, one might predict that the transcriptional 
networks induced by LPS signalling, overlap to a greater extent with those induced by 
IFN-β signalling than those induced by IFN-γ. Unravelling the individual transcriptional 
responses to these cytokines may go some way to increasing our understanding of 
how they contribute to the activated (M1) macrophage phenotype and indeed what 
we understand by this label. Furthermore dissecting the transcriptional response 
would considerably improve the transcriptional coverage of the pathway models, 
where currently the regulation of only a handful of target genes is depicted. Recent 
searches of microarray data repositories (Array Express and GEO) show there are no 
data-sets submitted where all three stimuli are compared over a time-course series in 
primary mouse (bone marrow derived) macrophages. Furthermore, datasets where 
the transcriptional responses to at least two of three stimuli of interest are measured 
across multiple time-points in murine BMDMs are not available. The analysis described 
in this Chapter therefore represents a valuable insight into the transcriptional 
networks associated with factors known to contribute towards ‘classical’ activation of 
macrophages (IFN-β, IFN-γ, and LPS). The work presented will contribute in part to a 
more detailed, focused analysis for publication purposes. There are however several 










Analysis of the transcriptional response to IFN-β, IFN-γ or LPS in BMDMs  
In order to analyse the transcriptional changes induced by three different stimuli (IFN-
β, IFN-γ and LPS) in mouse BMDMs, transcriptional profiling using microarrays was 
performed over a series of time-points pre- and post-treatment. Cells were challenged 
with 10 U/ml IFN-β, or 10 U/ml IFN-γ, or 5 ng/ml LPS for 1, 2, 4, 8, and 24 h, or were 
harvested pre-treatment (0 h). Two biological samples were generated for each time-
point per treatment regime. A description of the samples for this analysis is provided in 
Table 6.1. High quality RNA was processed for labelling and hybridisation to Affymetrix 
Mouse Gene 1.1. ST Arrays, which were obtained as part of 96-array plate (see 
Methods). 
 
Sample No Stimulus Concentration Time-points (hours) 
1 & 2 None N/A 0h (pre-treatment/ experiment start) 
3 & 4 IFN-β 10 U/ml 1 h post IFN-β 
5 & 6 IFN-β 10 U/ml 2 h post IFN-β 
7 & 8 IFN-β 10 U/ml 4 h post IFN-β 
9 & 10 IFN-β 10 U/ml 8 h post IFN-β 
11 & 12 IFN-β 10 U/ml 24 h post IFN-β 
13 & 14 IFN-γ 10 U/ml 1 h post IFN-γ 
15 & 16 IFN-γ 10 U/ml 2 h post IFN-γ 
17 & 18 IFN-γ 10 U/ml 4 h post IFN-γ 
19 & 20 IFN-γ 10 U/ml 8 h post IFN-γ 
21 & 22 IFN-γ 10 U/ml 24 h post IFN-γ 
23 & 24 LPS 5 ng/ml 1 h post LPS 
25 & 26 LPS 5 ng/ml 2 h post LPS 
27 & 28 LPS 5 ng/ml 4 h post LPS 
29 & 30 LPS 5 ng/ml 8 h post LPS 
31 & 32 LPS 5 ng/ml 24 h post LPS 
 
Table 6.1: The treatment regimes of 32 BMDM samples generated for genome wide transcriptional 
analysis. Mouse BMDMs were treated with 10 U/ml IFN-β or, 10 U/ml IFN-γ or 5 ng/ml LPS, over a time-
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A network graph of the normalised data for the 32 samples was generated in 
BioLayout Express3D, by filtering for transcripts that shared a Pearson Correlation of 
0.85 or above. This resulted in a graph of 11,258 nodes, connected by 270,601 edges 
(not shown). The graph was then clustered at an MCL inflation value of 2.2, resulting in 
over 600 clusters with ≥3 nodes. 9,122 transcripts were represented within clusters. 
This initial network graph was then used to identify clusters representing cohorts of 
genes that did not exhibit a profile of expression that varied with treatment (such as 
those unchanging across all arrays or technical artefacts), and transcripts within these 
clusters were removed from the graph.  As might be expected many transcripts were 
relatively evenly expressed across all treatments, and after filtering only 3,747 
transcripts remained in clusters representing regulated genes.  
A further network graph of the transcriptional data pertaining only to the 3,747 
transcripts was generated, (again using a Pearson Correlation threshold of 0.85). Again 
two major graph components were identifiable; one representing up-regulated 
transcripts, the other down-regulate transcripts. The graph of 3,747 nodes connected 
by 172,688 edges was clustered at an MCL inflation value of 2.2 (Figure 6.2), resulting 
in over 70 clusters with ≥3 nodes. The clusters were then inspected for patterns of 
expression related to the three treatment regimes and annotated accordingly. The 
annotation of clusters was based on two predominant factors: 
(i) The directionality of the change; where Up or Down defines up or down 
regulation of expression of transcripts within the cluster.  
(ii) The specificity of the change with respect to a given treatment regime. 
Clusters annotated “Specific” represent transcripts which are only 
regulated in a given treatment. Whereas clusters annotated “Preferential” 
are regulated in all treatments, but to a greater extent in the denoted 
treatment regime. 
For example cluster-1 “Down Preferentially in LPS” indicates the transcripts within this 
cluster are down regulated in all treatments but more so in those cells treated with 
LPS.  On the other hand cluster-2 “Up Specifically in LPS” implies the induction of 
transcripts within this cluster is observed only in cells stimulated with LPS.  A handful 
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of clusters represented changes occurring in all three treatments to a similar extent 
and these are annotated “Up/Down Similar in All Treatments”.  




Figure 6.2: Network graph of transcriptional changes occurring in mouse BMDMs in response to IFN-β, IFN-γ or LPS challenge. The network graph of transcriptional 
data pertaining to the treatment of BMDMs with IFN-β, IFN-γ or LPS over a time-course comprising 3,747 nodes (transcripts), connected by 172,688 edges at a Pearson 
correlation of 0.85 or above. The graph clustered at an MCL inflation value of 2.2 comprises over 70 clusters with ≥3 nodes. Nodes (transcripts) within the same cluster 
share the same colour. The upper component of the graph represents transcripts up-regulated in response to treatment, whereas the lower component represents 
transcripts down-regulated in response to treatment.  
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To further appreciate the structure of the transcriptional network generated (in Figure 
6.2) in response to the three treatments, a collapsed-cluster network graph was 
generated; whereby the nodes making up this graph represent the different clusters 
and the edges denote the relationships between the clusters. The size of the nodes 
shown in the graph is proportional to the cluster membership i.e. number of 
transcripts. The collapsed-cluster graph was arranged in 2-dimentions to reflect the 3-
dimentional (un-collapsed) network graph (Figure 6.3). The graph illustrates that only a 
few clusters represent transcriptional networks that are activated specifically in 
response to a given treatment. The majority of clusters represented transcriptional 
changes occurring preferentially in one treatment over the others. Furthermore the 
expression of most transcripts was preferentially altered in response to LPS treatment.  
 
As in previous Chapters the clusters generated from this analysis were annotated 
based on their gene membership and over-representation of cohorts of functionally 
associated genes using the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) [248-249]. The most over-represented terms (based on DAVID 
analysis of GO Ontology terms (GO FAT category)) were chosen to describe the biology 
of the clusters. Tables 6.2(a-e) provide an overview of all clusters (with ≥ 10 nodes); 
this includes the number of transcripts within each cluster, examples of gene members 
and the associated GO terms. The expression profiles of selected clusters of interest 
are also shown in Figures 6.4(a-d). The cluster profiles are sorted according to 
treatment centric changes (e.g. changing specifically/ preferentially in LPS/ IFN-β/ IFN-
γ), and the maximal/ minimal time of gene induction or repression, respectively.  
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Figure 6.3: Collapsed cluster relationship network of the transcriptional changes occurring in mouse 
BMDMs in response to IFN-β, IFN-γ or LPS challenge based on the transcriptional network shown in 
Figure 6.2.  Nodes represent individual clusters and are sized proportionally to their transcript 
membership and are coloured according to the treatment specific pattern of expression they represent. 
Edges denote relationships between clusters.  
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LPS Centric Clusters –Average Expression Profile 
 
 
Figure 6.4: (a) Average expression profiles across clusters associated with preferential or specific 
changes in LPS treated mouse BMDMs. Mean expression profiles for each sample (array) are calculated 
from the expression levels of all transcripts within the given clusters. Expression levels are plotted across 
the different time-points sampled and the three different treatment regimes (IFN-β, IFN-γ and LPS). GO 
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LPS Centric Clusters –Average Expression Profile 
 
 
Figure 6.4: ((a) continued from previous page) Average expression profiles across clusters associated 
with preferential or specific changes in LPS treated mouse BMDMs. Mean expression profiles for each 
sample (array) are calculated from the expression levels of all transcripts within the given clusters. 
Expression levels are plotted across the different time-points sampled and the three different treatment 
regimes (IFN-β, IFN-γ and LPS). GO terms associated with genes in each cluster are shown to the right of 
each plot.  
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IFN-β Centric Clusters –Average Expression Profile 
 
Figure 6.4: (b) Average expression profiles across clusters associated with preferential or specific 
changes in IFN-β treated mouse BMDMs. Mean expression profiles for each sample (array) are 
calculated from the expression levels of all transcripts within the given clusters. Expression levels are 
plotted across the different time-points sampled and the three different treatment regimes (IFN-β, IFN-γ 
and LPS). GO terms associated with genes in each cluster are shown to the right of each plot.  
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IFN-γ Centric Clusters –Average Expression Profile 
 
Figure 6.4: (c) Average expression profiles across clusters associated with preferential or specific 
changes in IFN-γ treated mouse BMDMs. Mean expression profiles for each sample (array) are 
calculated from the expression levels of all transcripts within the given clusters. Expression levels are 
plotted across the different time-points sampled and the three different treatment regimes (IFN-β, IFN-γ 
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Other Clusters –Average Expression Profile 
 
 
Figure 6.4: (d) Average expression profile across clusters associated with changes across all three 
treatments studied in mouse BMDMs. Mean expression profiles for each sample (array) are calculated 
from the expression levels of all transcripts within the given clusters. Expression levels are plotted across 
the different time-points sampled and the three different treatment regimes (IFN-β, IFN-γ and LPS). GO 
terms associated with genes in each cluster are shown to the right of each plot.  
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1 886 Down Preferentially in LPS  
Bub1, Bub1b, Cdk1, Cdc20, 
Cdc25b, Cdc7, Cenpe, Cenpf, 
Chek1, Ccna2, Ccnb2, Ccnf, 
Mcm2,  
Cell Cycle, M Phase, M Phase of Mitotic Cell Cycle, 
Mitosis, Nuclear Division 
6 157 Down Preferentially in LPS  
Agfg2, Agap2, Rasa3, Dock2, 
Dgkz 
Regulation of Small GTPase mediated Signal 
Transduction, Regulation of Ras Protein Signal 
Transduction 
8 122 Down Preferentially in LPS  
Cdt1, Sigirr, E2f2, Cdc6, Cdt1, 
Ccne1, Cdk2,  
 -ve Regulation of Macromoecule Metabolic Process, -
ve Regulation of Cellular Biosynthetic Process, Cell 
Cycle, -ve Regulation of Gene Expression 
15 35 Down Preferentially in LPS  
Decr1, Nqo2, Aldh9a1, Dhrs7, 
Gpd1l 
Oxidation Reduction 
19 27 Down Preferentially in LPS  Adcy3, Nme3, Padi2,  
Nitrogen Compound Biosynthetic Process, Purine 
Nucleotide Biosynthetic Process 
23 22 Down Preferentially in LPS  Nfam1, Card9, Eif2ak3,  
 +ve Regulation of Binding, +ve Regulation of Signal 
Transduction 
25 19 Down Preferentially in LPS > IFN-γ > IFN-β  
Atp2a3, Cacna1d, Slc24a3, 
L1cam 
Calcium Ion Transport, Cell Adhesion 
26 18 Down Preferentially in LPS  Kdm1b, Dhrs7b, Spr Oxidation Reduction 
30 15 Down Preferentially in LPS  Plau, Rassf2  --Unavailable-- 
31 13 Down Preferentially in LPS & IFN-β  Sf1, Hnrnpa1, Ckap2l RNA Splicing, mRNA Processing 
Table 6.2: (a) Description of clusters associated with down-regulated transcriptional changes occurring preferentially/ specifically in LPS treatment. 
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2 454 Up Specifically in LPS  
Ccl5, Cxcl5, Aox1, Nos2, Prdx5, 
Cd38, Cd5, Tlr1 
Response to Wounding, Immune Response, Inflammatory 
Response, Oxidation Reduction, +ve Regulation of 
Immune System Process, Macrophage Activation 
3 380 Up Preferentially in LPS  
Il1b, Il6, Il18, Il12a/b, Nod2, 
Tlr6, Ccl17, Ccl22, Cxcl16, 
Cxcl3, Traf1/2/5, Casp7 
Regulation of: Phosphorylation, Phosphate/Phosphorus 
Metabolic Process, Lymphocyte Activation, T Cell 
Activation, Leukocyte Activation, Cytokine Activity, Cell 
activation, Apoptosis, Mononuclear Cell Proliferation 
5 168 Up Early Preferentially/ Specifically in LPS  
Bcl3, Bcl10, Rel, Tnf, Rela, Tlr2, 
Ifnar1, Ccl9, Cxcl1, Cxcl2, Csf1, 
Relb, Nfkbie, Icam1, Cflar,  
Regulation of Cytokine Production, Immune Response, 
+ve Regulation of Multicellular Organismal Process, 
Regulation of Transcription, +ve Regulation of Cytokine 
Biosynthesis, Adaptive Immune Response, Regulation of 
apoptosis 
9 92 Up Early Specifically in LPS  
Dusp1, Dusp4, Dusp5, Dusp8, 
Dusp14, Egr1, Eg2, Fosl1, Irf4 
Dephosphorylation, +ve Regulation of transcription,  
11 66 Up Preferentially/ Specifically in LPS  
Atp2b4, Slc22a21, Slc22a5, 
Slc39a14, Stat5, Tnfsf15 
(Cation) Transport, Intracellular Signalling Cascade 
17 28 Up Preferentially in LPS  C2, Irf7, Bst2 
Immune Response, Immunoglobulin Mediated Imme 
Response, B Cell/ Lymphocyte Mediated Immunity 
21 24 Up Preferentially in LPS > IFN-β > IFN-γ  Il15, Casp4, Zfp800  --Unavailable-- 
24 20 Up Late Preferentially in LPS  Ddit3, Derl1, Alkbh2, Aifm2 
Cellular Response to Stress, Cellular Response to 
Unfolded Protein, +ve Regulation of Apoptosis 
35 11 Up Preferentially in LPS  Phldb1, Plscr1  --Unavailable-- 
Table 6.2: (b) Description of clusters associated with up-regulated transcriptional changes occurring preferentially/ specifically in LPS treatment.
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37 11 Down & Up Preferentially in IFN-β  Gba2, Gpr162, Map3k12  --Unavailable-- 
7 123 Up Preferentially in IFN-β > LPS  
Daxx, TCf4, Zfp213, Socs7, 
Usp12, Acvr1, Dll1, Foxf1a, 
Nr3c1 
Regulation of Transcription, Macromolecule Catabolic 
Process, Determination of Left/Right Symmetry, 
Chromatin Modification 
10 70 Up Preferentially/ Specifically in IFN-β  Il10, Casp2, Tnfsf8,   --Unavailable-- 
27 18 Up Preferentially in  IFN-β > IFN-γ > LPS  Fcgr1, Masp1, Treml2 
Acute Inflammatory Response, Innate Immune 
Response 
29 16 Up Preferentially in IFN-β  Abcb1a, Prnp Response to Metal Ion 
36 11 Up Late Preferentially/ Specifically in IFN-β  Cd4, Cdkn1c, Slc5a3, Spry3 
Protein Amino Acid N-linked Glycosylation, Sodium 
Ion Binding 
39 11 Up Preferentially in IFN-β  Pou3f1, Dennd1b  --Unavailable-- 
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13 53 Up Preferentially in IFN-γ > IFN-β > LPS   Cxcl9, Gbp4, IIgp1 
GTP Binding, Immune Response, Response to Cytokine 
Stimulus 
14 45 Up Preferentially/ Specifically in IFN-γ   
Il2rb1, H2-Dma, H2-Eb1, 
Ly6a, Ciita, C4b 
Immune/Adaptive Immune Response, Immunoglobulin 
Mediated Immune Response, Lymphocyte Mediated 
Immunity, Complement Activation 
32 13 Up Preferentially in IFN-γ   Gm2a, Pafah1b3, Scn3b Lipid Catabolic Process 
34 12 Up Preferentially in IFN-γ > LPS (not IFN-β)   Cd74, H2-Aa, H2-Ab1, H2-Ea 
Immune Response, Antigen Processing & Presentation 
of Peptide Antigen via MHC class II 
40 11 Up Preferentially in IFN-γ   Ccr1, Adora3, Sbno2, Gpr146 Myeloid Cell Activation During Immune Response 
44 10 Up Preferentially in IFN-γ   Selp, Traf3ip2, Ppard  +ve Regulation of Protein Kinase Cascade 



















































































18 27 Down Preferentially in IFN-γ & LPS  Cd9, Fn1, Clstn1, Itgax 
Cell Adhesion, Biological Adhesion, Cell Junction 
Assembly 
33 13 Down in all treatments  Ipo11, Psmg2, Chst11 Protein Complex Assembly 
41 10 Down & Up in IFN-β_Down in IFN-γ & LPS  Vash2, Gab3  --Unavailable-- 
4 335 Up Preferentially LPS-&-IFN-β > IFN-γ  
Oas2, Casp3, Pmepa1, Psma4, 
Usp18, Usp25, Ifih1, Tlr3, Tlr8, 
Usp18, Uba7, Ube2l6 
Cellular Macromolecule Catabolic Process, Response 
to Virus, ISG15-protein conjugation, Immune 
Response 
12 57 Up Similar in all treatments  
Gbp9, Gnb4, Gbp2, Gbp6, 
Irgm2, Gbp1, Irf5, Stat3 GTPase Activity, Immune Response, Transcription 
16 32 Up Similar in all treatments  Psme1, Psmb8, Tap2 
Antigen Processing & Presentation, Transmembrane 
Transport 
28 17 Up Similar in all treatments  Atxn7l3, Kdm2a, Mll5, Msl1 Chromatin Modification/Organisation 
43 10 Up Late Similar in all treatments  Tapbp, H2-T23, H2-T24 Antigen Processing & Presentation 
Table 6.2: (e) Description of clusters associated with transcriptional changes in response to any of IFN-β, IFN-γ or LPS. 
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To better visualise the overlap and distinction in the transcriptional response to IFN-β, 
IFN-γ, and LPS, network diagrams displaying the targets of each treatment (as 
determined in this analysis) were generated. Separate networks were generated for 
the up and down regulated gene targets. Connections (edges) were defined between 
the treatment-type (IFN-β, IFN-γ, and LPS) and the genes regulated in response to a 
given treatment. Therefore if a particular gene was regulated in response to all three 
treatments there would be thee input edges into that gene. Connections from 
treatment-type to genes were captured regardless of the extent of transcriptional 
induction/ repression, i.e. genes preferentially induced/repressed in LPS and also 
induced/repressed in response to IFN-β and IFN-γ (but to a lesser extent) are 
connected to all three treatment-types. 
 
The up-regulated response comprised transcriptional targets common to all three 
treatments (948 transcripts), targets shared between two treatments only (IFN-γ and 
IFN-β: 33, IFN-γ and LPS: 11, LPS and IFN-β: 111 transcripts), and genes unique to the 
individual treatments (IFN-γ: 50, IFN-β: 115, and LPS: 727 transcripts). In contrast to 
the inducible response all the down-regulated targets within clusters were common to 









Figure 6.5: Overlap in the up and down regulated transcriptional targets of IFN-β, IFN-γ, and LPS. (a) Overlap and divergences in the transcriptional networks induced 
by IFN-β, IFN-γ and LPS in mouse BMDMs. (b) Overlap in the transcriptional networks repressed by IFN-β, IFN-γ and LPS in mouse BMDMs. 




This final results Chapter presents a high-level analysis of the macrophage response to 
three stimuli which are considered to prime cells towards what is often described as an 
M1 phenotype [44]. IFN-β, IFN-γ and LPS activated signalling pathways converge at a 
number of levels and elicit an anti-microbial response by regulating the expression of 
hundreds of genes. “Classical” activation of macrophages is considered to be attained 
by IFN-γ exposure in concert with a microbial stimulus such as LPS. Arguably LPS is by 
far the most extensively studied microbial activator of macrophage signalling and 
transcriptional cascades. LPS stimulation of macrophages induces the expression a 
number of cytokines including IFN-β which then act in an autocrine manner to 
contribute to the LPS transcriptional response [276-277]. As discussed in previous 
Chapters (1 & 4) the type-I interferon, IFN-β, and the type-II interferon, IFN-γ are 
structurally unrelated and bind to different receptors however they do share 
downstream signalling machinery and overlap in their transcriptional response. The 
variance in the type-I and type-II transcriptional signatures are potentially fundamental 
in the non-redundant activities of these cytokines; i.e. where one interferon cannot 
substitute for the lack of another as demonstrated in both experimental and clinical 
states of infection [241-242, 314].   
Despite the acknowledged signal convergence of these three stimuli and their 
interrelated activation of the macrophage transcriptome, high-quality detailed 
transcriptional datasets comparing and contrasting the actions of IFN-β, IFN-γ and LPS 
are not currently available. In an attempt to begin to understand and identify the 
common and distinct patterns of gene expression the analyses of this chapter have 
attempted to delineate the transcriptional events in response to each of the three 
stimuli of interest in mouse BMDMs. It is acknowledged that the individual reposes to 
these stimuli have been studied in great deal in their own right [97, 238, 243-244, 246-
247, 302, 309, 322-326]. Thus this analysis did not attempt to describe all 
characteristics of the macrophage response to endotoxin or to interferons. Instead the 
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focus was on identifying patterns of expression unique and overlapping in the three 
treatments.  
Overall Transcriptional Network Structure in BMDMs Following IFN-β, 
IFN-γ, or LPS Stimulation 
For this analysis primary mouse BMDMs were treated with 10 U/ml IFN-β or, 10 U/ml 
IFN-γ or, 5 ng/ml LPS over a time-course. The time-points analysed in this study (0, 1, 2, 
4, 8 and 24 h) had been effective at distinguishing temporal classes of inducible and 
repressible genes in the previous analysis Chapter-4.  
A filtered network graph of transcripts regulated in this data-set comprised 3,747 
nodes connected by 172,688 edges. As with the time-course study of Chapter-4 the 
network graph had two main components; one comprising up-regulated transcripts 
and the other down regulated transcripts. The up-regulated graph component had two 
predominant sections; changes which were preferential/specific to LPS treatment and 
changes which were preferential/specific to other treatments. Whilst the up-regulated 
response comprised a number of clusters representing changes specific to given 
treatments (e.g. cluster-2, cluster-4, and cluster-9), no such clusters existed in the 
down regulated response. Therefore all the down-regulated targets in this analysis 
were common to all three treatments (Figure 6.5). However 1,313 of the 1,423 down-
regulated transcripts were repressed to a greater extent in LPS treatment, compared 
to the interferon treatments.  
Similar to the down-regulated response, the inducible transcriptional response was 
much broader and potent (in terms of fold-change induction) in LPS treated 
macrophages compared to those treated with either IFN-β or IFN-γ. 727 transcripts 
belonged to clusters which were specific to changes in LPS treatment (e.g. cluster-2 
and cluster-9) or highly specific to LPS treatment (those annotated 
“Preferential/Specific”). It was hypothesised that LPS would induce a broader 
transcriptional response since TLR-4 activation stimulates a number of downstream 
pathways in addition to autocrine IFN-β signalling. Indeed, this was the observed 
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outcome and many of the LPS-specific genes were related to signalling pathways 
activated directly downstream of TLR-4 ligation (i.e. MAPKinase signalling and NF-ĸB). 
948 transcripts overlapped between all three treatments however 50% of these 
transcripts were preferentially induced by LPS stimulation. Amongst the overlap 
specific to two treatments, LPS and IFN-β had more (inducible) transcripts in common 
(111) than LPS and IFN-γ (11 transcripts).  Both IFN-γ and IFN-β induced small subsets 
of transcripts unique to each treatment (50 and 115 respectively) and not overlapping 
with LPS. Therefore as predicted each treatment type (IFN-β, IFN-γ and LPS) induced 
unique sets of genes, which might be attributed to the differences in the signalling 
pathways employed by these stimuli. However, a large number of the transcriptional 
targets of these three stimuli were overlapping, suggesting a non-specific general 
macrophage response to interferon and LPS. Discussed herein are some of the key 
observations in the differential and overlapping transcriptional response to IFN-β, IFN-
γ or LPS in mouse BMDMs.  
 
LPS Specific and Centric Transcriptional Changes 
The most distinguishable “early” induced set of transcripts belonged to cluster-9- 
representing changes occurring specifically in LPS treated macrophages (Figure 6.4a). 
The 92 transcripts within this cluster were induced transiently from 1 hour post-LPS 
treatment. Amongst the genes represented within this cluster, there were five dual 
specificity phosphatases (Dusp1, Dusp4, Dusp5, Dusp8, and Dusp14), regulators of the 
NF-ĸB system (Nfkbia, Nfkbid, and Nfkbiz), a number of transcripts representing 
microRNA’s (Mir17, Mir18, Mir19a, Mir19b-1, Mir221, Mir222, and Mir92-1), and the 
interferon regulatory factor Irf4. The changes observed in this cluster are fitting with 
the literature and highly indicative of negative feedback control of the TLR-4 activated 
pathways. For example IRF4 has been demonstrated as negative regulator of TLR 
signalling and proinflammatory cytokine production [290, 327]. Moreover IRF4-/- mice 
display increased sensitivity to LPS-induced shock and exaggerated TNF-α and IL-6 
production [290].  
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As established in the literature and the pathway diagrams (Chapter-2), the MAPKinase 
signal transduction pathways acts downstream of TLR-4 receptor activation and this 
signalling cascade is involved in cytokine production. Many DUSP proteins (often 
referred to as MAPKinase phosphatases), are responsible for dephosphorylating 
threonine and tyrosine residues on MAPKkinase proteins and in doing so control the 
duration and intensity of MAPKinase signalling [328]. For example DUSP-1 has been 
shown to be a key negative regulator of the inflammatory response by regulating the 
p38 and JNK (Jun N-terminal protein kinase) MAPKinase pathways and thereby pro- 
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Figure 6.6: Extract from the integrated pathway diagram illustrating the action of the MAPKinase 
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NF-ĸB-signalling is also activated in response to TLR4 receptor engagement and 
evidence of negative regulation of NF-ĸB was also observed in cluster-9. Both NFKBIA 
and NFKBIZ are represented on the pathway maps as inhibitors of the NFKB1:RELA 
(p50:p65) complex.  NFKBID currently not represented on the macrophage pathway 
model (Chapter-2), has not been studied as extensively as the other NF-ĸB inhibitor 
proteins. However there is some evidence to suggest a role for NFKBID as a negative 
regulator of a subset of TLR-dependant genes through inhibition of the NFKB1:RELA 
(p50:p65) transcription factor [333]. Interestingly, NFKBIA was a gene of interest in the 
siRNA screens of Chapter-5. It was expected that knock-down of the murine Nfkbia 
gene might perturb transcriptional networks associated with type-I signalling and the 
type-I component of the LPS response. This was not the case however, and one 
explanation could be that the transcriptional networks associated with LPS signalling 
compensated for the lack of Nfkbia expression. As the data here demonstrates the 
magnitude of change in expression of most of the regulated transcripts is far higher in 
LPS treated cells compared to IFN(-β or –γ) treated.  
Seven microRNAs were also induced early (from 1 h) in response to LPS stimulation. 
microRNAs have a well established role in viral infections [334-335] and have now also 
been suggested as belonging to the first line of anti-bacterial defence. A number of 
microRNAs have been shown to mediate the LPS response in both RAW264.7 and 
primary murine macrophages [336-338].  The microRNAs within this cluster-9 are 
potentially interesting candidates for further investigation into their functional role in 
the macrophage response to LPS. One plausible prediction, based on function of other 
genes within this cluster could be that these microRNAs are involved in the (negative) 
regulation of signalling pathways downstream of TLR-receptor activation. 
The gene content of cluster-5 was comparable to some extent with that of cluster-9 
(Figure 6.4a). Cluster-5 also contained inhibitors of NF-ĸB signalling, (Nfkbib, Nfkbie), a 
number of transcripts encoding microRNAs (Mir146, Mir155, Mir191, Mir425) and 
cytokines (Ccl9, Cxcl1, Cxcl2, and Tnf).  However in contrast to cluster-9 where genes 
were transiently expressed, cluster-5 represented transcripts whose expression was 
sustained from 1 h to 8 h. Differences in the degradation rate of mRNA has been 
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proposed to determine some of the temporal changes in RNA levels in mammalian 
cells [339-342]. In LPS treated dendritic cells changes in transcription rates are shown 
to determine the majority of temporal changes in RNA levels, however it is changes in 
degradation rates that tend to shape sharp ‘peaked’ responses [342]. It is therefore 
possible that higher mRNA degradation rates are a feature of genes in clusters 
representing (very) transient expression (e.g. cluster-9). Many of the cluster-5 
transcripts were also induced by IFN-β/γ (4-8 h) although not to the same magnitude 
as LPS. Whilst cluster-9 was highly indicative of (the negative) regulation of TLR4 
activated pathways, cluster-5 comprised factors required to execute these pathways; 
For example members of the NF-ĸB transcription factor family: Bcl3, Rel, Rela, Relb, 
and type-I interferon signalling (Ifnb1 and the type-I receptor component Ifnar1).  
Other genes of interest in this cluster included the major macrophage growth and 
differentiation factor Csf-1 and eight transcripts encoding zinc finger proteins. LPS is 
known to induce CSF-1 in macrophages [309, 343], and a number of zinc finger 
proteins have been found to regulate pro-inflammatory activation in macrophages 
[344-346].  
Cluster-3 comprised 380 transcripts up-regulated preferentially in LPS treated 
macrophages compared to IFN-β or IFN-γ treated macrophages (Figure 6.4a). Maximal 
expression of cluster-3 transcripts was reached at 8 h post-treatment. GO annotation 
analysis of these transcripts revealed an over-representation of terms associated with 
regulation of phosphorylation, lymphocyte activation, and cytokine activity. Indeed, the 
gene content of this cluster was highly representative of an anti-microbial response 
which included chemokines (Ccl17, Ccl22, Ccl24, Cxcl1, Cxcl16, Cxcl3), interleukins 
(Il12a, Il12b, Il17rd, Il18, Il1a, Il12, Il6) and interleukin receptor subunits (Il17rd, Il20rb, 
Il2ra). Also within this cluster were genes encoding other NF-ĸB family members 
(Nfkb1, Nfkb2) and three MAPKinase signalling components Map3k10, Mapkapk2 and 
Mapkbp1. Mapkapk2 (MK2), as represented on the pathway diagram is 
phosphorylated by MAPK14 and is suggested to play a role in the regulation of mRNA 
stability and pathogen phagocytosis [347] (Figure 6.7).  
 




Figure 6.7: Extract from the integrated pathway diagram depicting the action of MAPKAPK2 protein. 
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Cluster-2 (454 transcripts) represented transcriptional changes occurring specifically in 
LPS treatment, reaching maximal expression at 24 h post-treatment. GO annotation for 
this cluster was enriched for terms such as “positive regulation of immune system 
process” and “macrophage activation”. Concurrent with this annotation was the 
presence of the Nos2 (nitric oxide synthase) gene, one of the most characteristic 
inducible markers of (M1) (mouse) macrophage activation [48, 348]. The chemokine 
Ccl5, and chemokine receptor Ccr7, (present within cluster-2) have been reported as 
being expressed in M1-polarised macrophages [46]. Also present within this cluster 
were 15 solute carrier family member transcripts and the janus kinases Jak1 and Jak2. 
The latter two genes are required for type-I and type-II interferon receptor signal 
transduction. The solute carrier family proteins are predominantly involved in the 
transport of divalent cations and small organic molecules. They have been associated 
with immune and inflammatory disease susceptibility [349-350] although a specific 
role in macrophage activation has yet to be elucidated. Others have found classically 
activated macrophages are characterised by increased expression of certain solute 
carrier family members; namely SLC21A15 and SLC31A2 [50] the latter of which was 
present in cluster-2. This cluster therefore presents a number of other solute carriers 
that are potential markers of macrophage activation by LPS.  
 
Overlapping Transcriptional Changes 
Universal to all three treatments was the repression of genes associated with cell cycle 
(cluster-1). These genes were repressed to a greater extent in LPS treatment compared 
to cells treated with IFN-β or IFN-γ (Figure 6.4a). Specific categories of genes included 
those associated with cell-cycle progression (e.g. Cdc20, Cdc25b, Cdc25c, Cdc45, Cdc7), 
cyclins (e.g. Ccna2, Ccnb1, Ccnb2, Ccne2), centromere proteins (Cenpa, Cenpe, Cenpf, 
Cenph, Cenpi), DNA polymerase subunits (e.g. Pola1, Pold1, Pold2, Pole, Pole2) and 49 
transcripts encoding histones. Histones constitute half the mass of chromatin, and play 
a crucial role in DNA packaging, efficient replication and segregation of chromosomes 
[351].  
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Cell cycle arrest by LPS has also been linked with the down-modulation of the CSF-1 
receptor and some genes are induced as a consequence of the ablation of CSF1R 
signalling [352]. The gene encoding this receptor (CSF-1R) was not present within 
clusters in these analyses; however its expression profile revealed it was repressed 
specifically in LPS treatment and not in response to IFN-β or IFN-γ (Figure 6.8). This 
might suggest CSF-1R repression is a cell cycle arrest mechanism employed in response 
to LPS stimulation, but is independent of the anti-mitotic action of IFN-β. This data may 
also indicate there is possibly a (small) subset of genes repressed in LPS treatment but 
not by IFN-γ or IFN-β, however such genes have not met the Pearson filtering 
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Figure 6.8: Csf1r expression in mouse BMDMs following treatment with any of IFN-β, IFN-γ, or LPS 
over 24 hours. Expression of the transcript encoding the Csf1r protein, plotted across three treatment 
regimes from samples representing pre-treatment (0 h) to specific time-points post treatment (1,2,4,8, 
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Transcripts within cluster-12 and cluster-16 were expressed to a similar extent in all 
three treatments (Figure 6.4d). The clusters differed marginally in the temporal 
patterns of their average expression profiles. Present within these clusters were the 
transcription factors Stat1, Stat3 and Irf5. Irf5 was a gene of interest in the siRNA 
screens of Chapter-5 and was pursued based on group findings that its siRNA induced 
repression perturbed transcriptional signatures associated with IFN-β signalling [146]. 
Recently high Irf5 expression has been suggested as being characteristic of M1 
macrophages, which encourage a T helper type 1 (TH1)-TH17 response [353]. The 
authors of the study demonstrated Irf5 was induced in the presence of GM-CSF [353]. 
This dataset shows Irf5 mRNA can also be induced by IFN-γ, IFN-β and LPS, further 
supporting its role in contributing towards an M1-type macrophage. Stat1 which is 
known to be required for executing both type-I and type-II interferon signalling as well 
as LPS induced gene expression [354] was induced to an almost identical magnitude 
and duration in each treatment (Figure 6.9). GO annotation analysis of cluster 16, 
indicated an over-representation of terms associated with antigen processing and 
presentation and included genes encoding proteasome subunits (Psme1, Psmb8, 
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Figure 6.9: Stat1 expression in mouse BMDMs following treatment with any of IFN-β, IFN-γ, or LPS 
over 24 hours. Expression of the transcript encoding the Stat1 protein, plotted across three treatment 
regimes from samples representing pre-treatment (0 h) to specific time-points post treatment (1,2,4,8, 
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Cluster-4 comprised 335 transcripts whose expression was preferentially induced in 
IFN-β and LPS treatment to a greater extent than IFN-γ treated cells (Figure 6.4d). The 
gene content of this cluster was highly characteristic of a ‘classical’ type-I interferon 
response and included a number of interferon inducible proteins (Ifi202b, Ifi204, 
Ifi205, Ifih1, Ifi35, Ifi44, Ifit2, Ifit3), oligoadenylate synthetases (Oas1a, Oas1b, Oas1g, 
Oas2, Oasl1, Oasl2), the GTPase Mx1 and the viral-RNA detecting endosomal toll-like-
receptors, Tlr3 and Tlr8. Based on the expression profiles and gene content, it is 
tenable that other genes in cluster-4 are regulated via type-I interferon signalling; this 
included 40 as of yet functionally un-annotated RIKEN cDNA transcripts. Cluster-7 was 
related to cluster-4 in terms of its expression pattern. Cluster-7 transcripts were 
preferentially expressed in IFN-β treatment, followed by LPS-treatment and to a lesser 
extent IFN-γ treatment (Figure 6.4b). The 123 cluster-7 members included the 
intracellular pattern recognition receptors; Nod1 and Aim2 and the interferon 
inducible Ifit1, and Mx2. Nod1 is a member of family of intracellular proteins that 
mediate host recognition of bacterial peptidoglycan [355-357], and AIM2 is sensor of 
cytoplasmic double stranded DNA (dsDNA) [358]. Thus the gene content of cluster-7 
would suggest a priming of the intracellular pathogen detection systems by IFN-β. 
As expected the response to IFN-β and LPS was more overlapping than that of LPS and 
IFN-γ.  There were however a handful of transcripts (in cluster-34) expressed 
specifically in IFN-γ or LPS treatment but not IFN-β treatment.  The most convincing of 
these LPS/IFN-γ specific genes were MHC Class II antigens (Cd74, H2-Aa, H2-Ab1, H2-
Ea) or related proteins (Ctsh (cathepsin H) which encodes a lysosomal cysteine 
proteinase required for degradation of lysosomal proteins). In macrophages MHC Class 
II expression is only efficiently induced by IFN-γ, whereas in other cells (such as B-cells) 
its expression is constitutive.  Others have demonstrated LPS increases the expression 
of MHC II molecules in dendritic cells and B cells [359-360] and this is brought about by 
enhancing MHC Class II transcription independently of CIITA [361]. In macrophages LPS 
may enhance or inhibit IFN-γ induced MHC class II depending on the sequence of 
treatment; simultaneous IFN-γ and LPS treatment is inhibitory, whereas LPS added 
after IFN-γ augments class II expression [362]. This data-set presents a number of MHC 
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class II candidates induced (at the message level at least) by LPS in mouse BMDMs 
independently of IFN-γ.   
Transcriptional Changes Specific or Centric to Either IFN-β or IFN-γ 
Treatment 
In addition to cluster-34, MHC Class II genes were also found in cluster 14 (45 
transcripts) (Figure 6.4c). This cluster represented transcripts whose expression was 
most specific to IFN-γ treated cells and included the MHC class II related transcripts; 
H2-DMa, H2-DMb2, H2-Eb1, Ciita, as well as transcripts encoding complement 
components; C1qb, C1qc, C1qa, C4b. The full spectrum of ‘classical’ activation of 
macrophages is thought to be induced by IFN-γ in concert with a microbial stimulus, 
such as LPS. The data here shows, apart from a handful of transcripts (including those 
in cluster 14), LPS is capable of regulating the same targets as IFN-γ. Thus the major 
contribution of IFN-γ to the classically activated macrophage would appear to be the 
capacity to efficiently induce MHC Class II antigen presentation and the complement 
system, which is less recognised. 
Cluster-10 and cluster-36 comprised transcripts whose expression was mostly 
restricted to IFN-β treatment. However the role of the genes (within these clusters) in 
the IFN-β response is not well characterised, as well the reasons to why they are 
expressed in IFN-β treatment but not following LPS stimulation. LPS induces IFN-β 
mRNA and protein expression, and therefore IFN-β signals in an autocrine manner to 
stimulate the cells and forms a significant portion of the LPS response, as has been 
previously studied [275-277]. However the existence of genes induced by IFN-β but not 
by LPS, (i.e. IFN-β targets which are repressed by the actions of LPS), have not been 
previously studied to date. This repression of cytokine inducible genes could 
potentially be an interesting aspect of the macrophage response to microbe.  
Functional annotation of these IFN-β clusters was poor. Following further inspection of 
the expression profiles of genes within these clusters, a refined list of most IFN-β 
specific transcripts was generated (Table 6.3). Amongst these genes was Casp2, which 
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was induced as early as 1 h by IFN-β, yet repressed in response to LPS treatment 
(Figure 6.10). The LPS response is known to possess an anti-apoptotic component 
[363][, and the repression of Casp2 could be an example of an anti-apoptotic 
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Figure 6.10: Casp2 expression in mouse BMDMs following treatment with any of IFN-β, IFN-γ, or LPS 
over 24 hours. Expression of the transcript encoding the Casp2 protein, plotted across three treatment 
regimes from samples representing pre-treatment (0 h) to specific time-points post treatment (1,2,4,8, 



















Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), member 1A  
Casp2 caspase 2  
Ccdc141 coiled-coil domain containing 141  
Ccdc39 coiled-coil domain containing 39  
Cd4 CD4 antigen  
Cdkn1c cyclin-dependent kinase inhibitor 1C (P57)  
Dio2 deiodinase, iodothyronine, type II  
Eif1 eukaryotic translation initiation factor 1  
Fgfbp3 fibroblast growth factor binding protein 3  
Gna14 guanine nucleotide binding protein, alpha 14  
Gprc5b G protein-coupled receptor, family C, group 5, member B  
Grap2 GRB2-related adaptor protein 2  
Il10 interleukin 10  
Klrg2 killer cell lectin-like receptor subfamily G, member 2  
Lrrc14b leucine rich repeat containing 14B  
Nsmaf neutral sphingomyelinase (N-SMase) activation associated factor  
Tnfsf8 tumor necrosis factor (ligand) superfamily, member 8  
Table 6.3: Gene expressed specifically in IFN-β of mouse BMDMs in a comparison of the transactional 
response to IFN-β, IFN-γ and LPS. A filtered list of genes expressed exclusively in response to IFN-β 
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Conclusions and Further Work 
The analyses of this Chapter set out to explore and better understand the overlap and 
distinctions in the transcriptional response generated in mouse BMDMs following 
stimulation with IFN-γ or IFN-β or LPS. The individual response to these three stimuli 
have been characterised previously and many of the major transcriptional changes 
found here confirmed the findings of previous studies [97, 238, 243-244, 246-247, 302, 
309, 322-326]. However to date no attempts have been made to thoroughly compare 
and contrast the response to these stimuli over time in primary macrophages.  
Therefore this data-set provides a valuable source of information to address this 
question. In these analyses it was found the treatments overlapped to a large degree 
in their transcriptional profiles but also induced unique sets of genes. LPS induced the 
greatest proportion of ‘unique’ transcripts in this comparison and shared a greater 
deal of overlap with IFN-β treatment, rather than IFN-γ. Surprisingly there were a 
group of genes induced in IFN-β treatment, yet not induced by LPS (and in some cases 
even repressed by LPS treatment). The response to LPS is generally assumed to 
comprise all aspects of the IFN-β response, thus the identification these “IFN-β-
exclusive” genes presents potentially interesting candidates for further study into a 
feature of the LPS response previously unexplored.   
The analyses presented in this Chapter are not exhaustive and represent the 
beginnings of attempts to delineate the shared and unique transcriptional response to 
the three stimuli. The clusters of co-ordinately expressed transcripts identified here 
could be further filtered to obtain a more refined list of transcripts preferentially or 
exclusively expressed in any given treatment or in two or more treatments. The study 
could also be complemented by sequence analysis of the promoter regions of the 
clusters of regulated genes to explore whether any particular transcriptional-factor 
binding sites were over-represented within these groups. It is also important to 
consider that the findings of this analysis may not fully correlate across species or 
indeed inter-species in other mice strain. Moreover some aspects of the transcriptional 
profiles generated in this study may well be specific to the doses studied (10 U/ml IFN-
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β/γ and 5 ng/ml LPS) on this occasion. Data in the preceding Chapter-(5), 
demonstrated the dose-dependant induction of certain LPS inducible genes. In a 
related analysis (also processed on this 96-array plate but) not discussed as part of 
thesis the macrophage response to three different doses of LPS was studied. The data 
revealed cohorts of genes which were clearly induced or repressed in a dose 
dependant manner, as well as genes unaffected by LPS dose (i.e. induced/repressed to 
the same extent regardless of treatment dose) (unpublished, data). This underscores 
another level of complexity when making comparisons across the treatment types, as 
genes found to be preferentially changing in one treatment over others may only hold 
true under the specific conditions studied.  
The analyses here, as with that of Chapter-4 highlights the fact that the full spectrum 
of macrophage activation is far from fully captured on our integrated pathway 
diagram. At the same time the function of many of the regulated components with 
respect to their role in macrophage activation has yet to be fully elucidated. For 
example many transcripts encoding microRNAs were found to be in clusters in this 
analysis, but are not currently represented on the macrophage pathways. However 
characterisation of the microRNAs themselves as well as their function in macrophage 
signalling has been an area of intense activity over recent years. This analysis also 
incorporates many regulated transcripts which are as of yet functionally un-annotated 
(e.g. Riken cDNA transcripts) but their expression is strongly co-ordinated with genes 
of know function and/or within clusters of genes contributing to a particular aspect of 
the macrophage activation response. Thus as with other analyses [143, 145, 364-366] 
there is the potential here to characterise as of yet un-annotated proteins since the 
likely function or process in which they are involved can be inferred by their co-
expression with genes encoding proteins of known function.  
Finally, one of the interests in exploring the overlap between these three stimuli is 
based on the fact the signalling pathways they activate are either inter-related or 
synergise at a number of levels.  As a means of extending this analyses and further 
characterising this synergy it would be interesting to compare the individual responses 
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to these stimuli with transcriptional data relating to the combinatorial stimulation of 
macrophage with the treatments.  
 
Methods and Materials 
 
Cell culture and treatment 
Cell culture is as described previously in Chapter-4 (for the IFN-β study), briefly; bone 
marrow derived macrophages (BMDM) were prepared from femurs of 7-8 week old 
male BALB/c mice, by differentiating bone marrow progenitors using the 
differentiation factor CSF-1. On day six of differentiation cells were harvested from 10 
cm square bacteriological plates and seeded into 24-well tissue culture plates at a 
density of 200,000 – 210,000 cells/ well. 24 hours later, (on day seven) cells were 
treated with one of; 10 U/ml recombinant mouse interferon-beta (IFN-β) (PBL 
Interferon Source, New Jersey, USA), 10 U/ml interferon-gamma (IFN-γ) (Perbio 
Science, Northumberland, UK), or 5 ng/ml LPS (from Salmonella minnesota Re595 
(Sigma, Gillingham, UK)) and harvested 1, 2, 4, 8 and 24 h following treatment or 
collected pre-treatment (0 h). All treatments were performed in the presence of CSF-1 
since CSF-1 is constitutively present in vivo. Moreover CSF-1 is itself induced upon 
macrophage activation with LPS and has been shown to enhance the activation of 
some genes by LPS [367]. It has therefore been argued that in vitro studies of 
macrophage activation should be performed in the presence of CSF-1 [283]. 
RNA extraction, QC and labelling for arrays 
Total RNA was harvested from the cells using an RNeasy Plus kit (Qiagen, Crawley, UK) 
according to manufacturer's instructions. RNA was quantified and quality controlled 
using a NanoDrop spectrophotometer (Nano-Drop Technologies, Delaware, USA) and 
BioAnalyser 2100 (Agilent, California, USA) to determine RNA purity and integrity. 
Replicate 250 ng samples of total RNA derived from two separate wells per time point 
were first processed using the Ambion WT (whole transcript) Expression Kit (Ambion) 
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to generate amplified and biotinylated sense strand DNA targets from the entire 
genome without bias. The senses strand DNA samples were then labelled, and 
hybridized to the Affymetrix® Mouse Gene 1.1 ST (obtained as part of a high-
throughput 96-array plate) using the Affymetrix GeneChip WT terminal labelling and 
hybridisation kit (Affymetrix) and according to manufacturer’s protocol. The 
Affymetrix® Mouse Gene 1.1 ST Array Plate enables the parallel processing and 
expression profiling of 96 samples. The individual arrays interrogate more than 28,000 
well-annotated genes with more than 770,000 distinct probes. Hybridisation, washing 
and scanning of the 96 arrays was performed using the Affymetrix GeneTitan 
instrument; this parallel and high-throughput processing reduces the chances of 
introducing technical variability that may well arise when processing the same number 
of samples of separate occasions.  
 
Data processing and network analysis 
Data (to be submitted to the GEO repository) was normalized using the RMA package 
within the Affymetrix Expression Console software and annotated. Network analysis of 
the normalised expression data was performed using BioLayout Express according to 
the network analysis principles described in Chapter-1 and as described in the 
Methods of Chapter-4. The parameters employed in this analysis included an initial 
filtering step of expression data relating to all the probes (transcripts) on the array) at 
a 0.85 Pearson correlation cut-off threshold. This network correlation graph of probes 
falling within this threshold (11,258 nodes, connected by 270,601 edges) was then 
filtered at an MCL inflation value of 2.2, to cluster the graph (and resulting in over 600 
clusters with at least ≥3 nodes). Clusters related to technical artefacts or patterns of 
expression unchanging across the 32 arrays were eliminated. A further network graph 
relating only to the data from probes within ‘interesting’ clusters of the filtered graph 
(3,747 nodes) was generated (by filtering relationships at a Pearson correlation of 0.85, 
and clustering the consequential graph at an MCL inflation value of 2.2). The clusters 
were inspected for patterns of expression associated with treatment over the time-
courses and gene lists associated with clusters were exported for GO annotation 
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analysis (Biological Processes Level-FAT) using the DAVID (Database for Annotation, 
Visualization and Integrated Discovery) tool.  
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Chapter 7. Conclusions  
 
Overview of main findings, challenges and future work 
 
The work described in this thesis explores the use of systems-level modelling and 
analysis methods to the study of macrophage activation and associated pathways. 
Specifically, the work outlined in Chapters 2 and 3 aimed to address the challenge of 
accurately modelling the large number of known interacting components and 
biological processes regulated in this cell.  Secondly, the interest was in investigating 
the transcriptional signatures generated in response to IFNs and what we understand 
by the classical-activation of macrophages (Chapters 4 and 6). Moreover was the 
desire to examine the role of genes of interest in the type-I IFN response pathway, by 
targeting their expression with siRNA. The exceptional plasticity and highly attuned 
pattern recognition systems of primary macrophages can complicate the use and 
reproducibility of functional genomics screening using siRNA, and therefore attempts 
were made to address this issue during the development of a cell-based assay 
(Chapter-5).  
 
Chapter-2 described the construction of pathway models of macrophage signalling. An 
initial framework map of macrophage activation comprising 272 interactions was 
published in 2008. During its construction process many challenges of converting 
pathway knowledge into computationally-tractable yet ‘understandable’ diagrams, 
were addressed. The lessons learnt and rules established from constructing the 
framework map then provided a more robust agenda for assembling further pathways 
of interest, and the subsequent integrated pathway resource included a total of 496 
unique proteins, 412 protein complexes, 81 genes, and 101 DNA sequence/promoter 
regions. In total the network comprised 2,170 nodes connected by 2,553 edges. This 
model of macrophage signalling is to our knowledge the most comprehensive pathway 
of its kind published to date. The work summarizes years of investigations, and brings 
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together thousands of published findings into one navigable, searchable, visual aid. 
The pathway has proven to be a valuable resource in the interpretation of functional 
genomics data. At the same time it is appreciated the model still only captures a 
modest number of changes occurring in the macrophage, as was evident from the 
transcriptional analyses performed in Chapters 4 and 6. Future efforts will need to 
integrate the transcriptional data as well as other signalling pathways known to be 
active in the macrophage, into the overall signalling network to improve the predictive 
value of the pathway diagrams. The longer term eventual aim will be to expand the 
pathway resource to create a more comprehensive in silico cell model of macrophage 
signalling with the predictive power to demonstrate the transcriptional networks 
activated in response to combinations of stimuli (pathogens and/or cytokines) as 
encountered in vivo.  
 
The desire to perform pathway analysis on the outputs of functional genomics screens 
and high-dimensional data has arguably never been greater. However the overhead of 
creating and maintaining pathway resources is often a thankless and onerous task. 
Recently (21 May 2011) it was announced the popular and previously free pathway 
repository KEGG pathways is to move away from its open-source/free-software roots 
and change to a paid-subscription system. Therefore in the interests of maintaining the 
availability of high-quality free-pathway resources to enhance academic research, the 
construction of such in-house pathways as described in Chapter-2 as well as keeping 
up the debate on how pathway information should be depicted and exchanged 
(Chapter-3) is more important than ever.  
 
Chapter-3 describes the development of the modified Edinburgh Pathway Notation 
(mEPN) scheme a graphical notation system for biology originally devised a number of 
years ago and now through use has been refined extensively. This development has 
been primarily driven by the attempts to produce process diagrams for a diverse range 
of biological pathways (described in Chapter-2). In addition to the pathways described 
in Chapter-2 the mEPN notation scheme has now been deployed to depict cell-cycle 
signalling as well as lipid-metabolism (unpublished). Through thorough testing and 
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refinement the mEPN has been found to be suitable to describe a number of biological 
concepts. The next challenge for both the mEPN and in a more general sense for 
systems biology is how we begin to model (in silico) the cellular interactions 
underpinning a biological process (in vivo) and their deregulation in disease states.  
With respect to the macrophage, its behaviour, phenotypic and genotypic properties 
vary depending on its surrounding cellular milieu. Thus to better understand the highly 
plastic nature of macrophages requires an understanding of its interactions with other 
cells in a given setting. Indeed, systems biology involves the study of biological 
processes at multiple levels of abstraction e.g. from molecules, to cells, to tissues, to 
organs and so on. The challenge remains in bridging the insights acquired from 
multiple levels and devising models to reflect multi-level concepts and observations. 
One of the key incentives for generating pathways with standard notations was to 
permit the conversion of graphical models into computationally tractable ones, 
suitable for simulation analyses. Efforts are now well advanced in the Group to convert 
the mEPN notation into language suitable of stochastic flow modelling (signalling Petri 
nets (SPN) [114]). This has required further adaptation of the notation scheme and 
development of supporting software (BioLayout Express3D) to visualise the output. 
Initial tests have been promising and the SPN approach is particularly well suited to 
large networks such as those generated in Chapter-2.  
 
Thus we are now closer to a pathway-model system where one can begin to perform 
computational predictions about pathway behaviour and the signalling response to 
pathway perturbation. In the latter case this could be how macrophage signalling 
responds to perturbation induced by siRNA gene knockdown. The potential for 
computational flow-modelling would not have been possible without first the 
development of the mEPN and the construction of extensive pathway models on which 
to perform/test the simulations. The longer term but ultimate objective in systems-
based therapeutics is to exploit the predictive power of these in silico models to 
identify novel drug targets. 
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The investigations of Chapter-4 set out to analyse the type-I and type-II interferon 
response in macrophages. Previous attempts to analyse the transcriptional response to 
these cytokines have predominantly relied on statistical fold-change cut offs. In this 
work the application of network-based explorations of correlation matrices were used 
to visualise and interpret the transcriptional events over a 24 h time-course. The IFN-β 
and IFN-γ time-course experiments were originally conceived and analysed separately. 
Later in the course of these investigations, the type-I and type-II time-course 
experiments were repeated under controlled conditions to allow for a more accurate 
comparison (Chapter-6). The clustering approach used to analyse the expression data 
provides a powerful method for identifying correlation amongst genes and from which 
the function of currently un-annotated genes may be inferred. The next challenge lies 
in unravelling the causality of the regulatory relationships in the transcriptional 
networks. This would require identifying negative and positive feedback loops in the 
response networks. Some feedback loop are very well characterised (e.g. CIITA 
regulation of MHC-Class II expression), whereas many other causal relationships 
remain to be identified.  
 
The studies of Chapter-5 set out to optimise an in vitro cell-based assay for 
investigating the role of selected genes in the type-I interferon and LPS response. The 
genes of interest were targeted with siRNA.  Genome-wide transcriptional analysis 
revealed that knockdown of genes of interest did not perturb transcriptional networks 
associated with the LPS response, including the expression of type-I response genes. 
On one level these observations may well have be indicative of the robustness of 
macrophage signalling networks, especially in response to a potent microbial stimulus 
(LPS). Future work could explore whether this robustness is impaired with 
combinatorial gene knockdowns (i.e. two or more genes targeted).  
 
The entire assay optimisation process also highlighted the complexities of using siRNA 
in primary macrophages. For example, increasing doses of different siRNAs generated 
different patterns of lipofection-induced type-I gene expression. siRNA pre-treatment 
would on some occasions enhance responsiveness to LPS and on other occasions 
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decrease responsiveness. The lack of reproducibility observed between investigations 
might be attributed to the innate plasticity of macrophages or variability in BMDMs 
prepared on different days. Ultimately targeting a heterogeneous cell type like the 
macrophage can generate a spectrum of responses depending on the collective state 
of the cells. Given their roles in numerous diseases, macrophages are attractive targets 
for siRNA based therapeutics. The observations of this Chapter mirror the obstacles 
faced in utilizing siRNA in the clinical setting.  
 
The final investigations described in this thesis set out to explore the transcriptional 
networks associated with the BMDM response to type-I interferon, type-II interferon 
and LPS stimulation. The investigations of Chapter-4 also attempted to contrast the 
type-I and type-II response in primary BMDMs, however this comparison was limited 
by the fact the experiments and microarrays were processed on separate occasions. 
Nevertheless Chapter-4 demonstrated the power of the network-based analysis 
approach for mining high-throughput transciptomics data, and this approach was again 
utilized in the analyses of Chapter-6. The overlapping and unique transcriptional 
responses to the three stimuli (LPS, IFN-β, and IFN-γ) were identified. Generally the 
inducible transcriptional response was much broader and potent (in terms of fold-
change induction) in LPS treated macrophages compared to those treated with either 
IFN-β or IFN-γ. Moreover under these experimental conditions 727 transcripts were 
specifically regulated in LPS treatment. 50 transcripts were unique to IFN-γ treatment 
and 115 transcripts were unique to IFN-β treatment. In concert with previous findings, 
MHC Class II related transcripts were among those specifically expressed in response 
to IFN-γ, as well as members of the complement system. The role of genes expressed 
specifically in IFN-β, is less well characterised. Interestingly some genes were induced 
by IFN-β, yet repressed by LPS treatment. The identification of “IFN-β-exclusive” genes 
presents potentially interesting candidates for further study into a feature of the LPS 
response previously unexplored. The output of the transcriptional screens in Chapters 
4 and 6, underscored the fact that the full spectrum of macrophage activation has yet 
to be fully captured on the integrated pathway diagram. The next steps in developing 
the macrophage pathway model will be its integration with transcriptional networks 
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identified in Chapters 4 and 6. Further work would also seek to build transcription 
factor networks, as a means of integrating the transcriptional data generated with the 
pathway model.    
 
Overall each of the aspects of the systems biology paradigm of model-manipulate-
measure and mine, have been explored in some sense in these investigations. The 
model in this case was the generation of in silico macrophage signalling pathways. The 
pathway resource then informed the stages of manipulation; by cytokine treatment or 
by gene knockdown using siRNA. Changes occurring in the macrophage were 
measured using appropriate techniques. Central to these investigations was 
measurement of transcriptional changes using microarray technology. The resulting 
data was then mined, and its interpretation can now inform further improvements and 
development of the macrophage pathways. For example developments could include 
the incorporation of feed-forward and negative feedback loops arising is response to 
specific treatments. Even with the integration of the additional information, it’s 
imperative to acknowledge the in silico model of macrophage signalling, is purely a 
model. Iterative cycles of development will continue to enhance the value of the 
model to inform further investigations. Eventually the hope is that such models will 
have the predictive power to identify targets for therapeutic intervention in diseases 
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